
<html lang="en"     class="pb-page"  data-request-id="f58ced6b-6a21-43e5-8727-180d6a3f42f3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-3;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b01375;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)" /></meta><meta name="dc.Creator" content="Pei-Pei  Kung" /></meta><meta name="dc.Creator" content="Patrick  Bingham" /></meta><meta name="dc.Creator" content="Alexei  Brooun" /></meta><meta name="dc.Creator" content="Michael  Collins" /></meta><meta name="dc.Creator" content="Ya-Li  Deng" /></meta><meta name="dc.Creator" content="Dac  Dinh" /></meta><meta name="dc.Creator" content="Connie  Fan" /></meta><meta name="dc.Creator" content="Ketan S.  Gajiwala" /></meta><meta name="dc.Creator" content="Rita  Grantner" /></meta><meta name="dc.Creator" content="Hovhannes J.  Gukasyan" /></meta><meta name="dc.Creator" content="Wenyue  Hu" /></meta><meta name="dc.Creator" content="Buwen  Huang" /></meta><meta name="dc.Creator" content="Robert  Kania" /></meta><meta name="dc.Creator" content="Susan E.  Kephart" /></meta><meta name="dc.Creator" content="Cody  Krivacic" /></meta><meta name="dc.Creator" content="Robert A.  Kumpf" /></meta><meta name="dc.Creator" content="Penney  Khamphavong" /></meta><meta name="dc.Creator" content="Manfred  Kraus" /></meta><meta name="dc.Creator" content="Wei  Liu" /></meta><meta name="dc.Creator" content="Karen A.  Maegley" /></meta><meta name="dc.Creator" content="Lisa  Nguyen" /></meta><meta name="dc.Creator" content="Shijian  Ren" /></meta><meta name="dc.Creator" content="Dan  Richter" /></meta><meta name="dc.Creator" content="Robert A.  Rollins" /></meta><meta name="dc.Creator" content="Neal  Sach" /></meta><meta name="dc.Creator" content="Shikhar  Sharma" /></meta><meta name="dc.Creator" content="John  Sherrill" /></meta><meta name="dc.Creator" content="Jillian  Spangler" /></meta><meta name="dc.Creator" content="Albert E.  Stewart" /></meta><meta name="dc.Creator" content="Scott  Sutton" /></meta><meta name="dc.Creator" content="Sean  Uryu" /></meta><meta name="dc.Creator" content="Dominique  Verhelle" /></meta><meta name="dc.Creator" content="Hui  Wang" /></meta><meta name="dc.Creator" content="Shuiwang  Wang" /></meta><meta name="dc.Creator" content="Martin  Wythes" /></meta><meta name="dc.Creator" content="Shuibo  Xin" /></meta><meta name="dc.Creator" content="Shinji  Yamazaki" /></meta><meta name="dc.Creator" content="Huichun  Zhu" /></meta><meta name="dc.Creator" content="JinJiang  Zhu" /></meta><meta name="dc.Creator" content="Luke  Zehnder" /></meta><meta name="dc.Creator" content="Martin  Edwards" /></meta><meta name="dc.Description" content="A new series of lactam-derived EZH2 inhibitors was designed via ligand-based and physicochemical-property-based strategies to address metabolic stability and thermodynamic solubility issues associa..." /></meta><meta name="Description" content="A new series of lactam-derived EZH2 inhibitors was designed via ligand-based and physicochemical-property-based strategies to address metabolic stability and thermodynamic solubility issues associa..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 27, 2017" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01375" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01375" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01375" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01375" /></link>
        
    
    

<title>Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01375" /></meta><meta property="og:title" content="Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0017.jpeg" /></meta><meta property="og:description" content="A new series of lactam-derived EZH2 inhibitors was designed via ligand-based and physicochemical-property-based strategies to address metabolic stability and thermodynamic solubility issues associated with previous lead compound 1. The new inhibitors incorporated an sp3 hybridized carbon atom at the 7-position of the lactam moiety present in lead compound 1 as a replacement for a dimethylisoxazole group. This transformation enabled optimization of the physicochemical properties and potency compared to compound 1. Analysis of relationships between calculated log D (clogD) values and in vitro metabolic stability and permeability parameters identified a clogD range that afforded an increased probability of achieving favorable ADME data in a single molecule. Compound 23a exhibited the best overlap of potency and pharmaceutical properties as well as robust tumor growth inhibition in vivo and was therefore advanced as a development candidate (PF-06821497). A crystal structure of 23a in complex with the three-protein PRC2 complex enabled understanding of the key structural features required for optimal binding." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01375"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01375">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01375&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01375&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01375&amp;href=/doi/10.1021/acs.jmedchem.7b01375" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 650-665</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00681" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.7b00530" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pei-Pei++Kung">Pei-Pei Kung</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-9203-7374" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++Bingham">Patrick Bingham</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexei++Brooun">Alexei Brooun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Collins">Michael Collins</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ya-Li++Deng">Ya-Li Deng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dac++Dinh">Dac Dinh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Connie++Fan">Connie Fan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ketan+S.++Gajiwala">Ketan S. Gajiwala</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rita++Grantner">Rita Grantner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hovhannes+J.++Gukasyan">Hovhannes J. Gukasyan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wenyue++Hu">Wenyue Hu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Buwen++Huang">Buwen Huang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Kania">Robert Kania</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan+E.++Kephart">Susan E. Kephart</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cody++Krivacic">Cody Krivacic</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+A.++Kumpf">Robert A. Kumpf</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Penney++Khamphavong">Penney Khamphavong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Manfred++Kraus">Manfred Kraus</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Liu">Wei Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karen+A.++Maegley">Karen A. Maegley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Nguyen">Lisa Nguyen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shijian++Ren">Shijian Ren</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dan++Richter">Dan Richter</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+A.++Rollins">Robert A. Rollins</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Neal++Sach">Neal Sach</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shikhar++Sharma">Shikhar Sharma</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John++Sherrill">John Sherrill</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jillian++Spangler">Jillian Spangler</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Albert+E.++Stewart">Albert E. Stewart</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Sutton">Scott Sutton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sean++Uryu">Sean Uryu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dominique++Verhelle">Dominique Verhelle</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hui++Wang">Hui Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuiwang++Wang">Shuiwang Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Wythes">Martin Wythes</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuibo++Xin">Shuibo Xin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shinji++Yamazaki">Shinji Yamazaki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Huichun++Zhu">Huichun Zhu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=JinJiang++Zhu">JinJiang Zhu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luke++Zehnder">Luke Zehnder</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Edwards">Martin Edwards</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Oncology Medicinal Chemistry, <sup>‡</sup>Oncology Research Unit, <sup>§</sup>Pharmacokinetics, Dynamics, and Metabolism, <sup>∥</sup>Pharmaceutical Science Research Enabling Group, and <sup>⊥</sup>Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">#</span> <span class="aff-text">Pfizer Global Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">∇</span> <span class="aff-text">WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#116174786174783f7a647f76516177786b74633f727e7c"><span class="__cf_email__" data-cfemail="1b6b7e726b7e7235706e757c5b6b7d72617e6935787476">[email protected]</span></a>. Phone: (858) 526-4867.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01375&amp;href=/doi/10.1021%2Facs.jmedchem.7b01375" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 650–665</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 6, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 September 2017</li><li><span class="item_label"><b>Published</b> online</span>27 December 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 February 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01375" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01375</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D650%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPei-Pei%2BKung%252C%2BPatrick%2BBingham%252C%2BAlexei%2BBrooun%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D3%26contentID%3Dacs.jmedchem.7b01375%26title%3DOptimization%2Bof%2BOrally%2BBioavailable%2BEnhancer%2Bof%2BZeste%2BHomolog%2B2%2B%2528EZH2%2529%2BInhibitors%2BUsing%2BLigand%2Band%2BProperty-Based%2BDesign%2BStrategies%253A%2BIdentification%2Bof%2BDevelopment%2BCandidate%2B%2528R%2529-5%252C8-Dichloro-7-%2528methoxy%2528oxetan-3-yl%2529methyl%2529-2-%2528%25284-methoxy-6-methyl-2-oxo-1%252C2-dihydropyridin-3-yl%2529methyl%2529-3%252C4-dihydroisoquinolin-1%25282H%2529-one%2B%2528PF-06821497%2529%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D665%26publicationDate%3DFebruary%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01375"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">7246</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">30</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01375" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Pei-Pei&quot;,&quot;last_name&quot;:&quot;Kung&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Bingham&quot;},{&quot;first_name&quot;:&quot;Alexei&quot;,&quot;last_name&quot;:&quot;Brooun&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Collins&quot;},{&quot;first_name&quot;:&quot;Ya-Li&quot;,&quot;last_name&quot;:&quot;Deng&quot;},{&quot;first_name&quot;:&quot;Dac&quot;,&quot;last_name&quot;:&quot;Dinh&quot;},{&quot;first_name&quot;:&quot;Connie&quot;,&quot;last_name&quot;:&quot;Fan&quot;},{&quot;first_name&quot;:&quot;Ketan&quot;,&quot;last_name&quot;:&quot;S. Gajiwala&quot;},{&quot;first_name&quot;:&quot;Rita&quot;,&quot;last_name&quot;:&quot;Grantner&quot;},{&quot;first_name&quot;:&quot;Hovhannes&quot;,&quot;last_name&quot;:&quot;J. Gukasyan&quot;},{&quot;first_name&quot;:&quot;Wenyue&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Buwen&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Kania&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;E. Kephart&quot;},{&quot;first_name&quot;:&quot;Cody&quot;,&quot;last_name&quot;:&quot;Krivacic&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;A. Kumpf&quot;},{&quot;first_name&quot;:&quot;Penney&quot;,&quot;last_name&quot;:&quot;Khamphavong&quot;},{&quot;first_name&quot;:&quot;Manfred&quot;,&quot;last_name&quot;:&quot;Kraus&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;A. Maegley&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Nguyen&quot;},{&quot;first_name&quot;:&quot;Shijian&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Dan&quot;,&quot;last_name&quot;:&quot;Richter&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;A. Rollins&quot;},{&quot;first_name&quot;:&quot;Neal&quot;,&quot;last_name&quot;:&quot;Sach&quot;},{&quot;first_name&quot;:&quot;Shikhar&quot;,&quot;last_name&quot;:&quot;Sharma&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Sherrill&quot;},{&quot;first_name&quot;:&quot;Jillian&quot;,&quot;last_name&quot;:&quot;Spangler&quot;},{&quot;first_name&quot;:&quot;Albert&quot;,&quot;last_name&quot;:&quot;E. Stewart&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Sutton&quot;},{&quot;first_name&quot;:&quot;Sean&quot;,&quot;last_name&quot;:&quot;Uryu&quot;},{&quot;first_name&quot;:&quot;Dominique&quot;,&quot;last_name&quot;:&quot;Verhelle&quot;},{&quot;first_name&quot;:&quot;Hui&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Shuiwang&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Wythes&quot;},{&quot;first_name&quot;:&quot;Shuibo&quot;,&quot;last_name&quot;:&quot;Xin&quot;},{&quot;first_name&quot;:&quot;Shinji&quot;,&quot;last_name&quot;:&quot;Yamazaki&quot;},{&quot;first_name&quot;:&quot;Huichun&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;JinJiang&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Luke&quot;,&quot;last_name&quot;:&quot;Zehnder&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Edwards&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;650-665&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01375&quot;},&quot;abstract&quot;:&quot;A new series of lactam-derived EZH2 inhibitors was designed via ligand-based and physicochemical-property-based strategies to address metabolic stability and thermodynamic solubility issues associated with previous lead compound 1. The new inhibitors incorporated an sp3 hybridized carbon atom at the 7-position of the lactam moiety present in lead compound 1 as a replacement for a dimethylisoxazole group. This transformation enabled optimization of the physicochemical properties and potency compared to compound 1. Analysis of relationships between calculated log D (clogD) values and in vitro metabolic stability and permeability parameters identified a clogD range that afforded an increased probability of achieving favorable ADME data in a single molecule. Compound 23a exhibited the best overlap of potency and pharmaceutical properties as well as robust tumor growth inhibition in vivo and was therefore advanced as a development candidate (PF-06821497). A crystal structure of 23a in complex with the three-protei&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01375&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01375" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01375&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01375" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01375&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01375" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01375&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01375&amp;href=/doi/10.1021/acs.jmedchem.7b01375" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01375" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01375" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01375%26sid%3Dliteratum%253Aachs%26pmid%3D29211475%26genre%3Darticle%26aulast%3DKung%26date%3D2018%26atitle%3DOptimization%2Bof%2BOrally%2BBioavailable%2BEnhancer%2Bof%2BZeste%2BHomolog%2B2%2B%2528EZH2%2529%2BInhibitors%2BUsing%2BLigand%2Band%2BProperty-Based%2BDesign%2BStrategies%253A%2BIdentification%2Bof%2BDevelopment%2BCandidate%2B%2528R%2529-5%252C8-Dichloro-7-%2528methoxy%2528oxetan-3-yl%2529methyl%2529-2-%2528%25284-methoxy-6-methyl-2-oxo-1%252C2-dihydropyridin-3-yl%2529methyl%2529-3%252C4-dihydroisoquinolin-1%25282H%2529-one%2B%2528PF-06821497%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D3%26spage%3D650%26epage%3D665%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292504" title="Permeability">Permeability</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/jmcmar.2018.61.issue-3/20180208/jmcmar.2018.61.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A new series of lactam-derived EZH2 inhibitors was designed via ligand-based and physicochemical-property-based strategies to address metabolic stability and thermodynamic solubility issues associated with previous lead compound <b>1</b>. The new inhibitors incorporated an sp<sup>3</sup> hybridized carbon atom at the 7-position of the lactam moiety present in lead compound <b>1</b> as a replacement for a dimethylisoxazole group. This transformation enabled optimization of the physicochemical properties and potency compared to compound <b>1</b>. Analysis of relationships between calculated log <i>D</i> (clogD) values and in vitro metabolic stability and permeability parameters identified a clogD range that afforded an increased probability of achieving favorable ADME data in a single molecule. Compound <b>23a</b> exhibited the best overlap of potency and pharmaceutical properties as well as robust tumor growth inhibition in vivo and was therefore advanced as a development candidate (PF-06821497). A crystal structure of <b>23a</b> in complex with the three-protein PRC2 complex enabled understanding of the key structural features required for optimal binding.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73577" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73577" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Polycomb group (PcG) and trithorax group (TrxG) proteins are key regulators of heritable gene expression patterns.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> PcG proteins are present in two major evolutionarily conserved multiprotein complexes, known as polycomb repressive complexes 1 and 2 (PRC1 and PRC2). The PRC2 complex contains three core subunits: (1) EZH2 (enhancer of zeste homolog 2) or its closely related homolog EZH1, (2) SUZ12 (suppressor of zeste 12), and (3) EED (embryonic ectoderm development) along with additional subcomponents such as histone and DNA interacting proteins RbAp46/48 and AEBP2.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> The EZH2 histone methyltransferase subunit of the complex contains the catalytic SET (Su[var]3-9, enhancer of zeste, trithorax) domain which catalyzes the mono-, di-, and trimethylation of lysine 27 on histone H3 (H3K27me, me2, and me3).</div><div class="NLM_p">Epigenetic alterations are a recognized hallmark of cancer cells, and several lines of evidence link aberrant EZH2 activity to tumor initiation and progression. EZH2 is overexpressed in multiple solid tumors and hematological malignancies, and elevated expression is often correlated with disease progression and poor survival.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In addition, oncogenic activating point mutations in the SET domain of EZH2 have been identified in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10">(6-10)</a> These genetic alterations in EZH2 alter the substrate specificity of the enzyme, resulting in elevated H3K27me3 levels and enhanced transcriptional repression. Moreover, cell lines harboring these mutations display sensitivity to small molecule EZH2 inhibitors, supporting the importance of EZH2 catalytic activity in these cancers. In addition to the genetic alterations of EZH2 in hematological cancers, cancer specific dependencies have also been identified in solid tumors in the context of wild-type EZH2. Genetic and pharmacological inhibition of EZH2 has uncovered synthetic lethal relationships in lung, ovarian, malignant rhabdoid, and synovial sarcoma models harboring mutations in the SMARCA2, SMARCA4, ARID1A, and SNF5/INI-1/SMARCB1 components of the SWI/SNF chromatin remodeling complex.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14 ref15 ref16">(11-16)</a> More recently, it has been demonstrated that EZH2 activity regulates transcriptional programs that control differentiation status and drug resistance in small-cell lung cancer and neuroendocrine prostate cancer.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17-19)</a> Collectively, these data provide a compelling rationale for the inhibition of EZH2 enzymatic function as a potential therapeutic approach for the treatment of cancer.</div><div class="NLM_p last">The abundance of preclinical data supporting EZH2 as a therapeutic target has stimulated drug discovery programs aimed at developing small molecule inhibitors that block EZH2 enzymatic function. Several examples of such inhibitors including GSK-126,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> tazemetostat (EPZ-6438),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and CPI-1205<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> have entered clinical trials for the treatment of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and SNF5/INI-1/SMARCB1 genetically defined solid tumors. The reported interim phase II objective response rates (ORR) for tazemetostat in DLBCL and FL patients harboring tumors with mutant EZH2 proteins were 29% and 92%, respectively. In contrast, these phase II ORR values dropped to 15% and 26%, respectively, in DLBCL and FL patients bearing tumors containing wild type EZH2.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> These results highlighted the important role for enhanced EZH2 catalytic function in these disease settings and demonstrated great potential for EZH2 inhibitors as new therapeutic options for these DLBCL and FL patients. In contrast to targeting the enzymatic function of the PRC2 complex, binders of the EED H3K27me3 pocket were also pursued to modulate the PRC2 complex activity.<a onclick="showRef(event, 'cit23a cit23b'); return false;" href="javascript:void(0);" class="ref cit23a cit23b">(23a, 23b)</a> These efforts provided additional confidence that targeting the PRC2 complex is a viable drug discovery strategy for identifying new cancer therapies.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28765" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28765" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We previously described a series of lactam-containing molecules as novel inhibitors of the EZH2 enzyme.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> An optimized representative of this compound class displayed potent EZH2 inhibitory activity in enzymatic and cell-based assays along with impressive tumor growth inhibition effects in a Karpas-422 xenograft model (<b>1</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). However, compound <b>1</b> also exhibited unfavorable metabolic stability in human liver microsome (HLM)/hepatocyte clearance assays along with poor thermodynamic solubility (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). These undesirable attributes prohibited further development of the molecule, and we therefore sought to improve these ADME and physicochemical parameters in order to identify a compound that could be advanced into clinical trials. In this report, we describe our progress in optimizing the HLM clearance (target of ≤30 (μL/min)/mg protein)<a onclick="showRef(event, 'cit25a cit25b'); return false;" href="javascript:void(0);" class="ref cit25a cit25b">(25a, null)</a> and thermodynamic solubility properties of lactams related to compound <b>1</b> while maintaining acceptable in vitro permeability characteristics (as measured by MDCK-LE, target of ≥5 × 10<sup>–6</sup> cm/s)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and EZH2 inhibition in both biochemical and cellular assessments.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. In vitro properties of compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our optimization efforts started by replacing the dimethylisoxazole moiety present in <b>1</b> with various nonaromatic moieties that incorporated sp<sup>3</sup> centers attached to the 7-position of the bicyclic lactam moiety. On the basis of prior literature reports, these alterations were anticipated to favorably impact the solubility properties of the new inhibitors relative to compound <b>1</b>.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> Importantly, our prior studies with lactam-containing EZH2 inhibitors related to <b>1</b> indicated that the molecular region occupied by the dimethylisoxazole moiety was much more amenable to structural modification relative to other portions of the molecule. Unfortunately, we did not have supporting crystallographic data at the time we initiated these efforts to guide the new optimization efforts. Accordingly, we adopted a ligand-based dimethylisoxazole replacement strategy with an initial goal of maintaining presumed protein–ligand contacts related to the two isoxazole methyl groups that our previous studies had shown were critical for potent anti-EZH2 activity.</div><div class="NLM_p">As shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, a lactam-containing compound (compound <b>2a</b>) bearing a 1-methoxypropyl substituent as a dimethylisoxazole replacement exhibited encouraging EZH2 inhibition activity in biochemical assessments employing the Y641N mutant form of the enzyme.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The 1-methoxypropyl moiety was designed based on its ability to mimic the spatial location of the two methyl groups present in the dimethylisoxazole of compound <b>1</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). As expected, on the basis of its biological mechanism of action, compound <b>2a</b> inhibited EZH2-mediated increases in histone methylation as evidenced by reduced H3K27me3 levels in Karpas-422 cells. These attributes afforded relatively potent antiproliferative effects when compound <b>2a</b> was tested against Karpas-422 cells in in vitro assessments (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). These biological activities confirmed that introduction of the sp<sup>3</sup>-carbon atom at the lactam 7-position was tolerated and supported the continued optimization of the new inhibitor series.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Impact of R Group on Potency, log <i>D</i>, and Kinetic Solubility<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0013.gif" alt="" id="GRAPHIC-d39e752-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0014.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All compounds bearing chiral centers are single stereoisomers. To help depict enatiomeric pairs, the sign of the optical rotation is provided below compound number.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last"><i>K</i><sub>i</sub> values are geometric mean values from at least three independent experiments. For each experiment, <i>K</i><sub>i</sub> values are determined from 11-point dose–response curves with each dose performed in duplicate.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Unless otherwise indicated, the reported IC<sub>50</sub> values are the geometric mean of values from two independent experiments.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">The log <i>D</i> was measured at pH 7.4.</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Single determination.</p></div><div class="footnote" id="t1fn6"><sup>Table f</sup><p class="last">ND: not determined.</p></div></div><div></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of minimized ligand conformations of <b>2a</b> and <b>2b</b> with compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We then prepared several additional analogs related to <b>2a</b> in an effort to improve EZH2 inhibition activity and in vitro ADME properties. To help maximize lipophilic ligand efficiency (LipE)<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and increase the chances of achieving good metabolic stability, a key feature of our inhibitor design strategy was to target low log <i>D</i>. This strategy required the inclusion of various heteroatoms (typically oxygen atoms) into the sp<sup>3</sup>-containing moieties that were employed as dimethylisoxazole replacements. In addition, the enantiomer of <b>2a</b> (compound <b>2b</b>) exhibited similar potencies in the described biological assessments (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). As shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, both <b>2a</b> and <b>2b</b> could reasonably mimic the spatial orientation of the two methyl groups present in the dimethylisoxazole of compound <b>1</b> and were thus likely to maintain similar interactions with the EZH2 protein. Given the near-equivalent activities exhibited by compounds <b>2a</b> and <b>2b</b>, we purposefully synthesized the new lactam-containing compounds in racemic form (or as mixtures of diastereomers) and relied on achiral and/or chiral separation techniques to provide purified single isomers for subsequent biological assessments. For selected compounds, the absolute configurations of the sp<sup>3</sup> centers were determined by obtaining small molecule crystal structures. We also monitored the kinetic solubility of all newly synthesized compounds to ensure that the molecules had good potential to achieve the desired improvement on the poor thermodynamic solubility exhibited by compound <b>1</b> (2 μg/mL in water with 0.5% CMC and 0.1% polysorbate 80 at 25 °C). Although determination of the latter parameter required distinct assessments employing crystalline forms of the test compounds, we anticipated that new molecules with poor kinetic solubility values would be unlikely to exhibit attractive thermodynamic solubility properties.</div><div class="NLM_p">As shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, removal of the methyl group from the methoxy group present in compounds <b>2a</b> and <b>2b</b> resulted in significant loss of EZH2 inhibition (compounds <b>3a</b> and <b>3b</b>). This result suggested that new moieties appended to the bicyclic lactam inhibitor core needed to occupy the same spatial region as the two methyl groups present in isoxazole-containing <b>1</b> in order to exhibit potent EZH2 inhibition. Consistent with this hypothesis, biochemical potency attenuation relative to <b>2a</b> and <b>2b</b> was observed for the truncated hydroxymethyl compounds <b>4a</b> and <b>4b</b> (ethyl to methyl; methoxy to hydroxymethyl, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Interestingly, however, compound <b>4a</b> displayed anti-EZH2 biochemical and cell potencies that were within 2-fold of those exhibited by <b>2a</b>, suggesting that locating the hydroxyl group further away from the bicyclic lactam core could favorably impact the potency. Accordingly, we prepared an elaborated hydroxyl-containing compound (<b>5a</b>) that displayed EZH2 biochemical inhibition and antiproliferation activities that were similar to those exhibited by inhibitors <b>2a</b> and <b>2b</b>. This outcome, coupled with the cell potency results observed for <b>4a</b>, suggested that a hydroxyl group could indeed be accommodated in the EZH2 inhibitor binding site if positioned in an appropriate location relative to the bicyclic lactam core. The significantly weakened activity of the enantiomers corresponding to <b>3a</b>, <b>4a</b>, and <b>5a</b> (<b>3b</b>, <b>4b</b>, and <b>5b</b>, respectively) also indicated that the stereochemistry of these hydroxyl-containing molecules’ sp<sup>3</sup> centers played a more important role in maintaining potency relative to what was observed for the related methoxy-containing inhibitors (cf., compounds <b>2a</b> and <b>2b</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Importantly, compound <b>5a</b> also exhibited improvements in HLM stability parameters relative to <b>2a</b>/<b>2b</b> that likely resulted from the former compound’s significantly lower log <i>D</i> value.</div><div class="NLM_p">Encouraged by the improved HLM stability and LipE parameters exhibited by <b>5a</b>, we enlarged the ethyl moiety present in the compound via the incorporation of a tetrahydrofuran ring into the inhibitor design. This alteration reduced log <i>D</i> by 0.8 units relative to <b>5a</b> and introduced a second stereocenter into the resulting molecules. Nonstereospecific synthesis afforded four unique entities following achiral and chiral purifications of the initial compound mixture (compounds <b>6a</b>–<b>d</b>). As shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, two of the four compounds prepared (<b>6a</b> and <b>6b</b>) exhibited very potent EZH2 biochemical and cellular inhibition that were comparable to those displayed by compound <b>1</b>. These inhibitors presumably made additional favorable contacts with the EZH2 enzyme relative to molecules <b>2</b>–<b>5</b>, and the oxygen atoms contained in the new entities maintained favorable overall lipophilicity values (log <i>D</i> = 2.0–2.1). Somewhat unexpectedly, however, the absolute configuration of the sp<sup>3</sup> center adjacent to the bicyclic lactam core in the potent <b>6a</b> was determined to be opposite that of the corresponding sp<sup>3</sup> center present in the potent truncated compound <b>4a</b>. This apparent discrepancy will be explored in greater detail below as part of the cocrystal structure discussion. As expected given their lower log <i>D</i> values and improved biochemical potency relative to <b>1</b>, <b>6a</b> and <b>6b</b> also exhibited improved HLM stability and LipE parameters (by about two units, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). However, the increased polarity and hydrogen bond donors of <b>6a</b>/<b>6b</b> resulted in relatively low in vitro permeability values that were below the threshold typically associated with well-absorbed molecules in vivo (MDCK-LE ≥ 5 × 10<sup>–6</sup> cm/s).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> To address this potential liability, we incorporated an alternative isomeric tetrahydrofuran ring into the inhibitor design that might be able to form an internal hydrogen bond with the hydroxyl group present in the compounds (<b>7a</b>–<b>d</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Although some of these compounds (<b>7a</b> and <b>7c</b>) exhibited improved MDCK-LE permeability relative to <b>6a</b>/<b>6b</b>, none displayed anti-EZH2 activities that were superior to those associated with compound <b>1</b>. Further expansion of the tetrahydrofuran ring present in compounds <b>6a</b>–<b>d</b> and <b>7a</b>–<b>d</b> afforded tetrahydropyran-containing inhibitors <b>8a</b> and <b>8b</b>. This transformation also removed the tetrahydrofuran stereocenter and thereby reduced the number of compounds that were prepared and separated. Compound <b>8a</b> displayed promising EZH2 biochemical and cell-based inhibition that was similar to that exhibited by compound <b>1</b>. However, without the intramolecular hydrogen bond present in tetrahydrofuran-containing inhibitors such as <b>7a</b> and <b>7c</b>, both <b>8a</b> and <b>8b</b> exhibited unacceptable permeability values in the MDCK-LE assessment.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. LipE and HLM clearance/permeability comparison of compounds depicted in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. Symbols indicate binned compound permeability (MDCK-LE): (×) MDCK-LE < 5 × 10<sup>–6</sup> cm/s; (○) MDCK-LE > 5 ×10<sup>–6</sup> cm/s. Colors indicate binned compound HLM clearance (HLM CL): blue, low; yellow, moderate; red, high. The log <i>D</i> was measured at pH 7.4. LipE = −[log<sub>10</sub>(Y641N <i>K</i><sub>i</sub>)] – log <i>D</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also explored whether modification of the ethyl substituent present in compounds <b>2a</b> and <b>2b</b> could lead to the desired improvements in inhibitor potency. As shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, truncation of this ethyl moiety resulted in 4- to 5-fold loss of anti-EZH2 activity (compare <b>9a</b> and <b>9b</b> with <b>2a</b>/<b>2b</b>). This result paralleled the outcomes observed when the methoxy group present in <b>2a</b>/<b>2b</b> was truncated (cf., compounds <b>3a</b>/<b>3b</b> above) and was consistent with the need for the new compounds to occupy the same spatial region as the two isoxazole methyl groups present in <b>1</b> in order to exhibit potent EZH2 inhibition properties (see <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). In contrast, expansion of the ethyl group present in <b>2a</b>/<b>2b</b> via incorporation of a tetrahydrofuran ring afforded several molecules with excellent anti-EZH2 properties that were comparable to those exhibited by compound <b>1</b> (<b>10a</b> and <b>10b</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). These inhibitors also exhibited significantly improved in vitro permeability values relative to those displayed by the analogous hydroxyl-containing compounds (compare MDCK-LE data for <b>10a</b>–<b>d</b> with <b>6a</b>–<b>d</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). However, inhibitors <b>10a</b>–<b>d</b> were all relatively labile in the in vitro metabolic stability assessments which precluded further progression of the compounds. Additional expansion of the tetrahydrofuran ring present in <b>10a</b>–<b>d</b> via incorporation of a tetrahydropyran moiety did not afford meaningful cell potency improvements (compare <b>11a</b> with <b>10a</b>). As this change unproductively increased the lipophilicity of the inhibitor series and decreased the kinetic solubility (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), additional exploration of related tetrahydropyran-containing compounds was not performed.</div><div class="NLM_p">Several piperidine moieties were then incorporated into the inhibitor design as alternatives to the tetrahydropyran (THP) moiety. These piperidine entities were envisioned to occupy space in a manner similar to the THP groups but also imparted lower log <i>D</i> values to the resulting lactam inhibitors. As shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, almost all of these new entities displayed either improved or similar EZH2 inhibitory potency and LipE values relative to <b>1</b>. However, <b>12a</b> suffered from poor permeability and <b>13a</b> displayed metabolic instability. Importantly, all of the compounds depicted in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> displayed acceptable kinetic solubility values, supporting our design strategy to improve solubility by replacing the dimethylisoxazole with the sp<sup>3</sup>-containing, nonaromatic, moieties in the lactam inhibitor series. In addition, the thermodynamic solubility of compound <b>4a</b> determined using a crystalline form of the material was significantly superior to that exhibited by compound <b>1</b> (<b>4a</b> = 34 μg/mL vs <b>1</b> = 2 μg/mL, in water with 0.5% CMC and 0.1% polysorbate 80 at 25 °C). This result provided confidence that continued optimization of the bicyclic lactams bearing a 7-position sp<sup>3</sup>-carbon atom could afford molecules that addressed the key concerns associated with compound <b>1</b>.</div><div class="NLM_p">From analysis of the data for the compounds described in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, it became apparent that the unfavorable HLM stability exhibited by compound <b>1</b> could be significantly improved while retaining potent anti-EZH2 activity. However, these enhancements typically resulted in the simultaneous erosion of in vitro permeability properties for many of the compounds in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> (e.g., compare inhibitors <b>6a</b>, <b>12a</b> with <b>1</b>). As alterations in lipophilicity frequently impact these in vitro parameters in an opposing manner (i.e., increasing log <i>D</i> often increases permeability but decreases metabolic stability), we assessed the relationship between these in vitro outcomes and the calculated compound lipophilicity to better understand and define these relationships for the lactam-containing EZH2 inhibitor series. Analysis of previously prepared compounds bearing aromatic (i.e., sp<sup>2</sup>-containing) or phenoxy (sp<sup>3</sup>-containing) R moieties appended to 7-position of the bicyclic lactam core indicated that those with calculated log <i>D</i> (clogD) values in excess of 2.9 were much less likely to afford favorable in vitro metabolic stability properties relative to molecules that were below this cutoff (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Figure 3S in Supporting Information</a>). Similar comparison of clogD values with measured MDCK-LE data suggested that inhibitors with clogD greater than 1.5 would be more likely to display acceptable in vitro permeability outcomes (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Figure 3S, Supporting Information</a>). An analysis of the joint probability of observing a molecule that is simultaneously permeable and metabolically stable as a function of clogD (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Figure 3S, Supporting Information</a>) revealed an improved likelihood of a favorable outcome for ligands with a clogD in the range of 1.5–2.9. Subsequent compound designs were prioritized to lie within this clogD range. When combined with the ligand-based inhibitor design strategy described at the beginning of this work, we anticipated that this physicochemical property-based design approach would improve the chances of identifying potent EZH2 inhibitors that also displayed superior LipE and reasonable in vitro ADME profiles.</div><div class="NLM_p">With the above strategies in mind, we revisited our exploration of utilizing piperidines as replacements for the dimethylisoxazole moiety present in compound <b>1</b>. Our prior studies with lactam-containing compounds related to <b>1</b> demonstrated that a 4-methoxy-6-methylpyridone<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> could substitute for the 4,6-dimethyl analog typically present in many EZH2 inhibitors without potency loss (e.g., <b>14</b>, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, compare to <b>1</b>). Accordingly, we frequently utilized this alternative pyridone fragment during our resumed optimization efforts as one means of modulating compound lipophilicity into the desired range. Such introduction typically reduced calculated log <i>D</i> values by 0.2–0.5 units relative to incorporation of the 4,6-dimethylpyridone moiety with larger differences sometimes noted in measured log <i>D</i> parameters. Several new piperidine-containing compounds incorporating either 4,6-dimethylpyridone or 4-methoxy-6-methylpyridone were designed to modulate the p<i>K</i><sub>a</sub> of <b>12a</b> (<b>15a/15b</b>) or to reduce the log <i>D</i> of <b>13a</b> (<b>16a</b>/<b>16b</b>, <b>17a</b>/<b>17b</b>). As shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, some of these compounds displayed potent EZH2 inhibition (<b>15a</b>, <b>16a</b>, and <b>17a</b>) and one (<b>16b</b>) exhibited the desired combination of favorable HLM stability and in vitro permeability outcomes. Encouragingly, incorporation of various sulfones into the inhibitor design in lieu of the piperidine moiety afforded several molecules with anti-EZH2 activities comparable to those of compound <b>1</b>, improved in vitro stability properties, and acceptable MDCK-LE values (e.g., <b>18a</b> and <b>19a</b>). However, extension of the methoxy group present in <b>19a</b> to a larger ethoxy moiety resulted in erosion of anti-EZH2 inhibitory properties (compounds <b>20a</b>/<b>20b</b>). We also briefly explored the use of heterocycles as piperidine replacements (e.g., the isoxazole present in <b>21a</b>/<b>21b</b>). However, the incorporation of such entities typically resulted in significant potency loss (compared with <b>6a</b>/<b>6b</b>, <b>7a</b>/<b>7b</b>, and <b>8a</b> in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Influence of R and R′ Substitutions on log <i>D</i>, Potency, and ADME Properties<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0015.gif" alt="" id="GRAPHIC-d39e1479-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0016.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">All compounds bearing chiral centers are single stereoisomers. To help depict enatiomeric pairs, the sign of the optical rotation is provided below compound number.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last"><i>K</i><sub>i</sub> values are geometric mean values from at least three independent experiments. For each experiment, <i>K</i><sub>i</sub> values are determined from 11-point dose–response curves with each dose performed in duplicate.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Unless otherwise indicated, the reported IC<sub>50</sub> values are the geometric mean of values from two independent experiments.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">The log <i>D</i> was measured at pH 7.4.</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">ND: not determined.</p></div></div><div></div></div><div class="NLM_p">In pursuit of EZH2 inhibitor potency superior to compound <b>1</b>, we also applied our ligand-based and property-based design strategies to the generation of new inhibitors that contained various cyclic ethers in their chemical structures. On the basis of the outcomes observed for related entities during our initial efforts, we anticipated that the new molecules might exhibit very potent anti-EZH2 inhibition properties (cf., compounds <b>6a</b>/<b>6b</b>, <b>8a</b>, <b>10a</b>/<b>10b</b>; <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). A comparison of the lipophilic metabolism efficiency (LipMetE)<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> of <b>6a</b> (0.7), <b>8a</b> (0.6), and <b>10a</b> (0.9) indicated that <b>10a</b> displayed the best LipMetE value among all three analogs and therefore represented a good starting point for further log <i>D</i> reduction. Therefore, in order to improve the metabolic stability for <b>10a</b>, we utilized the 4-methoxy-6-methylpyridone moiety to replace the 4,6-dimethylpyridone present in <b>10a</b>. This transformation afforded compounds <b>22a</b>–<b>d</b> that possessed calculated log <i>D</i> values between 2.0 and 2.1. As expected, these compounds generally exhibited improved in vitro HLM clearance outcomes relative to the <b>10a</b>–<b>d</b> analogs which incorporated the more lipophilic 4,6-dimethylpyridone moiety (cf., <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In spite of these enhancements, however, the absolute in vitro HLM clearance values for <b>22a</b>–<b>d</b> were not sufficiently low to support further advancement of the compounds (target of ≤30 (μL/min)/mg protein). These outcomes were consistent with the property-based analysis described above in which approximately 53% of the molecules with optimal calculated log <i>D</i> values (1.5–2.9) did not exhibit the desired in vitro stability properties. In the case of compounds <b>22a</b>–<b>d</b>, the corresponding measured log <i>D</i> values were somewhat higher than the calculated parameters (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), and this increased actual vs calculated lipophilicity likely contributed to the undesired in vitro stability.</div><div class="NLM_p">Accordingly, we decided to further reduce the clogD of new designs containing related cyclic ethers by another 0.5 units in order to further improve in vitro metabolic stability relative to compounds <b>22a</b>–<b>d</b>. This approach led to introduction of an oxetane ring into the inhibitor series as a replacement for the tetrahydrofuran moiety present in several other potent molecules. This transformation afforded compounds <b>23a</b>/<b>23b</b> which displayed improved in vitro HLM clearance values relative to both <b>22a</b>–<b>d</b> and the dimethylisoxazole-containing lead compound <b>1</b>. This modification also removed a chiral center from the tetrahydrofuran-containing structures such as <b>22a</b>–<b>d</b> and thereby simplified the molecular complexity associated with the new (sp<sup>3</sup>-center containing) inhibitors. Importantly, the more potent enantiomer (<b>23a</b>) exhibited biochemical and cell-based EZH2 inhibition activities that were superior to those displayed by compound <b>1</b> and all other analogs in this lactam series along with acceptable in vitro permeability and good kinetic solubility properties. The absolute configuration of <b>23a</b> was determined by small molecule crystal structure to be the same as that present in the potent tetrahydrofuran-containing inhibitor <b>6a</b> described above (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). This result suggested that the tetrahydrofuran and oxetane rings present in the corresponding inhibitors occupied similar regions of the EZH2 binding pocket (more details regarding such interactions are provided in the cocrystal structure discussion below). A methyl group was also added to the oxetane present in <b>23a</b>/<b>23b</b> thereby affording <b>24a</b>/<b>24b</b> to explore the impact on potency and metabolic stability. As shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, potent cellular EZH2 inhibitory activity was retained in one of the resulting enantiomers (<b>24a</b>). However, the in vitro stability parameters of the new molecules were dramatically eroded (compare <b>24a</b>/<b>24b</b> with <b>23a</b>/<b>23b</b>, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Similar replacement of the methoxy group adjacent to the oxetane in <b>23a</b>/<b>23b</b> with a hydroxy moiety resulted in unfavorably low calculated log <i>D</i> values and unacceptable measured in vitro permeability outcomes (<b>25a</b>/<b>25b</b>; clogD = 1.3).</div><div class="NLM_p">We found that emphasizing ligand designs in the clogD range of 1.5–2.9 was a useful component of our optimization strategy as it successfully afforded several new compounds with improved HLM stabilities relative to compound <b>1</b> and acceptable in vitro permeability properties. These molecules also typically exhibited LipE values that were significantly superior to that of <b>1</b> indicating that potency improvements in the new series were achieved with adequate control of molecular lipophilicity (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Unfortunately, and for unknown reasons, the more biologically potent compound among a given enantiomer pair was almost invariably also less stable in the in vitro HLM experiments. Among all the molecules depicted in <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, compound <b>23a</b> displayed the best combination of EZH2 inhibitory activity, lipophilic ligand efficiency (LipE), in vitro metabolic stability, and permeability characteristics. Although the compound’s in vitro HLM stability was slightly higher than our initial target value (39 vs 30 (μL/min)/mg protein), the molecule exhibited more favorable stability in the in vitro human hepatocyte assessments that were significantly improved relative to those observed for compound <b>1</b> (12 vs 75 (μL/min)/million cells). In addition, the thermodynamic solubility of a crystalline form of the compound was dramatically superior to that exhibited by compound <b>1</b> (<b>23a</b> = 315 μg/mL in water with 0.5% CMC and 0.1% polysorbate 80 at 25 °C). Compound <b>23a</b> also displayed longer residence time relative to <b>1</b>. The biochemical half-lives for target engagement of <b>23a</b> were determined to be about 22 and 6 h against the wild type and Y641N mutant of EZH2, respectively (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Figure 1S, Supporting Information</a>). These collective properties suggested that <b>23a</b> might overcome the liabilities that prevented progression of <b>1</b> into development, and <b>23a</b> was therefore advanced into in vivo studies to further define this potential.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. LipE and HLM clearance/permeability comparison of compounds depicted in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. Symbols indicate binned compound permeability (MDCK-LE): (×) MDCK-LE < 5 × 10<sup>–6</sup> cm/s; (○) MDCK-LE > 5 × 10<sup>–6</sup> cm/s. Colors indicate binned compound HLM clearance (HLM CL): blue, low; yellow, moderate; red, high. The log <i>D</i> was measured at pH 7.4. LipE = −[log<sub>10</sub>(Y641N <i>K</i><sub>i</sub>)] – log <i>D</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A and <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B, twice-daily oral administration of crystalline <b>23a</b> suspension formulation to mice bearing Karpas-422 DLBCL tumor xenografts (which contain the Y641N EZH2 mutation) resulted in significant inhibition of tumor growth (100 mg/kg dose) or tumor regression (300 mg/kg) with minimal impact on animal body weights. Even more profound tumor regression outcomes were observed when <b>23a</b> was dosed subcutaneously once-daily at the 100 mg/kg level (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). This profound tumor regression effect was also sustained for another 40 days after the termination of the treatment on day 31. Importantly, analysis of samples collected on day 9 of the in vivo experiment 4 h after the last dose was administered showed significant reductions in H3K27me3 levels in all tumors treated with compound <b>23a</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C). In the case of the subcutaneous dosing arm, strong day 9 reductions in tumor H3K27me3 levels correlated well with the observed tumor regressions (compare <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A and <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C). The intermediate levels of H3K27me3 reductions noted in the oral dosing arms relative to the subcutaneous group also correlated with the corresponding efficacy results (i.e., both oral arms afforded fewer H3K27me3 reductions and efficacy outcomes relative to the 100 mg/kg sc group). For reasons that are not understood at this time, analysis of the day 9 H3K27me3 tumor levels did not correlate well with the disparate long-term efficacy results observed for the two oral dosing arms. However, the tumor growth inhibition (TGI) plots corresponding to these two oral dosing groups were not well-separated at the day 9 juncture, and it is possible that additional sampling of the H3K27me3 pharmacodynamic marker beyond the day 9 time point would provide further insights into these long-term outcomes.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PK/TGI relationship for <b>23a</b> in Karpas-422 xenograft model: (A) tumor growth inhibition graph for all treatment groups; (B) body weight measurement; (C) H3K27me3 reduction for all treatment groups at day 9 (4 h after last dose); (D) plasma exposure of <b>23a</b> po 7 h/17 h b.i.d. dosing; (E) plasma exposure of <b>23a</b> sc q.d. dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also assessed the pharmacokinetic properties of compound <b>23a</b> in the tumor-bearing mice so as to better define the plasma exposures associated with strong pharmacodynamic and efficacy impacts. As shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>D, twice-daily oral administration of 300 mg/kg <b>23a</b> afforded free mouse plasma levels that exceeded the compound’s measured in vitro Karpas-422 antiproliferation IC<sub>90</sub> value for approximately 24 h (IC<sub>90</sub> = 60 nM). In contrast, similar oral dosing of <b>23a</b> at the 100 mg/kg level resulted in lower free exposures that fell below this cell IC<sub>90</sub> threshold sometime during the 7–24 h portion of the two-dose administration cycle. These exposure differences correlated with the different long-term efficacy results observed for the two oral dosing groups (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A, lower exposure = less TGI after day 35). This correlation suggested that continuous and near-complete suppression of EZH2 activity (approximated by maintaining free inhibitor levels in excess of cellular antiproliferation IC<sub>90</sub> values) was required to afford meaningful long-term TGI outcomes in the Karpas-422 model. In support of this hypothesis, free mouse plasma exposures of <b>23a</b> associated with the subcutaneous dosing arm (for which tumor regressions were observed) were even greater than those determined for either oral dosing group (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>E). The subcutaneous dosing likely bypassed the first-pass clearance of <b>23a</b> in mice (mouse hepatocytes clearance = 60.1 (μL/min)/million cells) and thus resulted in the high exposures relative to the oral dosing groups. Additional low-dose (2 mg/kg) PK studies in rats showed that the in vivo intravenous clearance was hepatic-blood-flow-limited (∼70 (mL/min)/kg). This result was consistent with in vitro metabolic clearance in rat hepatocytes (109 (μL/min)/million cells).</div><div class="NLM_p">Compound <b>23a</b> was profiled in the CEREP histone methyltransferase and broad-ligand screening panels along with kinase panel (Life Technologies) and was shown to be a highly selective EZH2 inhibitor (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Tables 1S, 2S, and 3S in Supporting Information</a>). The only other methyltransferase showing significant inhibition was EZH1. The <i>K</i><sub>i</sub> for EZH1 was determined to be 70 nM (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Figure 2S</a>) compared to a <i>K</i><sub>i</sub> of <0.1 nM for EZH2. In addition, the compound did not impair the function of various cytochrome P450 (CYPs) isoforms when tested in vitro against these enzymes (IC<sub>50</sub> values of >30 μM for CYP 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4). The molecule also did not exhibit appreciable inhibition of the human ether-à-go-go-related gene (hERG) ion channel (IC<sub>50</sub> > 100 μM) and was negative in Ames and micronucleus in vitro assessments of genotoxicity. These favorable properties, along with the encouraging in vivo PK and efficacy data described in this work and several other attributes that will be described elsewhere, enabled the selection of compound <b>23a</b> as a clinical development candidate (PF-06821497). Further details regarding related development activities and the clinical characterization of the molecule will be reported in subsequent disclosures. Importantly, <b>23a</b> displayed superior LipE among all analogs synthesized in the lactam series. This superior LipE enabled the combination of excellent potency, sufficient metabolic stability, permeability, and solubility properties. Specifically, the good thermodynamic solubility and acceptable permeability provided prediction of sufficient absorption for an oral drug to treat EZH2-related diseases.</div><div class="NLM_p">After <b>23a</b> was selected for advancement into development, we obtained a cocrystal structure of the compound with the PRC2 complex consisting of engineered <i>Anolis carolinensis</i> (American chameleon) EZH2, human EED, and the VEFS domain of human Suz12 proteins as described previously.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This structure enabled understanding of the key features required for optimal binding of the lactam inhibitors to EZH2. A related cocrystal structure of compound <b>1</b> with the identical EZH2-containing three protein complex was also obtained in order to better understand the improved potency of <b>23a</b> compared to <b>1</b>. As depicted in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A, the 4-methoxy-6-methylpyridone group of <b>23a</b> formed hydrogen bond interactions with the backbone carbonyl and amide NH moieties of Trp624 (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A). Similar interactions were observed between the EZH2 and the 4,6-dimethylpyridone moiety present in compound <b>1</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> This region of the EZH2 binding site is known to accommodate a portion of the <i>S</i>-adenosyl-<span class="smallcaps smallerCapital">l</span>-methionine (SAM) cofactor involved in the methyl transfer reaction catalyzed by the enzyme.<a onclick="showRef(event, 'cit34a cit34b'); return false;" href="javascript:void(0);" class="ref cit34a cit34b">(34a, 34b)</a> Binding of pyridone-containing inhibitors such as <b>1</b> and <b>23a</b> to EZH2 likely disrupts the ability of SAM to associate with the protein and thereby impairs the enzyme’s biological function.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Cocrystal structure of compound <b>23a</b> in complex with EZH2 (2.8 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W2R">4W2R</a>). (B) Cocrystal structure of compound <b>1</b> in complex with EZH2 (3.0 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B3W">6B3W</a>). EZH2 residues involved in key interactions with <b>23a</b> or <b>1</b> are depicted in pink.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The 4-methoxypyridone substituent of <b>23a</b> bound somewhat more favorably in the EZH2 binding pocket relative to the corresponding 4-methylpyridone group of <b>1</b>, and this difference may account for some of the subtle potency improvements observed for inhibitors described above that incorporated the former fragment in place of the latter (e.g., compare <b>22a</b> with <b>10a</b> and <b>17a</b> with <b>16a</b>, <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). The carbonyls of the lactam cores in both <b>23a</b> and <b>1</b> formed hydrogen bonds with the backbone NH of EZH2 Tyr111 (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B). As expected based on the ligand design strategy pursued above, the sp<sup>3</sup>-containing oxetane-methoxy group (R group) of <b>23a</b> occupied the same space as the dimethylisoxazole of <b>1</b>. A potential donor−π interaction between the partially polarized oxetane ring hydrogens and the EZH2 Tyr111 side chain was also observed in the <b>23a</b> cocrystal structure. This interaction, which may contribute on the order of 0.5 kcal/mol (relative to the methyl group forming a corresponding aliphatic interaction in <b>1</b>),<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and the pyridone substituent changes mentioned above are expected to account for at least some of the anti-EZH2 potency differences observed for these two inhibitors. MM-GBSA calculations (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Supporting Information</a>) were able to correctly rank this pair of compounds and therefore provided the opportunity to gain some additional insights into the binding affinity differences. Energy components from these calculations suggest that the potency improvement observed for <b>23a</b> can be primarily attributed to a significant increase in favorable electrostatic interactions between the ligand and the protein while being partially attenuated by a corresponding increase in the desolvation penalty (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Calculated MM-GBSA Binding Energy (Δ<i>E</i>) and Components<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">MM-GBSA binding energy components</th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">electrostatic</th><th class="colsep0 rowsep0" align="center" char=".">van der Waals</th><th class="colsep0 rowsep0" align="center" char=".">desolvation (GBSA)</th><th class="colsep0 rowsep0" align="center" char=".">ligand strain</th><th class="colsep0 rowsep0" align="center" char=".">protein strain</th><th class="colsep0 rowsep0" align="center" char=".">calcd Δ<i>E</i></th><th class="colsep0 rowsep0" align="center" char=".">calcd relative Δ<i>E</i></th><th class="colsep0 rowsep0" align="center" char=".">exptl Δ<i>G</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" align="char" char=".">–47.1</td><td class="colsep0 rowsep0" align="char" char=".">–59.2</td><td class="colsep0 rowsep0" align="char" char=".">42.8</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char=".">–56.8</td><td class="colsep0 rowsep0" align="char" char=".">0.0</td><td class="colsep0 rowsep0" align="char" char=".">–13.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="char" char=".">–45.2</td><td class="colsep0 rowsep0" align="char" char=".">–58.0</td><td class="colsep0 rowsep0" align="char" char=".">42.5</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">–55.8</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">–13.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">–43.3</td><td class="colsep0 rowsep0" align="char" char=".">–59.0</td><td class="colsep0 rowsep0" align="char" char=".">40.7</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char=".">–54.5</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">–12.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">–38.1</td><td class="colsep0 rowsep0" align="char" char=".">–58.8</td><td class="colsep0 rowsep0" align="char" char=".">37.0</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">–52.9</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="char" char=".">–12.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23b</b></td><td class="colsep0 rowsep0" align="char" char=".">–35.8</td><td class="colsep0 rowsep0" align="char" char=".">–58.2</td><td class="colsep0 rowsep0" align="char" char=".">34.3</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">–52.5</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char=".">–10.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6c</b></td><td class="colsep0 rowsep0" align="char" char=".">–39.2</td><td class="colsep0 rowsep0" align="char" char=".">–62.8</td><td class="colsep0 rowsep0" align="char" char=".">40.0</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td><td class="colsep0 rowsep0" align="char" char=".">–51.0</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="char" char=".">–8.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4a</b></td><td class="colsep0 rowsep0" align="char" char=".">–38.4</td><td class="colsep0 rowsep0" align="char" char=".">–53.8</td><td class="colsep0 rowsep0" align="char" char=".">37.1</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">–50.1</td><td class="colsep0 rowsep0" align="char" char=".">6.7</td><td class="colsep0 rowsep0" align="char" char=".">–10.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25a</b></td><td class="colsep0 rowsep0" align="char" char=".">–43.6</td><td class="colsep0 rowsep0" align="char" char=".">–55.1</td><td class="colsep0 rowsep0" align="char" char=".">42.7</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="char" char=".">–50.0</td><td class="colsep0 rowsep0" align="char" char=".">6.8</td><td class="colsep0 rowsep0" align="char" char=".">–12.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4b</b></td><td class="colsep0 rowsep0" align="char" char=".">–36.9</td><td class="colsep0 rowsep0" align="char" char=".">–51.1</td><td class="colsep0 rowsep0" align="char" char=".">35.3</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">–49.4</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="char" char=".">–8.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25b</b></td><td class="colsep0 rowsep0" align="char" char=".">–37.3</td><td class="colsep0 rowsep0" align="char" char=".">–56.0</td><td class="colsep0 rowsep0" align="char" char=".">38.4</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">–48.4</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td><td class="colsep0 rowsep0" align="char" char=".">–9.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>a</sup><p class="last">All units in kcal/mol.</p></div></div></div><div class="NLM_p">The <b>23a</b>-PRC2 cocrystal structure also provided useful insights regarding the reason for the stereochemistry switch associated with the active enantiomers <b>4a</b> and <b>6a</b> and the difference in binding affinities between the stereoisomers <b>6a</b>/<b>6c</b> and <b>4a</b>/<b>4b</b>. Computational modeling of the enantiomeric tetrahydrofuran-containing inhibitors <b>6a</b> and <b>6c</b> into the EZH2 binding pocket revealed a strong energetic preference for the <i>R</i>,<i>R</i>-isomer, <b>6a</b> (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A and <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>B; <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). For all stereoisomeric pairs of compounds modeled, the best-scoring binding poses from automated protein–ligand docking oriented the R-group so that the methine hydrogen was syn to the adjacent chloro group, thereby avoiding the allylic 1,3-strain present in the significantly higher-energy conformations.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> This conformational constraint resulted in the exchange of the hydroxymethyl and tetrahydrofuran groups within the protein binding pocket. MM-GBSA calculations correctly ranked the potencies of <b>6a</b> and <b>6c</b>, and an analysis of the energy components indicated that the potency differences were primarily due to more favorable protein–ligand electrostatic interactions for compound <b>6a</b> along with an increase in protein and ligand strain for <b>6c</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Optimized MM-GBSA models for stereochemical ligand pairs <b>6a</b>/<b>6c</b> and <b>4a</b>/<b>4b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It is noteworthy that for the smaller R-group in the <b>4a</b>/<b>4b</b> pair, the <i>S</i>-isomer was observed to be more potent. Modeling studies predicted that the hydroxyl group in the more potent ligand, <b>4a</b>, would bind analogously to the less potent compound, <b>6c</b> (compare <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>B and <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>C). Although the MM-GBSA calculations correctly rank the binding affinities for this ligand pair, the predicted energy difference is small (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). The slightly improved van der Waals and electrostatic interactions for <b>4a</b> are largely offset by an increase in protein strain and desolvation leading to this small predicted difference in potency. The marginal improvement in the electrostatic binding component may appear counterintuitive given the hydrogen bond present in <b>4b</b> but absent in the <b>4a</b> model; however, the relatively poor geometry<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>D) observed for this interaction suggests that its contribution should be small.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31703" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31703" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Synthesis of the Templates</h3><div class="NLM_p">The syntheses of 7-bromo-5,8-dichloro-3,4-dihydroisoquinolin-1(2<i>H</i>)-one <b>26</b> and the 4,6-dimethylpyridine-containing bromide template <b>27</b> were described in an earlier publication.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The synthesis of bromide template <b>28</b>, which featured the 4-methoxy-6-methylpyridine side chain, began with regioselective alkylation of commercially available ethyl 2,4-dihydroxy-6-methylnicotinate at the 2-hydroxy moiety using benzyl bromide in the presence of Ag<sub>2</sub>CO<sub>3</sub> at 60 °C (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The silver carbonate directed O-alkylation was selected as a deliberate synthesis strategy since O-debenzylation of the alkylated 2-pyridone was expected to be a facile process using TFA. In contrast, deprotection of <i>N</i>-benzyl 2-pyridone would likely require more forcing or hydrogenolysis conditions<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> which might cause cleavage of the aryl chlorides. Alkylation of the 2-OBn intermediate with methyl iodide in the presence of K<sub>2</sub>CO<sub>3</sub> gave methyl ether <b>29</b>. Lithium aluminum hydride reduction of the ethyl ester followed by chlorination of the benzyl alcohol with thionyl chloride afforded the alkyl chloride <b>30</b>. Finally, N-alkylation of <b>26</b><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> using KO<sup><i>t</i></sup>Bu in EtOAc provided <b>28</b>. Templates <b>27</b> and <b>28</b> were further elaborated by the following methods to produce the test compounds <b>2a</b>/<b>2b</b> through <b>25a</b>/<b>25b</b>.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 4-Methoxy-6-methylpyridine Template <b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) BnBr, Ag<sub>2</sub>CO<sub>3</sub>, THF, 60 °C, 62%; (ii) MeI, K<sub>2</sub>CO<sub>3</sub>, DMF, 89%; (iii) LiAlH<sub>4</sub>, THF, 0–25 °C, 97%; (iv) SOCl<sub>2</sub>, EtOAc, 0 °C, 95%; (v) <b>26</b>, KO<sup><i>t</i></sup>Bu, EtOAc, 75 °C, 81%.</p></p></figure></div><div id="sec3-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Synthesis of Primary Alcohols</h3><div class="NLM_p">To synthesize primary alcohol analogs <b>4a/4b</b>, <b>5a</b>/<b>5b</b>, <b>6a</b>–<b>d</b>, and <b>8a</b>/<b>8b</b>, the 4,6-dimethylpyridine template <b>27</b> was functionalized with a CH<sub>2</sub>CO<sub>2</sub>Me group at the 7-position of the dihydroisoquinolinone to serve as a flexible handle for incorporation of sp<sup>3</sup>-containing side chains (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Using modified Hartwig α-arylation conditions,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> the lithium enolate of methyl acetate, prepared in situ using <i>tert</i>-butyl((1-methoxyvinyl)oxy)dimethylsilane and LiF, was coupled with <b>27</b> in a reaction catalyzed by (<i>t-</i>Bu<sub>3</sub>P)<sub>2</sub>Pd. These α-arylation conditions afforded ester <b>31</b> in 61% yield, setting the stage for introduction of branching R groups. A representative example of this method (R = CH<sub>3</sub>), leading to compounds <b>4a</b> and <b>4b</b>, is shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The methyl branch was incorporated via alkylation α to the ester using iodomethane and sodium hydride in DMF. Ester reduction using lithium borohydride was followed by acid-catalyzed deprotection of the benzyl group to reveal the 2-pyridone. The racemic mixture was separated using chiral SFC to afford single stereoisomers. The absolute (<i>R</i>) stereochemistry of <b>4b</b> was determined by small-molecule X-ray crystallography. Crystallographic data for <b>4b</b> are available in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Supporting Information</a>.</div><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Synthetic Route of Primary Alcohols<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) [(<i>t-</i>Bu)<sub>3</sub>P]<sub>2</sub>Pd, LiF, DMF, 61%; (ii) CH<sub>3</sub>I, NaH, DMF, 0 °C, 56%; (iii) LiBH<sub>4</sub>, THF, 50 °C, 79%; (iv) TFA, DCM; then K<sub>2</sub>CO<sub>3</sub>, MeOH, 99%; (v) chiral SFC, (<i>S</i>)-isomer <b>4a</b>, 42%; (<i>R</i>)-isomer <b>4b</b>, 40%.</p></p></figure><div class="NLM_p last">Synthesis and characterization of additional analogs made by the method of <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> (<b>5a</b>/<b>5b</b>, <b>6a</b>–<b>d</b>, and <b>8a</b>/<b>8b</b>) are reported in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Supporting Information</a>, as well as an alternative C–H insertion route used to make analogs <b>7a</b>–<b>d</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Scheme S1, Supporting Information</a>).</div></div><div id="sec3-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Synthesis of Secondary Alcohols and Ethers</h3><div class="NLM_p">Synthesis of simple methyl- and ethyl-substituted secondary alcohols and ethers <b>2a</b>/<b>2b</b>, <b>3a</b>/<b>3b</b>, and <b>9a</b>/<b>9b</b> began with a Suzuki–Miyaura cross-coupling reaction of isopropenylboronic acid pinacol ester or (<i>Z</i>)-3-hexenyl-3-boronic acid catechol ester on the 4,6-dimethylpyridine template <b>27</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Ozonolysis of the alkenes (<b>32</b> and <b>33</b>) gave ketones <b>34</b> and <b>35</b>, which were reduced with NaBH<sub>4</sub> in MeOH to afford racemic mixtures of secondary alcohols. At this stage, deprotection of the benzyl group and separation of the racemic mixture by chiral SFC yielded single-enantiomer secondary alcohol analogs <b>3a</b> and <b>3b</b>. Alternatively, after reduction of ketones <b>34</b> and <b>35</b>, the resulting racemic alcohol mixtures were converted to methyl ethers (KO<sup><i>t</i></sup>Bu, MeI, DMF). The benzyl groups were then removed and the resulting racemates were separated by chiral SFC to prepare the pyridones <b>2a</b>, <b>2b</b>, <b>9a</b>, and <b>9b</b>.</div><figure id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Secondary Alcohols and Ethers <b>2a</b>, <b>2b</b>, <b>3a</b>, <b>3b</b>, <b>9a</b>, and <b>9b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) isopropenylboronic acid pinacol ester, Pd(dppf)Cl<sub>2</sub>–DCM, Na<sub>2</sub>CO<sub>3</sub>, dioxane, 70 °C, 66%; (ii) (<i>Z</i>)-3-hexenyl-3-boronic acid catechol ester, CsF, Pd(PPh<sub>3</sub>)<sub>4</sub>, dioxane, 100 °C, 88%; (iii) ozone, DCM, −70 °C, 67–94%; (iv) NaBH<sub>4</sub>, MeOH; (v) TFA, DCM; (vi) KO<sup><i>t</i></sup>Bu, MeI, DMF; (vii) chiral SFC.</p></p></figure><div class="NLM_p">More complex sp<sup>3</sup>-containing side chains were introduced via a turbo Grignard<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> reaction on an aldehyde monomer set. <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> shows a representative example of this method which led to the synthesis of the THP analogs <b>11a</b> and <b>11b</b>. The Grignard reagent was generated from the 4,6-dimethylpyridine template <b>27</b> using <i>i</i>-PrMgCl–LiCl in THF, and the resulting anion was quenched with tetrahydro-2<i>H</i>-pyran-4-carbaldehyde to give racemic secondary alcohol <b>36</b>. Alkylation of the alcohol with iodomethane/KO<i><sup>t</sup></i>Bu, TFA-promoted deprotection of the benzyl group, and separation of the racemate by chiral SFC afforded (+)-isomer <b>11a</b> and (−)-isomer <b>11b</b>. The absolute stereochemistry for these compounds was not determined.</div><figure id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Representative Synthetic Route of Secondary Alcohols and Ethers from Aldehydes<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>i</i>-PrMgCl–LiCl, tetrahydro-2<i>H</i>-pyran-4-carbaldehyde, THF, −40 to 0 °C, 46%; (ii) KO<sup>t</sup>Bu, CH<sub>3</sub>I, THF, 0–25 °C, 65%; (iii) TFA, DCM; (iv) chiral SFC; <b>11a</b>, 35%; <b>11b</b>, 34%.</p></p></figure><div class="NLM_p">Synthesis and characterization of additional analogs made by the method of <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> (<b>10a</b>–<b>d</b>, <b>18a</b>/<b>18b</b>, <b>19a</b>/<b>19b</b>, <b>20a</b>/<b>20b</b>, and <b>22a</b>–<b>d</b>) are reported in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Supporting Information</a>. A variation of this method using <i>N</i>-Boc-4-formylpiperidine as the aldehyde and additional N-functionalization steps after simultaneous Boc and benzyl deprotection by TFA afforded piperidine-containing analogs <b>12a</b>/<b>12b</b>, <b>13a</b>/<b>13b</b>, <b>15a</b>/<b>15b</b>, <b>16a</b>/<b>16b</b>, <b>17a</b>/<b>17b</b>. These procedures are described in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Supporting Information</a>.</div><figure id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Oxetane Analogs <b>23a</b> and <b>23b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) PDC, DCM, rt, 26%; (ii) <i>i</i>-PrMgCl·LiCl, THF, −65 to −10 °C, 59%; (iii) CH<sub>3</sub>I, KO<sup><i>t</i></sup>Bu, THF, 0 °C, 91%; (iv) PtO<sub>2</sub>, H<sub>2</sub> (1 atm), EtOAc, rt, 54%; (v) chiral SFC, 36% (<i>R</i>) isomer <b>23a</b> and 16% (<i>S</i>) isomer <b>23b</b>.</p></p></figure><div class="NLM_p last">Due to the chemical sensitivity of the oxetane ring, synthesis of oxetane containing analogs, including <b>23a</b>, required slightly modified conditions (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Oxidation of commercially available oxetane-3-methanol by pyridinium dichromate (PDC) with minimal workup gave crude oxetane-3-carbaldehyde <b>37</b> as a solution in dichloromethane,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> which was used immediately in the subsequent Grignard reaction. Metal–halogen exchange of 4-methoxy-6-methylpyridine-containing bromide template <b>28</b> was performed using turbo Grignard, and the resultant anion was quenched with crude aldehyde <b>37</b>. The racemic secondary alcohol thus produced, <b>38</b>, was alkylated with iodomethane as described before to give racemic ether <b>39</b>. To avoid acid-catalyzed oxetane ring opening,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> it was necessary to use hydrogenolysis to remove the benzyl group, yielding racemic pyridone <b>40</b>. The enantiomers were separated using chiral SFC to give <b>23a</b> and <b>23b</b>. The absolute stereochemistry of each enantiomer was determined by small-molecule X-ray crystallography. Crystallographic data for <b>23a</b> and <b>23b</b> are available in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Supporting Information</a>. Synthesis and characterization of additional oxetane analogs made by the method of <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> (<b>24a</b>/<b>24b</b>, <b>25a</b>/<b>25b</b>) are reported in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">Supporting Information</a> along with the methods used to prepare the remaining analogs discussed in this paper (<b>14</b>, <b>21a</b>/<b>21b</b>).</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35650" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35650" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A new series of lactam-derived EZH2 inhibitors was designed to improve in vitro human metabolic stability and thermodynamic solubility issues associated with the previously described lead compound <b>1</b>. In the absence of supporting crystallographic information, several replacements for the dimethylisoxazole group present in <b>1</b> were identified that incorporated an sp<sup>3</sup>-hybridized carbon atom attached to the 7 position of the bicyclic lactam inhibitor core. A separate property based design strategy was also employed during the optimization efforts in which correlation of calculated log <i>D</i> values with in vitro measurements of both metabolic stability and permeability identified a clogD range (1.5–2.9) that afforded an increased probability of simultaneously achieving favorable outcomes for these ADME parameters. The ligand-based and property-based design strategies described in this paper led to the identification of an oxetane-containing compound (<b>23a</b>) that displayed an adequate overlap of EZH2 inhibitory potency, in vitro ADME properties, and physical chemical properties (e.g., thermodynamic solubility). The molecule also displayed robust tumor growth inhibition activity in mouse xenograft models along with strong associated pharmacodynamic effects (such as reduction of H3K27me3 in tumors). Importantly, compound <b>23a</b> improved LipE by 2 units relative to lead compound <b>1</b> (calculated using enzyme inhibition values) and also enhanced anti-EZH2 cell potency by 5- to 6-fold. This potency improvement, coupled with the observed moderate in vitro human microsomal clearance, favorable thermodynamic solubility properties, and strong in vivo antitumor efficacy observed in preclinical models, suggested a good potential for compound <b>23a</b> to effectively modulate EZH2 activity in human clinical settings. The molecule was therefore advanced as a clinical candidate, and further details regarding its development will be reported in subsequent disclosures.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03444" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03444" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry</h3><div class="NLM_p last">All final compounds were purified to ≥95% purity. For most compounds, purity was determined by Agilent 1200 or 1260 series HPLCs coupled to an Agilent 6120 or 6140 quadrupole LC/MS with simultaneous UV (220 and 254 nm) and TIC detection (either APCI or ESI) or using a Shimadzu LC-20 HPLC with UV 220 nm detection. Purity of compounds <b>12a</b> and <b>12b</b> was determined using an Agilent 1260 Infinity Hybrid HPLC/SFC with an Aurora A5 SFC control module, DAD, Leap PAL autosampler, and 6120 single quadrupole MS detection. Purity of compounds <b>24a</b> and <b>24b</b> was determined using a Bruker XWIN-NMR (400 MHz) spectrometer with supporting data from chiral SFC analysis using the Agilent 1260 Infinity Hybrid HPLC/SFC.</div></div><div id="sec5-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Cell Culture</h3><div class="NLM_p last">Human B-cell non-Hodgkin lymphoma cell line Karpas-422 was obtained from Deutsche Sammlung von Mikroorganismen and Zellkulturen (DSMZ) in Germany, catalog no. ACC-32. Cells were cultured in RPMI 1640 plus 10–20% (v/v) FBS and 1% Pen/Strep.</div></div><div id="sec5-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> H3K27me3 ELISA Assay</h3><div class="NLM_p last">Karpas-422 cells were plated in complete cell culture medium (100 μL/well) in a 96-well clear, V bottom polystyrene cell culture plate (Costar, catalog no. 3894) at a density of 2500 cells/well. Cells were then incubated for 2–3 h at 37 °C and 5% CO<sub>2</sub>. Compound dilution plates were prepared in 96-well, clear U-bottom, polypropylene plates (Corning, catalog no. 3365) in 100% DMSO at 10 mM stock concentration in duplicate wells, using an 11-point serial dilution (1:3 dilutions). Compounds were further diluted in growth medium, and an amount of 25 μL was added to each well of the cell plates using a Beckman FX liquid handling system such that the highest compound concentration tested was 50 μM final, with a 0.5% final DMSO concentration. Plates were then incubated for 72 h at 37 °C and 5% CO<sub>2</sub>. At the end of the incubation period with compound, plates were centrifuged at 2000 rpm for 5 min at room temperature and medium was removed. Then, 100 μL of acid extracted solution was added to each well. Plates were shaken for 50 min at 4 °C to lyse cells, and then 38 μL of neutralization buffer was added. Plates were then frozen at −80 °C. The next day, plates were shaken at room temperature to thaw. Cell lysates (50 μL/well) were then transferred to ELISA plates. Plates were covered and incubated for 2.5 h at room temperature, with constant slow speed shaking. After incubation, plates were washed seven times (300 μL/well) with 1× wash buffer using a BioTek plate washer. Then 100 μL of biotinylated trimethyl histone H3K27 detection antibody was added to each well and incubated for 2 h at room temperature with constant slow speed shaking. After incubation, plates were washed as described. An amount of 100 μL of HRP-linked antibody was added to each well and incubated for 60 min at room temperature with constant slow speed shaking. After incubation, plates were washed as described. Finally, 100 μL of TMB substrate reagent was added to each well and incubated for 5 min at room temperature in the dark with slow shaking and 100 μL of stop solution was added to stop the reaction. Plates were read on the PerkinElmer Envision plate reader using the 96-well with OD reading mode. The IC<sub>50</sub> values were determined from 11-point dose–response curves and were calculated using a four-parameter fit with GraphPad Prism or in house modified IDBS ActivityBase data analyzing package.</div></div><div id="sec5-4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Cell Growth Inhibition Assay</h3><div class="NLM_p last">Karpas-422 cells were plated in complete cell culture medium (100 μL/well) in a 96-well clear, flat bottom polystyrene cell culture plate (Greiner, catalog no. 655182) at a density of 2000 cells/well. Cells were then incubated for 2–3 h at 37 °C and 5% CO<sub>2</sub>. Compound dilution plates were prepared, and compounds were further diluted in growth medium as described above. Then, 25 μL of the diluted compound was added to each well of the cell plates using a Beckman FX liquid handling system. Plates were then incubated for 72 h at 37 °C and 5% CO<sub>2.</sub> At the end of the incubation period with compound, compounds were again diluted in growth medium and an amount of 30 μL was added to each well of the cell plates using a Beckman FX liquid handling system. Plates were then incubated for 96 h at 37 °C and 5% CO<sub>2.</sub> At the end of the incubation period, plates were centrifuged at 2000 rpm for 5 min at room temperature and medium was removed. Then 100 μL of fresh complete cell culture medium was added to each well. Compounds were once more diluted in growth medium, and an amount of 25 μL was added to each well of the cell plates using a Beckman FX liquid handling system. Plates were then incubated for 72 h at 37 °C and 5% CO<sub>2</sub>. After the incubation period, plates were centrifuged at 2000 rpm for 5 min at room temperature and medium was removed. Then 100 μL of fresh complete cell culture medium was added to each well. Finally, rezasurin in PBS (1 mg/mL) was added to each well of the cell plate (15 μL/well). The plates were incubated at 37 °C and 5% CO<sub>2</sub> for 6 h in the dark. Plates were read on the PerkinElmer Envision plate reader using the 96-well with fluorescent reading mode at 530 nm excitation and 590 nm emissions. The IC<sub>50</sub> values were determined from 11-point dose–response curves and were calculated using a four-parameter fit with GraphPad Prism or in house modified IDBS ActivityBase data analyzing package.</div></div><div id="sec5-5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Microsomal Stability Assay</h3><div class="NLM_p last">Compounds (1 μM) were incubated at 37 °C for 45 min in a final volume of 200 μL of 100 mM potassium phosphate buffer (pH 7.4) containing pooled liver microsomes (0.8 mg/mL protein) and 2 mM NADPH. Reactions were initiated with the addition of NADPH following a 10 min preincubation. Aliquots of incubation samples were protein precipitated with cold methanol containing 0.1 μM buspirone (internal standard) and centrifuged, and supernatants were analyzed by LC–MS/MS. All incubations were performed in triplicate. In vitro intrinsic clearance (CL<sub>int</sub>) was calculated from half-life (<i>t</i><sub>1/2</sub>) of the parent drug disappearance, which was determined by the slope (<i>k</i>) of log–linear regression analysis from the concentration versus time profiles, i.e., <i>t</i><sub>1/2</sub> = −ln(2)/<i>k</i>.</div></div><div id="sec5-6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Cell Culture and High Throughput Permeability Assay</h3><div class="NLM_p last">The cell culturing conditions for in-house low efflux transporter MDCK (MDCK-LE) cell line (clonal cells isolated from Madin–Darby canine kidney cells, selected for low endogenous efflux transporter expression) were used to determine passive permeability. MDCK-LE cells were cultured at 37 °C, 5% CO<sub>2</sub>, 95% relative humidity in minimum essential medium that contained 10% FBS, 1% NEAA, 100 U/mL penicillin, 100 μg/mL streptomycin, and 1% <span class="smallcaps smallerCapital">l</span>-glutamine. Cells were passaged each week at about 90%, confluency. Cells were trypsinized and resuspended in complete media to obtain a cell suspension of 2.5 × 105 cells/mL and then plated onto 96-well membrane inserts, with each insert receiving a volume of 75 μL. The inserts were placed into a feeder tray containing complete growth medium. Plates were used on day 4 for transport studies. Cell inserts were washed with prewarmed transport buffer before the experiment. Monodirectional transport studies were performed with 2 μM drug solution in transport buffer with 0.1% DMSO. Drug solution was added to the donor wells, and buffer was added to the receiver wells to initiate the transport assay. The plates were incubated at 37 °C, and samples from both the donor and receiver were taken at time 0 and 90 min for LC–MS/MS analysis. Permeability was determined at donor pH 6.5 and 7.4, with receiver medium always at pH 7.4.</div></div><div id="sec5-7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> In Vivo Studies</h3><div class="NLM_p last">All procedures performed on these animals were in accordance with regulations and established guidelines and were reviewed and approved by Pfizer’s Institutional Animal Care and Use Committee.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01375">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36846" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36846" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01375" class="ext-link">10.1021/acs.jmedchem.7b01375</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic experimental procedures, analytical data, and small molecule X-ray crystal strucutres for all compounds from <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, enzymatic assay, biology experimental details, and computational method (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and compound purity data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_002.xlsx" class="ext-link">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf">jm7b01375_si_001.pdf (1.61 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_002.xlsx">jm7b01375_si_002.xlsx (15.07 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are the following: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B3W">6B3W</a> for compound <b>1</b> complexed with EZH2/EED/SUZ12; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W2R">4W2R</a> for compound <b>23a</b> complexed with EZH2/EED/SUZ12.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b01375" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42274" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42274" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pei-Pei Kung</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9203-7374" title="Orcid link">http://orcid.org/0000-0002-9203-7374</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#deaebbb7aebbb7f0b5abb0b99eaeb8b7a4bbacf0bdb1b3"><span class="__cf_email__" data-cfemail="9bebfef2ebfef2b5f0eef5fcdbebfdf2e1fee9b5f8f4f6">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Bingham</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexei Brooun</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Collins</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ya-Li Deng</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dac Dinh</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Connie Fan</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ketan S. Gajiwala</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rita Grantner</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hovhannes J. Gukasyan</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenyue Hu</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Buwen Huang</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Kania</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan E. Kephart</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cody Krivacic</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert A. Kumpf</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Penney Khamphavong</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manfred Kraus</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Liu</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen A. Maegley</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Nguyen</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shijian Ren</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dan Richter</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert A. Rollins</span> - <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neal Sach</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shikhar Sharma</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Sherrill</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jillian Spangler</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Albert E. Stewart</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Sutton</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sean Uryu</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dominique Verhelle</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui Wang</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuiwang Wang</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Wythes</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuibo Xin</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shinji Yamazaki</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huichun Zhu</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">JinJiang Zhu</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luke Zehnder</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Edwards</span> - <span class="hlFld-Affiliation affiliation">†Oncology Medicinal Chemistry, ‡Oncology Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Pharmaceutical Science
Research Enabling Group, and ⊥Drug Safety Research and Development, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pfizer Global
Research and Development, 401 N. Middletown Road, Pearl River, New York 10965, United States</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Klaus Dress for data management and visualization help and to Jeff Elleraas, Loanne Chung, and Phuong Tran for purification assistance. We also thank Curtis Moore and Alex Yanovsky for small molecule X-ray structure determination.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i27" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i27"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i28" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i28"> Abbreviations Used</h2><tr><td class="NLM_term">SMARCA2</td><td class="NLM_def"><p class="first last">SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2</p></td></tr><tr><td class="NLM_term">SMARCA4</td><td class="NLM_def"><p class="first last">SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4</p></td></tr><tr><td class="NLM_term">ARID1A</td><td class="NLM_def"><p class="first last">AT-rich interaction domain 1A</p></td></tr><tr><td class="NLM_term">SMARCB1</td><td class="NLM_def"><p class="first last">SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1</p></td></tr><tr><td class="NLM_term">SWI/SNF</td><td class="NLM_def"><p class="first last">switch/sucrose nonfermentable</p></td></tr><tr><td class="NLM_term">log <i>D</i></td><td class="NLM_def"><p class="first last">octanol/buffer (pH 7.4) distribution coefficient</p></td></tr><tr><td class="NLM_term">MDCK-LE</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney, low efflux</p></td></tr><tr><td class="NLM_term">CMC</td><td class="NLM_def"><p class="first last">carboxymethylcellulose</p></td></tr><tr><td class="NLM_term">CEREP</td><td class="NLM_def"><p class="first last">Eurofins Cerep SA</p></td></tr><tr><td class="NLM_term">MM-GBSA</td><td class="NLM_def"><p class="first last">molecular mechanics generalized born surface area</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 43 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Schuettengruber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, G.</span><span> </span><span class="NLM_article-title">Recruitment of polycomb group complexes and their role in the dynamic regulation of cell fate choice</span> <span class="citation_source-journal">Development</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">3531</span><span class="NLM_x">–</span> <span class="NLM_lpage">3542</span><span class="refDoi"> DOI: 10.1242/dev.033902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1242%2Fdev.033902" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=3531-3542&author=B.+Schuettengruberauthor=G.+Cavalli&title=Recruitment+of+polycomb+group+complexes+and+their+role+in+the+dynamic+regulation+of+cell+fate+choice&doi=10.1242%2Fdev.033902"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1242%2Fdev.033902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdev.033902%26sid%3Dliteratum%253Aachs%26aulast%3DSchuettengruber%26aufirst%3DB.%26aulast%3DCavalli%26aufirst%3DG.%26atitle%3DRecruitment%2520of%2520polycomb%2520group%2520complexes%2520and%2520their%2520role%2520in%2520the%2520dynamic%2520regulation%2520of%2520cell%2520fate%2520choice%26jtitle%3DDevelopment%26date%3D2009%26volume%3D136%26spage%3D3531%26epage%3D3542%26doi%3D10.1242%2Fdev.033902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Lewis, E. B.</span><span> </span><span class="NLM_article-title">A gene complex controlling segmentation in Drosophila</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span><span class="refDoi"> DOI: 10.1038/276565a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2F276565a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=103000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A280%3ADyaE1M%252FntlWgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1978&pages=565-570&author=E.+B.+Lewis&title=A+gene+complex+controlling+segmentation+in+Drosophila&doi=10.1038%2F276565a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A gene complex controlling segmentation in Drosophila</span></div><div class="casAuthors">Lewis E B</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">5688</span>),
    <span class="NLM_cas:pages">565-70</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The bithorax gene complex in Drosophila contains a minimum of eight genes that seem to code for substances controlling levels of thoracic and abdominal development.  The state of repression of at least four of these genes is controlled by cis-regulatory elements and a separate locus (Polycomb) seems to code for a repressor of the complex.  The wild-type and mutant segmentation patterns are consistent with an antero-posterior gradient in repressor concentration along the embryo and a proximo-distal gradient along the chromosome in the affinities for repressor of each gene's cis-regulatory element.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkFLr2ycH_oSsZ1x6zOs0vfW6udTcc2eZGPKdHURWeKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE1M%252FntlWgsQ%253D%253D&md5=984f6a3650a54711616639bbdc5fa131</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F276565a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F276565a0%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DE.%2BB.%26atitle%3DA%2520gene%2520complex%2520controlling%2520segmentation%2520in%2520Drosophila%26jtitle%3DNature%26date%3D1978%26volume%3D276%26spage%3D565%26epage%3D570%26doi%3D10.1038%2F276565a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Margueron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinberg, D.</span><span> </span><span class="NLM_article-title">The polycomb complex PRC2 and its mark in life</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">469</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span><span class="refDoi"> DOI: 10.1038/nature09784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnature09784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=21248841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVOisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=343-349&author=R.+Margueronauthor=D.+Reinberg&title=The+polycomb+complex+PRC2+and+its+mark+in+life&doi=10.1038%2Fnature09784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The Polycomb complex PRC2 and its mark in life</span></div><div class="casAuthors">Margueron, Raphael; Reinberg, Danny</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7330</span>),
    <span class="NLM_cas:pages">343-349</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Polycomb group proteins maintain the gene-expression pattern of different cells that is set during early development by regulating chromatin structure.  In mammals, 2 main Polycomb group complexes exist: Polycomb repressive complex 1 (PRC1) and 2 (PRC2).  PRC1 compacts chromatin and catalyzes the monoubiquitination of histone H2A.  PRC2 also contributes to chromatin compaction, and catalyzes the methylation of histone H3 at Lys-27.  PRC2 is involved in various biol. processes, including differentiation, maintaining cell identity and proliferation, and stem-cell plasticity.  Recent studies of PRC2 have expanded the perspectives on its function and regulation, and uncovered a role for non-coding RNA in the recruitment of PRC2 to target genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7fYmuBqnMA7Vg90H21EOLACvtfcHk0lgPqiLl9SXVUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVOisA%253D%253D&md5=5f15e91cc6ff765f649842041f333841</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature09784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09784%26sid%3Dliteratum%253Aachs%26aulast%3DMargueron%26aufirst%3DR.%26aulast%3DReinberg%26aufirst%3DD.%26atitle%3DThe%2520polycomb%2520complex%2520PRC2%2520and%2520its%2520mark%2520in%2520life%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D343%26epage%3D349%26doi%3D10.1038%2Fnature09784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Di Croce, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helin, K.</span><span> </span><span class="NLM_article-title">Transcriptional regulation by polycomb group proteins</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1147</span><span class="NLM_x">–</span> <span class="NLM_lpage">1155</span><span class="refDoi"> DOI: 10.1038/nsmb.2669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnsmb.2669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=24096405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOiurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1147-1155&author=L.+Di+Croceauthor=K.+Helin&title=Transcriptional+regulation+by+polycomb+group+proteins&doi=10.1038%2Fnsmb.2669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional regulation by Polycomb group proteins</span></div><div class="casAuthors">Di Croce, Luciano; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1147-1155</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Polycomb group (PcG) proteins are epigenetic regulators of transcription that have key roles in stem-cell identity, differentiation and disease.  Mechanistically, they function within multiprotein complexes, called Polycomb repressive complexes (PRCs), which modify histones (and other proteins) and silence target genes.  The dynamics of PRC1 and PRC2 components has been the focus of recent research.  Here we discuss our current knowledge of the PRC complexes, how they are targeted to chromatin and how the high diversity of the PcG proteins allows these complexes to influence cell identity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrArNyrbNU897Vg90H21EOLACvtfcHk0lgPqiLl9SXVUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOiurrP&md5=004c2682edbda681e9f6de84ba87e639</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2669%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BCroce%26aufirst%3DL.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DTranscriptional%2520regulation%2520by%2520polycomb%2520group%2520proteins%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1147%26epage%3D1155%26doi%3D10.1038%2Fnsmb.2669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Yamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span> </span><span class="NLM_article-title">Regulation and role of EZH2 in cancer</span> <span class="citation_source-journal">Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span><span class="refDoi"> DOI: 10.4143/crt.2014.46.3.209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.4143%2Fcrt.2014.46.3.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=25038756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlaisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=209-222&author=H.+Yamaguchiauthor=M.+C.+Hung&title=Regulation+and+role+of+EZH2+in+cancer&doi=10.4143%2Fcrt.2014.46.3.209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and role of EZH2 in cancer</span></div><div class="casAuthors">Yamaguchi, Hirohito; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-222</span>CODEN:
                <span class="NLM_cas:coden">CRTAC2</span>;
        ISSN:<span class="NLM_cas:issn">2005-9256</span>.
    
            (<span class="NLM_cas:orgname">Korean Cancer Association</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) is the epigenetic regulator that induces histone H3 lysine 27 methylation (H3K27me3) and silences specific gene transcription.  Enhancer of zeste homolog 2 (EZH2) is an enzymic subunit of PRC2, and evidence shows that EZH2 plays an essential role in cancer initiation, development, progression, metastasis, and drug resistance.  EZH2 expression is indeed regulated by various oncogenic transcription factors, tumor suppressor miRNAs, and cancer-assocd. non-coding RNA.  EZH2 activity is also controlled by post-translational modifications, which are deregulated in cancer.  The canonical role of EZH2 is gene silencing through H3K27me3, but accumulating evidence shows that EZH2 methlyates substrates other than histone and has methylase-independent functions.  These non-canonical functions of EZH2 are shown to play a role in cancer progression.  In this review, we summarize current information on the regulation and roles of EZH2 in cancer.  We also discuss various therapeutic approaches to targeting EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdVidEmS4fsrVg90H21EOLACvtfcHk0lhvKQw3khy7Kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlaisLk%253D&md5=78ba72a545b0b8c2c8bb8b255cc76259</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2014.46.3.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2014.46.3.209%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DRegulation%2520and%2520role%2520of%2520EZH2%2520in%2520cancer%26jtitle%3DCancer%2520Res.%2520Treat.%26date%3D2014%26volume%3D46%26spage%3D209%26epage%3D222%26doi%3D10.4143%2Fcrt.2014.46.3.209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Morin, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mungall, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goya, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolcock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuchenbauer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, O. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimbara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shashkin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlot, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tcherpakov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varhol, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smailus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moksa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birol, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirst, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marra, M. A.</span><span> </span><span class="NLM_article-title">Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1038/ng.518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fng.518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=20081860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntVGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=181-185&author=R.+D.+Morinauthor=N.+A.+Johnsonauthor=T.+M.+Seversonauthor=A.+J.+Mungallauthor=J.+Anauthor=R.+Goyaauthor=J.+E.+Paulauthor=M.+Boyleauthor=B.+W.+Woolcockauthor=F.+Kuchenbauerauthor=D.+Yapauthor=R.+K.+Humphriesauthor=O.+L.+Griffithauthor=S.+Shahauthor=H.+Zhuauthor=M.+Kimbaraauthor=P.+Shashkinauthor=J.+F.+Charlotauthor=M.+Tcherpakovauthor=R.+Corbettauthor=A.+Tamauthor=R.+Varholauthor=D.+Smailusauthor=M.+Moksaauthor=Y.+Zhaoauthor=A.+Delaneyauthor=H.+Qianauthor=I.+Birolauthor=J.+Scheinauthor=R.+Mooreauthor=R.+Holtauthor=D.+E.+Horsmanauthor=J.+M.+Connorsauthor=S.+Jonesauthor=S.+Aparicioauthor=M.+Hirstauthor=R.+D.+Gascoyneauthor=M.+A.+Marra&title=Somatic+mutations+altering+EZH2+%28Tyr641%29+in+follicular+and+diffuse+large+B-cell+lymphomas+of+germinal-center+origin&doi=10.1038%2Fng.518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin</span></div><div class="casAuthors">Morin, Ryan D.; Johnson, Nathalie A.; Severson, Tesa M.; Mungall, Andrew J.; An, Jianghong; Goya, Rodrigo; Paul, Jessica E.; Boyle, Merrill; Woolcock, Bruce W.; Kuchenbauer, Florian; Yap, Damian; Humphries, R. Keith; Griffith, Obi L.; Shah, Sohrab; Zhu, Henry; Kimbara, Michelle; Shashkin, Pavel; Charlot, Jean F.; Tcherpakov, Marianna; Corbett, Richard; Tam, Angela; Varhol, Richard; Smailus, Duane; Moksa, Michelle; Zhao, Yongjun; Delaney, Allen; Qian, Hong; Birol, Inanc; Schein, Jacqueline; Moore, Richard; Holt, Robert; Horsman, Doug E.; Connors, Joseph M.; Jones, Steven; Aparicio, Samuel; Hirst, Martin; Gascoyne, Randy D.; Marra, Marco A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-185</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Follicular lymphoma (FL) and the GCB subtype of diffuse large B-cell lymphoma (DLBCL) derive from germinal center B cells.  Targeted resequencing studies have revealed mutations in various genes encoding proteins in the NF-κB pathway that contribute to the activated B-cell (ABC) DLBCL subtype, but thus far few GCB-specific mutations have been identified.  Here the authors report recurrent somatic mutations affecting the polycomb-group oncogene EZH2, which encodes a histone methyltransferase responsible for trimethylating Lys27 of histone H3 (H3K27).  After the recent discovery of mutations in KDM6A (UTX), which encodes the histone H3K27me3 demethylase UTX, in several cancer types, EZH2 is the second histone methyltransferase gene mutated in cancer.  These mutations, which result in the replacement of a single tyrosine in the SET domain of the EZH2 protein (Tyr641), occur in 21.7% of GCB DLBCLs and 7.2% of FLs and are absent from ABC DLBCLs.  The authors' data are consistent with the notion that EZH2 proteins with mutant Tyr641 have reduced enzymic activity in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvpFnajONCXbVg90H21EOLACvtfcHk0lhvKQw3khy7Kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntVGitQ%253D%253D&md5=ab68fe6e8932e720c4e7be82fe35932a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fng.518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.518%26sid%3Dliteratum%253Aachs%26aulast%3DMorin%26aufirst%3DR.%2BD.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DSeverson%26aufirst%3DT.%2BM.%26aulast%3DMungall%26aufirst%3DA.%2BJ.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DGoya%26aufirst%3DR.%26aulast%3DPaul%26aufirst%3DJ.%2BE.%26aulast%3DBoyle%26aufirst%3DM.%26aulast%3DWoolcock%26aufirst%3DB.%2BW.%26aulast%3DKuchenbauer%26aufirst%3DF.%26aulast%3DYap%26aufirst%3DD.%26aulast%3DHumphries%26aufirst%3DR.%2BK.%26aulast%3DGriffith%26aufirst%3DO.%2BL.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DKimbara%26aufirst%3DM.%26aulast%3DShashkin%26aufirst%3DP.%26aulast%3DCharlot%26aufirst%3DJ.%2BF.%26aulast%3DTcherpakov%26aufirst%3DM.%26aulast%3DCorbett%26aufirst%3DR.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DVarhol%26aufirst%3DR.%26aulast%3DSmailus%26aufirst%3DD.%26aulast%3DMoksa%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DDelaney%26aufirst%3DA.%26aulast%3DQian%26aufirst%3DH.%26aulast%3DBirol%26aufirst%3DI.%26aulast%3DSchein%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DHolt%26aufirst%3DR.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DAparicio%26aufirst%3DS.%26aulast%3DHirst%26aufirst%3DM.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26atitle%3DSomatic%2520mutations%2520altering%2520EZH2%2520%2528Tyr641%2529%2520in%2520follicular%2520and%2520diffuse%2520large%2520B-cell%2520lymphomas%2520of%2520germinal-center%2520origin%26jtitle%3DNat.%2520Genet.%26date%3D2010%26volume%3D42%26spage%3D181%26epage%3D185%26doi%3D10.1038%2Fng.518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Morin, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez-Lago, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mungall, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goya, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mungall, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzywinski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinh, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura-Wells, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firme, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakovenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smailus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moksa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chittaranjan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimsza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks-Wilson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinelli, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Neriah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meissner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolcock, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterfield, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birol, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirst, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marra, M. A.</span><span> </span><span class="NLM_article-title">Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">476</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">303</span><span class="refDoi"> DOI: 10.1038/nature10351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnature10351" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=476&publication_year=2011&pages=298-303&author=R.+D.+Morinauthor=M.+Mendez-Lagoauthor=A.+J.+Mungallauthor=R.+Goyaauthor=K.+L.+Mungallauthor=R.+D.+Corbettauthor=N.+A.+Johnsonauthor=T.+M.+Seversonauthor=R.+Chiuauthor=M.+Fieldauthor=S.+Jackmanauthor=M.+Krzywinskiauthor=D.+W.+Scottauthor=D.+L.+Trinhauthor=J.+Tamura-Wellsauthor=S.+Liauthor=M.+R.+Firmeauthor=S.+Rogicauthor=M.+Griffithauthor=S.+Chanauthor=O.+Yakovenkoauthor=I.+M.+Meyerauthor=E.+Y.+Zhaoauthor=D.+Smailusauthor=M.+Moksaauthor=S.+Chittaranjanauthor=L.+Rimszaauthor=A.+Brooks-Wilsonauthor=J.+J.+Spinelliauthor=S.+Ben-Neriahauthor=B.+Meissnerauthor=B.+Woolcockauthor=M.+Boyleauthor=H.+McDonaldauthor=A.+Tamauthor=Y.+Zhaoauthor=A.+Delaneyauthor=T.+Zengauthor=K.+Tseauthor=Y.+Butterfieldauthor=I.+Birolauthor=R.+Holtauthor=J.+Scheinauthor=D.+E.+Horsmanauthor=R.+Mooreauthor=S.+J.+Jonesauthor=J.+M.+Connorsauthor=M.+Hirstauthor=R.+D.+Gascoyneauthor=M.+A.+Marra&title=Frequent+mutation+of+histone-modifying+genes+in+non-Hodgkin+lymphoma&doi=10.1038%2Fnature10351"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature10351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10351%26sid%3Dliteratum%253Aachs%26aulast%3DMorin%26aufirst%3DR.%2BD.%26aulast%3DMendez-Lago%26aufirst%3DM.%26aulast%3DMungall%26aufirst%3DA.%2BJ.%26aulast%3DGoya%26aufirst%3DR.%26aulast%3DMungall%26aufirst%3DK.%2BL.%26aulast%3DCorbett%26aufirst%3DR.%2BD.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DSeverson%26aufirst%3DT.%2BM.%26aulast%3DChiu%26aufirst%3DR.%26aulast%3DField%26aufirst%3DM.%26aulast%3DJackman%26aufirst%3DS.%26aulast%3DKrzywinski%26aufirst%3DM.%26aulast%3DScott%26aufirst%3DD.%2BW.%26aulast%3DTrinh%26aufirst%3DD.%2BL.%26aulast%3DTamura-Wells%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DFirme%26aufirst%3DM.%2BR.%26aulast%3DRogic%26aufirst%3DS.%26aulast%3DGriffith%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DYakovenko%26aufirst%3DO.%26aulast%3DMeyer%26aufirst%3DI.%2BM.%26aulast%3DZhao%26aufirst%3DE.%2BY.%26aulast%3DSmailus%26aufirst%3DD.%26aulast%3DMoksa%26aufirst%3DM.%26aulast%3DChittaranjan%26aufirst%3DS.%26aulast%3DRimsza%26aufirst%3DL.%26aulast%3DBrooks-Wilson%26aufirst%3DA.%26aulast%3DSpinelli%26aufirst%3DJ.%2BJ.%26aulast%3DBen-Neriah%26aufirst%3DS.%26aulast%3DMeissner%26aufirst%3DB.%26aulast%3DWoolcock%26aufirst%3DB.%26aulast%3DBoyle%26aufirst%3DM.%26aulast%3DMcDonald%26aufirst%3DH.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DDelaney%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DT.%26aulast%3DTse%26aufirst%3DK.%26aulast%3DButterfield%26aufirst%3DY.%26aulast%3DBirol%26aufirst%3DI.%26aulast%3DHolt%26aufirst%3DR.%26aulast%3DSchein%26aufirst%3DJ.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DS.%2BJ.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DHirst%26aufirst%3DM.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26atitle%3DFrequent%2520mutation%2520of%2520histone-modifying%2520genes%2520in%2520non-Hodgkin%2520lymphoma%26jtitle%3DNature%26date%3D2011%26volume%3D476%26spage%3D298%26epage%3D303%26doi%3D10.1038%2Fnature10351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">McCabe, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganji, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halsey, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitheman, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappalardi, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Pietra, A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dul, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thrall, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruger, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creasy, C. L.</span><span> </span><span class="NLM_article-title">Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">2989</span><span class="NLM_x">–</span> <span class="NLM_lpage">2994</span><span class="refDoi"> DOI: 10.1073/pnas.1116418109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1073%2Fpnas.1116418109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=22323599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wmtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=2989-2994&author=M.+T.+McCabeauthor=A.+P.+Gravesauthor=G.+Ganjiauthor=E.+Diazauthor=W.+S.+Halseyauthor=Y.+Jiangauthor=K.+N.+Smithemanauthor=H.+M.+Ottauthor=M.+B.+Pappalardiauthor=K.+E.+Allenauthor=S.+B.+Chenauthor=A.+Della+Pietraauthor=E.+Dulauthor=A.+M.+Hughesauthor=S.+A.+Gilbertauthor=S.+H.+Thrallauthor=P.+J.+Tumminoauthor=R.+G.+Krugerauthor=M.+Brandtauthor=B.+Schwartzauthor=C.+L.+Creasy&title=Mutation+of+A677+in+histone+methyltransferase+EZH2+in+human+B-cell+lymphoma+promotes+hypertrimethylation+of+histone+H3+on+lysine+27+%28H3K27%29&doi=10.1073%2Fpnas.1116418109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)</span></div><div class="casAuthors">McCabe, Michael T.; Graves, Alan P.; Ganji, Gopinath; Diaz, Elsie; Halsey, Wendy S.; Jiang, Yong; Smitheman, Kimberly N.; Ott, Heidi M.; Pappalardi, Melissa B.; Allen, Kimberly E.; Chen, Stephanie B.; Della Pietra, Anthony, III; Dul, Edward; Hughes, Ashley M.; Gilbert, Seth A.; Thrall, Sara H.; Tummino, Peter J.; Kruger, Ryan G.; Brandt, Martin; Schwartz, Benjamin; Creasy, Caretha L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2989-2994, S2989/1-S2989/21</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Trimethylation of histone H3 on lysine 27 (H3K27me3) is a repressive posttranslational modification mediated by the histone methyltransferase EZH2.  EZH2 is a component of the polycomb repressive complex 2 and is overexpressed in many cancers.  In B-cell lymphomas, its substrate preference is frequently altered through somatic mutation of the EZH2 Y641 residue.  Herein, we identify mutation of EZH2 A677 to a glycine (A677G) among lymphoma cell lines and primary tumor specimens.  Similar to Y641 mutant cell lines, an A677G mutant cell line revealed aberrantly elevated H3K27me3 and decreased monomethylated H3K27 (H3K27me1) and dimethylated H3K27 (H3K27me2).  A677G EZH2 possessed catalytic activity with a substrate specificity that was distinct from those of both WT EZH2 and Y641 mutants.  Whereas WT EZH2 displayed a preference for substrates with less methylation [unmethylated H3K27 (H3K27me0):me1:me2 kcat/Km ratio = 9:6:1] and Y641 mutants preferred substrates with greater methylation (H3K27me0:me1:me2 kcat/Km ratio = 1:2:13), the A677G EZH2 demonstrated nearly equal efficiency for all three substrates (H3K27me0:me1:me2 kcat/Km ratio = 1.1:0.6:1).  When transiently expressed in cells, A677G EZH2, but not WT EZH2, increased global H3K27me3 and decreased H3K27me2.  Structural modeling of WT and mutant EZH2 suggested that the A677G mutation acquires the ability to methylate H3K27me2 through enlargement of the lysine tunnel while preserving activity with H3K27me0/me1 substrates through retention of the Y641 residue that is crucial for orientation of these smaller substrates.  This mutation highlights the interplay between Y641 and A677 residues in the substrate specificity of EZH2 and identifies another lymphoma patient population that harbors an activating mutation of EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-iaHX1dsb2rVg90H21EOLACvtfcHk0li4gXIj8Ydfjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wmtrc%253D&md5=4c7febc82c66aa88f27642eb7267291b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1116418109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1116418109%26sid%3Dliteratum%253Aachs%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DGraves%26aufirst%3DA.%2BP.%26aulast%3DGanji%26aufirst%3DG.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DHalsey%26aufirst%3DW.%2BS.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DOtt%26aufirst%3DH.%2BM.%26aulast%3DPappalardi%26aufirst%3DM.%2BB.%26aulast%3DAllen%26aufirst%3DK.%2BE.%26aulast%3DChen%26aufirst%3DS.%2BB.%26aulast%3DDella%2BPietra%26aufirst%3DA.%26aulast%3DDul%26aufirst%3DE.%26aulast%3DHughes%26aufirst%3DA.%2BM.%26aulast%3DGilbert%26aufirst%3DS.%2BA.%26aulast%3DThrall%26aufirst%3DS.%2BH.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26atitle%3DMutation%2520of%2520A677%2520in%2520histone%2520methyltransferase%2520EZH2%2520in%2520human%2520B-cell%2520lymphoma%2520promotes%2520hypertrimethylation%2520of%2520histone%2520H3%2520on%2520lysine%252027%2520%2528H3K27%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D2989%26epage%3D2994%26doi%3D10.1073%2Fpnas.1116418109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Sneeringer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutson, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span> </span><span class="NLM_article-title">Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">20980</span><span class="NLM_x">–</span> <span class="NLM_lpage">20985</span><span class="refDoi"> DOI: 10.1073/pnas.1012525107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1073%2Fpnas.1012525107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=21078963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFyrsbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=20980-20985&author=C.+J.+Sneeringerauthor=M.+P.+Scottauthor=K.+W.+Kuntzauthor=S.+K.+Knutsonauthor=R.+M.+Pollockauthor=V.+M.+Richonauthor=R.+A.+Copeland&title=Coordinated+activities+of+wild-type+plus+mutant+EZH2+drive+tumor-associated+hypertrimethylation+of+lysine+27+on+histone+H3+%28H3K27%29+in+human+B-cell+lymphomas&doi=10.1073%2Fpnas.1012525107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas</span></div><div class="casAuthors">Sneeringer, Christopher J.; Scott, Margaret Porter; Kuntz, Kevin W.; Knutson, Sarah K.; Pollock, Roy M.; Richon, Victoria M.; Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">20980-20985, S20980/1-S20980/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">EZH2, the catalytic subunit of the PRC2 complex, catalyzes the mono- through trimethylation of lysine 27 on histone H3 (H3K27).  Histone H3K27 trimethylation is a mechanism for suppressing transcription of specific genes that are proximal to the site of histone modification.  Point mutations of the EZH2 gene (Tyr641) have been reported to be linked to subsets of human B-cell lymphoma.  The mutant allele is always found assocd. with a wild-type allele (heterozygous) in disease cells, and the mutations were reported to ablate the enzymic activity of the PRC2 complex for methylating an unmodified peptide substrate.  Here we demonstrate that the WT enzyme displays greatest catalytic efficiency (kcat/K) for the zero to monomethylation reaction of H3K27 and diminished efficiency for subsequent (mono- to di- and di- to trimethylation) reactions.  In stark contrast, the disease-assocd. Y641 mutations display very limited ability to perform the first methylation reaction, but have enhanced catalytic efficiency for the subsequent reactions, relative to the WT enzyme.  These results imply that the malignant phenotype of disease requires the combined activities of a H3K27 monomethylating enzyme (PRC2 contg. WT EZH2 or EZH1) together with the mutant PRC2s for augmented conversion of H3K27 to the trimethylated form.  To our knowledge, this is the first example of a human disease that is dependent on the coordinated activities of normal and disease-assocd. mutant enzymic function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSX_ULvZOGabVg90H21EOLACvtfcHk0li4gXIj8Ydfjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFyrsbnF&md5=6766432aad387c36c29e7763750e4254</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1012525107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1012525107%26sid%3Dliteratum%253Aachs%26aulast%3DSneeringer%26aufirst%3DC.%2BJ.%26aulast%3DScott%26aufirst%3DM.%2BP.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DCoordinated%2520activities%2520of%2520wild-type%2520plus%2520mutant%2520EZH2%2520drive%2520tumor-associated%2520hypertrimethylation%2520of%2520lysine%252027%2520on%2520histone%2520H3%2520%2528H3K27%2529%2520in%2520human%2520B-cell%2520lymphomas%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D20980%26epage%3D20985%26doi%3D10.1073%2Fpnas.1012525107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">McCabe, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganji, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korenchuk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Aller, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Pietra, A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaFrance, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duquenne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruger, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhanak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creasy, C. L.</span><span> </span><span class="NLM_article-title">EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">492</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1038/nature11606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnature11606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=23051747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyktbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=108-112&author=M.+T.+McCabeauthor=H.+M.+Ottauthor=G.+Ganjiauthor=S.+Korenchukauthor=C.+Thompsonauthor=G.+S.+Van+Allerauthor=Y.+Liuauthor=A.+P.+Gravesauthor=A.+Della+Pietraauthor=E.+Diazauthor=L.+V.+LaFranceauthor=M.+Mellingerauthor=C.+Duquenneauthor=X.+Tianauthor=R.+G.+Krugerauthor=C.+F.+McHughauthor=M.+Brandtauthor=W.+H.+Millerauthor=D.+Dhanakauthor=S.+K.+Vermaauthor=P.+J.+Tumminoauthor=C.+L.+Creasy&title=EZH2+inhibition+as+a+therapeutic+strategy+for+lymphoma+with+EZH2-activating+mutations&doi=10.1038%2Fnature11606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations</span></div><div class="casAuthors">McCabe, Michael T.; Ott, Heidi M.; Ganji, Gopinath; Korenchuk, Susan; Thompson, Christine; Van Aller, Glenn S.; Liu, Yan; Graves, Alan P.; Della Pietra, Anthony , III; Diaz, Elsie; LaFrance, Louis V.; Mellinger, Mark; Duquenne, Celine; Tian, Xinrong; Kruger, Ryan G.; McHugh, Charles F.; Brandt, Martin; Miller, William H.; Dhanak, Dashyant; Verma, Sharad K.; Tummino, Peter J.; Creasy, Caretha L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7427</span>),
    <span class="NLM_cas:pages">108-112</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In eukaryotes, post-translational modification of histones is crit. for regulation of chromatin structure and gene expression.  EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is involved in repressing gene expression through methylation of histone H3 on lysine 27 (H3K27).  EZH2 overexpression is implicated in tumorigenesis and correlates with poor prognosis in several tumor types.  Addnl., somatic heterozygous mutations of Y641 and A677 residues within the catalytic SET domain of EZH2 occur in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.  The Y641 residue is the most frequently mutated residue, with up to 22% of germinal center B-cell DLBCL and follicular lymphoma harbouring mutations at this site.  These lymphomas have increased H3K27 tri-methylation (H3K27me3) owing to altered substrate preferences of the mutant enzymes.  However, it is unknown whether specific, direct inhibition of EZH2 methyltransferase activity will be effective in treating EZH2 mutant lymphomas.  Here we demonstrate that GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-mol. inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes.  GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice.  Together, these data demonstrate that pharmacol. inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxw5cLmW3Lc7Vg90H21EOLACvtfcHk0li3bIF57ez_EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyktbjL&md5=a1dff99556de004c48aae88bc45dffab</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature11606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11606%26sid%3Dliteratum%253Aachs%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DOtt%26aufirst%3DH.%2BM.%26aulast%3DGanji%26aufirst%3DG.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGraves%26aufirst%3DA.%2BP.%26aulast%3DDella%2BPietra%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DLaFrance%26aufirst%3DL.%2BV.%26aulast%3DMellinger%26aufirst%3DM.%26aulast%3DDuquenne%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DVerma%26aufirst%3DS.%2BK.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26atitle%3DEZH2%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520lymphoma%2520with%2520EZH2-activating%2520mutations%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D108%26epage%3D112%26doi%3D10.1038%2Fnature11606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karnezis, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colborne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendricks, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlando, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kommoss, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bally, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trent, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissman, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntsman, D. G.</span><span> </span><span class="NLM_article-title">The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">242</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span><span class="refDoi"> DOI: 10.1002/path.4912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1002%2Fpath.4912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=28444909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVGgtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=242&publication_year=2017&pages=371-383&author=Y.+Wangauthor=S.+Y.+Chenauthor=A.+N.+Karnezisauthor=S.+Colborneauthor=N.+D.+Santosauthor=J.+D.+Langauthor=W.+P.+Hendricksauthor=K.+A.+Orlandoauthor=D.+Yapauthor=F.+Kommossauthor=M.+B.+Ballyauthor=G.+B.+Morinauthor=J.+M.+Trentauthor=B.+E.+Weissmanauthor=D.+G.+Huntsman&title=The+histone+methyltransferase+EZH2+is+a+therapeutic+target+in+small+cell+carcinoma+of+the+ovary%2C+hypercalcaemic+type&doi=10.1002%2Fpath.4912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type</span></div><div class="casAuthors">Wang, Yemin; Chen, Shary Yuting; Karnezis, Anthony N.; Colborne, Shane; Santos, Nancy Dos; Lang, Jessica D.; Hendricks, William P. D.; Orlando, Krystal A.; Yap, Damian; Kommoss, Friedrich; Bally, Marcel B.; Morin, Gregg B.; Trent, Jeffrey M.; Weissman, Bernard E.; Huntsman, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">242</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-383</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare but aggressive and untreatable malignancy affecting young women.  We and others recently discovered that SMARCA4, a gene encoding the ATPase of the SWI/SNF chromatin-remodelling complex, is the only gene recurrently mutated in the majority of SCCOHT.  The low somatic complexity of SCCOHT genomes and the prominent role of the SWI/SNF chromatin-remodelling complex in transcriptional control of genes suggest that SCCOHT cells may rely on epigenetic rewiring for oncogenic transformation.  Herein, we report that approx. 80% (19/24) of SCCOHT tumor samples have strong expression of the histone methyltransferase EZH2 by immunohistochem., with the rest expressing variable amts. of EZH2.  Re-expression of SMARCA4 suppressed the expression of EZH2 in SCCOHT cells.  In comparison to other ovarian cell lines, SCCOHT cells displayed hypersensitivity to EZH2 shRNAs and two selective EZH2 inhibitors, GSK126 and EPZ-6438.  EZH2 inhibitors induced cell cycle arrest, apoptosis, and cell differentiation in SCCOHT cells, along with the induction of genes involved in cell cycle regulation, apoptosis, and neuron-like differentiation.  EZH2 inhibitors suppressed tumor growth and improved the survival of mice bearing SCCOHT xenografts.  Therefore, our data suggest that loss of SMARCA4 creates a dependency on the catalytic activity of EZH2 in SCCOHT cells and that pharmacol. inhibition of EZH2 is a promising therapeutic strategy for treating this disease.  Copyright © 2017 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCsuuR8BhKEbVg90H21EOLACvtfcHk0li3bIF57ez_EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVGgtLnE&md5=1cd2e025db63df09b8ec3bf5e1a6e1ae</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fpath.4912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4912%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DS.%2BY.%26aulast%3DKarnezis%26aufirst%3DA.%2BN.%26aulast%3DColborne%26aufirst%3DS.%26aulast%3DSantos%26aufirst%3DN.%2BD.%26aulast%3DLang%26aufirst%3DJ.%2BD.%26aulast%3DHendricks%26aufirst%3DW.%2BP.%26aulast%3DOrlando%26aufirst%3DK.%2BA.%26aulast%3DYap%26aufirst%3DD.%26aulast%3DKommoss%26aufirst%3DF.%26aulast%3DBally%26aufirst%3DM.%2BB.%26aulast%3DMorin%26aufirst%3DG.%2BB.%26aulast%3DTrent%26aufirst%3DJ.%2BM.%26aulast%3DWeissman%26aufirst%3DB.%2BE.%26aulast%3DHuntsman%26aufirst%3DD.%2BG.%26atitle%3DThe%2520histone%2520methyltransferase%2520EZH2%2520is%2520a%2520therapeutic%2520target%2520in%2520small%2520cell%2520carcinoma%2520of%2520the%2520ovary%252C%2520hypercalcaemic%2520type%26jtitle%3DJ.%2520Pathol.%26date%3D2017%26volume%3D242%26spage%3D371%26epage%3D383%26doi%3D10.1002%2Fpath.4912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Chan-Penebre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grassian, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutson, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuplast-Barr, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesworth, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilhack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribich, S. A.</span><span> </span><span class="NLM_article-title">Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type cells by inhibition of EZH2: <i>in vitro</i> and <i>in vivo</i> preclinical models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">850</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1158%2F1535-7163.MCT-16-0678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=28292935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFemt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=850-860&author=E.+Chan-Penebreauthor=K.+Armstrongauthor=A.+Drewauthor=A.+R.+Grassianauthor=I.+Feldmanauthor=S.+K.+Knutsonauthor=K.+Kuplast-Barrauthor=M.+Rocheauthor=J.+Campbellauthor=P.+Hoauthor=R.+A.+Copelandauthor=R.+Chesworthauthor=J.+J.+Smithauthor=H.+Keilhackauthor=S.+A.+Ribich&title=Selective+killing+of+SMARCA2-+and+SMARCA4-deficient+small+cell+carcinoma+of+the+ovary%2C+hypercalcemic+type+cells+by+inhibition+of+EZH2%3A+in+vitro+and+in+vivo+preclinical+models&doi=10.1158%2F1535-7163.MCT-16-0678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models</span></div><div class="casAuthors">Chan-Penebre, Elayne; Armstrong, Kelli; Drew, Allison; Grassian, Alexandra R.; Feldman, Igor; Knutson, Sarah K.; Kuplast-Barr, Kristy; Roche, Maria; Campbell, John; Ho, Peter; Copeland, Robert A.; Chesworth, Richard; Smith, Jesse J.; Keilhack, Heike; Ribich, Scott A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">850-860</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The SWI/SNF complex is a major regulator of gene expression and is increasingly thought to play an important role in human cancer, as evidenced by the high frequency of subunit mutations across virtually all cancer types.  We previously reported that in preclin. models, malignant rhabdoid tumors, which are deficient in the SWI/SNF core component INI1 (SMARCB1), are selectively killed by inhibitors of the H3K27 histone methyltransferase EZH2.  Given the demonstrated antagonistic activities of the SWI/SNF complex and the EZH2-contg. PRC2 complex, we investigated whether addnl. cancers with SWI/SNF mutations are sensitive to selective EZH2 inhibition.  It has been recently reported that ovarian cancers with dual loss of the redundant SWI/SNF components SMARCA4 and SMARCA2 are characteristic of a rare rhabdoid-like subtype known as small-cell carcinoma of the ovary hypercalcemic type (SCCOHT).  Here, we provide evidence that a subset of commonly used ovarian carcinoma cell lines were misdiagnosed and instead were derived from a SCCOHT tumor.  We also demonstrate that tazemetostat, a potent and selective EZH2 inhibitor currently in phase II clin. trials, induces potent antiproliferative and antitumor effects in SCCOHT cell lines and xenografts deficient in both SMARCA2 and SMARCA4.  These results exemplify an addnl. class of rhabdoid-like tumors that are dependent on EZH2 activity for survival.  Mol Cancer Ther; 16(5); 850-60. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVWFUB-yp1_LVg90H21EOLACvtfcHk0lg4mF05zrXPCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFemt74%253D&md5=863efce9718055b13357361992e59242</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0678%26sid%3Dliteratum%253Aachs%26aulast%3DChan-Penebre%26aufirst%3DE.%26aulast%3DArmstrong%26aufirst%3DK.%26aulast%3DDrew%26aufirst%3DA.%26aulast%3DGrassian%26aufirst%3DA.%2BR.%26aulast%3DFeldman%26aufirst%3DI.%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DKuplast-Barr%26aufirst%3DK.%26aulast%3DRoche%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DRibich%26aufirst%3DS.%2BA.%26atitle%3DSelective%2520killing%2520of%2520SMARCA2-%2520and%2520SMARCA4-deficient%2520small%2520cell%2520carcinoma%2520of%2520the%2520ovary%252C%2520hypercalcemic%2520type%2520cells%2520by%2520inhibition%2520of%2520EZH2%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520preclinical%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D850%26epage%3D860%26doi%3D10.1158%2F1535-7163.MCT-16-0678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Bitler, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aird, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garipov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amatangelo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kossenkov, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, I.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conejo-Garcia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speicher, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span> </span><span class="NLM_article-title">Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span><span class="refDoi"> DOI: 10.1038/nm.3799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnm.3799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=25686104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVSit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=231-238&author=B.+G.+Bitlerauthor=K.+M.+Airdauthor=A.+Garipovauthor=H.+Liauthor=M.+Amatangeloauthor=A.+V.+Kossenkovauthor=D.+C.+Schultzauthor=Q.+Liuauthor=I.-M.+Shihauthor=J.+R.+Conejo-Garciaauthor=D.+W.+Speicherauthor=R.+Zhang&title=Synthetic+lethality+by+targeting+EZH2+methyltransferase+activity+in+ARID1A-mutated+cancers&doi=10.1038%2Fnm.3799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers</span></div><div class="casAuthors">Bitler, Benjamin G.; Aird, Katherine M.; Garipov, Azat; Li, Hua; Amatangelo, Michael; Kossenkov, Andrew V.; Schultz, David C.; Liu, Qin; Shih, Ie-Ming; Conejo-Garcia, Jose R.; Speicher, David W.; Zhang, Rugang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">231-238</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The gene encoding ARID1A, a chromatin remodeler, shows one of the highest mutation rates across many cancer types.  Notably, ARID1A is mutated in over 50% of ovarian clear cell carcinomas, which currently have no effective therapy.  To date, clin. applicable targeted cancer therapy based on ARID1A mutational status has not been described.  Here we show that inhibition of the EZH2 methyltransferase acts in a synthetic lethal manner in ARID1A-mutated ovarian cancer cells and that ARID1A mutational status correlated with response to the EZH2 inhibitor.  We identified PIK3IP1 as a direct target of ARID1A and EZH2 that is upregulated by EZH2 inhibition and contributed to the obsd. synthetic lethality by inhibiting PI3K-AKT signaling.  Importantly, EZH2 inhibition caused regression of ARID1A-mutated ovarian tumors in vivo.  To our knowledge, this is the first data set to demonstrate a synthetic lethality between ARID1A mutation and EZH2 inhibition.  Our data indicate that pharmacol. inhibition of EZH2 represents a novel treatment strategy for cancers involving ARID1A mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEiQfgiO8t4LVg90H21EOLACvtfcHk0lg4mF05zrXPCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVSit7k%253D&md5=2521906b5e6ef9b7fc51a09ceb1f0c9d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnm.3799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3799%26sid%3Dliteratum%253Aachs%26aulast%3DBitler%26aufirst%3DB.%2BG.%26aulast%3DAird%26aufirst%3DK.%2BM.%26aulast%3DGaripov%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DAmatangelo%26aufirst%3DM.%26aulast%3DKossenkov%26aufirst%3DA.%2BV.%26aulast%3DSchultz%26aufirst%3DD.%2BC.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DShih%26aufirst%3DI.-M.%26aulast%3DConejo-Garcia%26aufirst%3DJ.%2BR.%26aulast%3DSpeicher%26aufirst%3DD.%2BW.%26aulast%3DZhang%26aufirst%3DR.%26atitle%3DSynthetic%2520lethality%2520by%2520targeting%2520EZH2%2520methyltransferase%2520activity%2520in%2520ARID1A-mutated%2520cancers%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D231%26epage%3D238%26doi%3D10.1038%2Fnm.3799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Wilson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, C. W.</span><span> </span><span class="NLM_article-title">SWI/SNF nucleosome remodellers and cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">492</span><span class="refDoi"> DOI: 10.1038/nrc3068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnrc3068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=21654818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntFKrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=481-492&author=B.+G.+Wilsonauthor=C.+W.+Roberts&title=SWI%2FSNF+nucleosome+remodellers+and+cancer&doi=10.1038%2Fnrc3068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">SWI/SNF nucleosome remodelers and cancer</span></div><div class="casAuthors">Wilson, Boris G.; Roberts, Charles W. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">481-492</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  SWI/SNF chromatin remodelling complexes use the energy of ATP hydrolysis to remodel nucleosomes and to modulate transcription.  Growing evidence indicates that these complexes have a widespread role in tumor suppression, as inactivating mutations in several SWI/SNF subunits have recently been identified at a high frequency in a variety of cancers.  However, the mechanisms by which mutations in these complexes drive tumorigenesis are unclear.  In this Review we discuss the contributions of SWI/SNF mutations to cancer formation, examine their normal functions and discuss opportunities for novel therapeutic interventions for SWI/SNF-mutant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOPkgJoPg1hbVg90H21EOLACvtfcHk0lg4mF05zrXPCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntFKrsLw%253D&md5=fee4e1c406f02388a1acd75048db8511</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrc3068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3068%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DB.%2BG.%26aulast%3DRoberts%26aufirst%3DC.%2BW.%26atitle%3DSWI%252FSNF%2520nucleosome%2520remodellers%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D481%26epage%3D492%26doi%3D10.1038%2Fnrc3068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vazquez, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsherniak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haswell, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walensky, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orkin, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, C. W.</span><span> </span><span class="NLM_article-title">SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1491</span><span class="NLM_x">–</span> <span class="NLM_lpage">1496</span><span class="refDoi"> DOI: 10.1038/nm.3968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnm.3968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=26552009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1491-1496&author=K.+H.+Kimauthor=W.+Kimauthor=T.+P.+Howardauthor=F.+Vazquezauthor=A.+Tsherniakauthor=J.+N.+Wuauthor=W.+Wangauthor=J.+R.+Haswellauthor=L.+D.+Walenskyauthor=W.+C.+Hahnauthor=S.+H.+Orkinauthor=C.+W.+Roberts&title=SWI%2FSNF-mutant+cancers+depend+on+catalytic+and+non-catalytic+activity+of+EZH2&doi=10.1038%2Fnm.3968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2</span></div><div class="casAuthors">Kim, Kimberly H.; Kim, Woojin; Howard, Thomas P.; Vazquez, Francisca; Tsherniak, Aviad; Wu, Jennifer N.; Wang, Weishan; Haswell, Jeffrey R.; Walensky, Loren D.; Hahn, William C.; Orkin, Stuart H.; Roberts, Charles W. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1491-1496</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human cancer genome sequencing has recently revealed that genes that encode subunits of SWI/SNF chromatin remodeling complexes are frequently mutated across a wide variety of cancers, and several subunits of the complex have been shown to have bona fide tumor suppressor activity.  However, whether mutations in SWI/SNF subunits result in shared dependencies is unknown.  Here we show that EZH2, a catalytic subunit of the polycomb repressive complex 2 (PRC2), is essential in all tested cancer cell lines and xenografts harboring mutations of the SWI/SNF subunits ARID1A, PBRM1, and SMARCA4, which are several of the most frequently mutated SWI/SNF subunits in human cancer, but that co-occurrence of a Ras pathway mutation is correlated with abrogation of this dependence.  Notably, we demonstrate that SWI/SNF-mutant cancer cells are primarily dependent on a non-catalytic role of EZH2 in the stabilization of the PRC2 complex, and that they are only partially dependent on EZH2 histone methyltransferase activity.  These results not only reveal a shared dependency of cancers with genetic alterations in SWI/SNF subunits, but also suggest that EZH2 enzymic inhibitors now in clin. development may not fully suppress the oncogenic activity of EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNjhQKP01U5bVg90H21EOLACvtfcHk0liI_xG1FmAo3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7nK&md5=a30c11fe7ce3c20e982e824105b8d640</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnm.3968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3968%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DHoward%26aufirst%3DT.%2BP.%26aulast%3DVazquez%26aufirst%3DF.%26aulast%3DTsherniak%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%2BN.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHaswell%26aufirst%3DJ.%2BR.%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DOrkin%26aufirst%3DS.%2BH.%26aulast%3DRoberts%26aufirst%3DC.%2BW.%26atitle%3DSWI%252FSNF-mutant%2520cancers%2520depend%2520on%2520catalytic%2520and%2520non-catalytic%2520activity%2520of%2520EZH2%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D1491%26epage%3D1496%26doi%3D10.1038%2Fnm.3968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Kawano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grassian, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutson, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warholic, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuznetsov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minoshima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilhack, H.</span><span> </span><span class="NLM_article-title">Preclinical evidence of anti-tumor activity induced by EZH2 inhibition in human models of synovial sarcoma</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0158888</span><span class="refDoi"> DOI: 10.1371/journal.pone.0158888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1371%2Fjournal.pone.0158888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=27391784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1OqtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0158888&author=S.+Kawanoauthor=A.+R.+Grassianauthor=M.+Tsudaauthor=S.+K.+Knutsonauthor=N.+M.+Warholicauthor=G.+Kuznetsovauthor=S.+Xuauthor=Y.+Xiaoauthor=R.+M.+Pollockauthor=J.+S.+Smithauthor=K.+K.+Kuntzauthor=S.+Ribichauthor=Y.+Minoshimaauthor=J.+Matsuiauthor=R.+A.+Copelandauthor=S.+Tanakaauthor=H.+Keilhack&title=Preclinical+evidence+of+anti-tumor+activity+induced+by+EZH2+inhibition+in+human+models+of+synovial+sarcoma&doi=10.1371%2Fjournal.pone.0158888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evidence of anti-tumor activity induced by EZH2 inhibition in human models of synovial sarcoma</span></div><div class="casAuthors">Kawano, Satoshi; Grassian, Alexandra R.; Tsuda, Masumi; Knutson, Sarah K.; Warholic, Natalie M.; Kuznetsov, Galina; Xu, Shanqin; Xiao, Yonghong; Pollock, Roy M.; Smith, Jesse S.; Kuntz, Kevin K.; Ribich, Scott; Minoshima, Yukinori; Matsui, Junji; Copeland, Robert A.; Tanaka, Shinya; Keilhack, Heike</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0158888/1-e0158888/22</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The catalytic activities of covalent and ATP-dependent chromatin remodeling are central to regulating the conformational state of chromatin and the resultant transcriptional output.  The enzymes that catalyze these activities are often contained within multiprotein complexes in nature.  Two such multiprotein complexes, the polycomb repressive complex 2 (PRC2) methyltransferase and the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeler have been reported to act in opposition to each other during development and homeostasis.  An imbalance in their activities induced by mutations/deletions in complex members (e.g. SMARCB1) has been suggested to be a pathogenic mechanism in certain human cancers.  Here we show that preclin. models of synovial sarcoma-a cancer characterized by functional SMARCB1 loss via its displacement from the SWI/SNF complex through the pathognomonic SS18-SSX fusion protein-display sensitivity to pharmacol. inhibition of EZH2, the catalytic subunit of PRC2.  Treatment with tazemetostat, a clinicalstage, selective and orally bioavailable small-mol. inhibitor of EZH2 enzymic activity reverses a subset of synovial sarcoma gene expression and results in concn.-dependent cell growth inhibition and cell death specifically in SS18-SSX fusion-pos. cells in vitro.  Treatment of mice bearing either a cell line or two patient-derived xenograft models of synovial sarcoma leads to dose-dependent tumor growth inhibition with correlative inhibition of trimethylation levels of the EZH2-specific substrate, lysine 27 on histone H3.  These data demonstrate a dependency of SS18-SSX-pos., SMARCB1-deficient synovial sarcomas on EZH2 enzymic activity and suggests the potential utility of EZH2-targeted drugs in these genetically defined cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo35o6Xw1yZorVg90H21EOLACvtfcHk0liI_xG1FmAo3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1OqtLbF&md5=9bb3342fc63df57ba607b297175a1f40</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0158888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0158888%26sid%3Dliteratum%253Aachs%26aulast%3DKawano%26aufirst%3DS.%26aulast%3DGrassian%26aufirst%3DA.%2BR.%26aulast%3DTsuda%26aufirst%3DM.%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DKuznetsov%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DSmith%26aufirst%3DJ.%2BS.%26aulast%3DKuntz%26aufirst%3DK.%2BK.%26aulast%3DRibich%26aufirst%3DS.%26aulast%3DMinoshima%26aufirst%3DY.%26aulast%3DMatsui%26aufirst%3DJ.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DKeilhack%26aufirst%3DH.%26atitle%3DPreclinical%2520evidence%2520of%2520anti-tumor%2520activity%2520induced%2520by%2520EZH2%2520inhibition%2520in%2520human%2520models%2520of%2520synovial%2520sarcoma%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0158888%26doi%3D10.1371%2Fjournal.pone.0158888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Gardner, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lok, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneeberger, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmeules, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khodos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Stanchina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sage, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massion, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, J. T.</span><span> </span><span class="NLM_article-title">Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">286</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span><span class="refDoi"> DOI: 10.1016/j.ccell.2017.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1016%2Fj.ccell.2017.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=28196596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=286-299&author=E.+E.+Gardnerauthor=B.+H.+Lokauthor=V.+E.+Schneebergerauthor=P.+Desmeulesauthor=L.+A.+Milesauthor=P.+K.+Arnoldauthor=A.+Niauthor=I.+Khodosauthor=E.+de+Stanchinaauthor=T.+Nguyenauthor=J.+Sageauthor=J.+E.+Campbellauthor=S.+Ribichauthor=N.+Rekhtmanauthor=A.+Dowlatiauthor=P.+P.+Massionauthor=C.+M.+Rudinauthor=J.+T.+Poirier&title=Chemosensitive+relapse+in+small+cell+lung+cancer+proceeds+through+an+EZH2-SLFN11+axis&doi=10.1016%2Fj.ccell.2017.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis</span></div><div class="casAuthors">Gardner, Eric E.; Lok, Benjamin H.; Schneeberger, Valentina E.; Desmeules, Patrice; Miles, Linde A.; Arnold, Paige K.; Ni, Andy; Khodos, Inna; de Stanchina, Elisa; Nguyen, Thuyen; Sage, Julien; Campbell, John E.; Ribich, Scott; Rekhtman, Natasha; Dowlati, Afshin; Massion, Pierre P.; Rudin, Charles M.; Poirier, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">286-299</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Small cell lung cancer is initially highly responsive to cisplatin and etoposide but in almost every case becomes rapidly chemoresistant, leading to death within 1 yr.  We modeled acquired chemoresistance in vivo using a series of patient-derived xenografts to generate paired chemosensitive and chemoresistant cancers.  Multiple chemoresistant models demonstrated suppression of SLFN11, a factor implicated in DNA-damage repair deficiency.  In vivo silencing of SLFN11 was assocd. with marked deposition of H3K27me3, a histone modification placed by EZH2, within the gene body of SLFN11, inducing local chromatin condensation and gene silencing.  Inclusion of an EZH2 inhibitor with std. cytotoxic therapies prevented emergence of acquired resistance and augmented chemotherapeutic efficacy in both chemosensitive and chemoresistant models of small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOHlJpt8Un_bVg90H21EOLACvtfcHk0liI_xG1FmAo3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yltL8%253D&md5=d3c18e960fcc543438026062387f7c40</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2017.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2017.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DGardner%26aufirst%3DE.%2BE.%26aulast%3DLok%26aufirst%3DB.%2BH.%26aulast%3DSchneeberger%26aufirst%3DV.%2BE.%26aulast%3DDesmeules%26aufirst%3DP.%26aulast%3DMiles%26aufirst%3DL.%2BA.%26aulast%3DArnold%26aufirst%3DP.%2BK.%26aulast%3DNi%26aufirst%3DA.%26aulast%3DKhodos%26aufirst%3DI.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DSage%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DRibich%26aufirst%3DS.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DMassion%26aufirst%3DP.%2BP.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DPoirier%26aufirst%3DJ.%2BT.%26atitle%3DChemosensitive%2520relapse%2520in%2520small%2520cell%2520lung%2520cancer%2520proceeds%2520through%2520an%2520EZH2-SLFN11%2520axis%26jtitle%3DCancer%2520Cell%26date%3D2017%26volume%3D31%26spage%3D286%26epage%3D299%26doi%3D10.1016%2Fj.ccell.2017.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Dardenne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gayvert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyrta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sboner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noorzad, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eilers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosquera, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elemento, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demichelis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickman, D. S.</span><span> </span><span class="NLM_article-title">N-myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">563</span><span class="NLM_x">–</span> <span class="NLM_lpage">577</span><span class="refDoi"> DOI: 10.1016/j.ccell.2016.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1016%2Fj.ccell.2016.09.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=563-577&author=E.+Dardenneauthor=H.+Beltranauthor=M.+Benelliauthor=K.+Gayvertauthor=A.+Bergerauthor=L.+Pucaauthor=J.+Cyrtaauthor=A.+Sbonerauthor=Z.+Noorzadauthor=T.+MacDonaldauthor=C.+Cheungauthor=K.+S.+Yuenauthor=D.+Gaoauthor=Y.+Chenauthor=M.+Eilersauthor=J.+M.+Mosqueraauthor=B.+D.+Robinsonauthor=O.+Elementoauthor=M.+A.+Rubinauthor=F.+Demichelisauthor=D.+S.+Rickman&title=N-myc+induces+an+EZH2-mediated+transcriptional+program+driving+neuroendocrine+prostate+cancer&doi=10.1016%2Fj.ccell.2016.09.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DDardenne%26aufirst%3DE.%26aulast%3DBeltran%26aufirst%3DH.%26aulast%3DBenelli%26aufirst%3DM.%26aulast%3DGayvert%26aufirst%3DK.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DPuca%26aufirst%3DL.%26aulast%3DCyrta%26aufirst%3DJ.%26aulast%3DSboner%26aufirst%3DA.%26aulast%3DNoorzad%26aufirst%3DZ.%26aulast%3DMacDonald%26aufirst%3DT.%26aulast%3DCheung%26aufirst%3DC.%26aulast%3DYuen%26aufirst%3DK.%2BS.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEilers%26aufirst%3DM.%26aulast%3DMosquera%26aufirst%3DJ.%2BM.%26aulast%3DRobinson%26aufirst%3DB.%2BD.%26aulast%3DElemento%26aufirst%3DO.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DDemichelis%26aufirst%3DF.%26aulast%3DRickman%26aufirst%3DD.%2BS.%26atitle%3DN-myc%2520induces%2520an%2520EZH2-mediated%2520transcriptional%2520program%2520driving%2520neuroendocrine%2520prostate%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D563%26epage%3D577%26doi%3D10.1016%2Fj.ccell.2016.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ku, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosario, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshadri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labbe, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, D. W.</span><span> </span><span class="NLM_article-title">Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span><span class="refDoi"> DOI: 10.1126/science.aah4199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1126%2Fscience.aah4199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=28059767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Wjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=78-83&author=S.+Y.+Kuauthor=S.+Rosarioauthor=Y.+Wangauthor=P.+Muauthor=M.+Seshadriauthor=Z.+W.+Goodrichauthor=M.+M.+Goodrichauthor=D.+P.+Labbeauthor=E.+C.+Gomezauthor=J.+Wangauthor=H.+W.+Longauthor=B.+Xuauthor=M.+Brownauthor=M.+Lodaauthor=C.+L.+Sawyersauthor=L.+Ellisauthor=D.+W.+Goodrich&title=Rb1+and+Trp53+cooperate+to+suppress+prostate+cancer+lineage+plasticity%2C+metastasis%2C+and+antiandrogen+resistance&doi=10.1126%2Fscience.aah4199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance</span></div><div class="casAuthors">Ku, Sheng Yu; Rosario, Spencer; Wang, Yanqing; Mu, Ping; Seshadri, Mukund; Goodrich, Zachary W.; Goodrich, Maxwell M.; Labbe, David P.; Gomez, Eduardo Cortes; Wang, Jianmin; Long, Henry W.; Xu, Bo; Brown, Myles; Loda, Massimo; Sawyers, Charles L.; Ellis, Leigh; Goodrich, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6320</span>),
    <span class="NLM_cas:pages">78-83</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Prostate cancer relapsing from antiandrogen therapies can exhibit variant histol. with altered lineage marker expression, suggesting that lineage plasticity facilitates therapeutic resistance.  The mechanisms underlying prostate cancer lineage plasticity are incompletely understood.  Studying mouse models, we demonstrate that Rb1 loss facilitates lineage plasticity and metastasis of prostate adenocarcinoma initiated by Pten mutation.  Addnl. loss of Trp53 causes resistance to antiandrogen therapy.  Gene expression profiling indicates that mouse tumors resemble human prostate cancer neuroendocrine variants; both mouse and human tumors exhibit increased expression of epigenetic reprogramming factors such as Ezh2 and Sox2.  Clin. relevant Ezh2 inhibitors restore androgen receptor expression and sensitivity to antiandrogen therapy.  These findings uncover genetic mutations that enable prostate cancer progression; identify mouse models for studying prostate cancer lineage plasticity; and suggest an epigenetic approach for extending clin. responses to antiandrogen therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDQEfrg7Zcb7Vg90H21EOLACvtfcHk0ljKHAyIdor2sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Wjtw%253D%253D&md5=c3f2e7070cabe82a3667653a62915224</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.aah4199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aah4199%26sid%3Dliteratum%253Aachs%26aulast%3DKu%26aufirst%3DS.%2BY.%26aulast%3DRosario%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMu%26aufirst%3DP.%26aulast%3DSeshadri%26aufirst%3DM.%26aulast%3DGoodrich%26aufirst%3DZ.%2BW.%26aulast%3DGoodrich%26aufirst%3DM.%2BM.%26aulast%3DLabbe%26aufirst%3DD.%2BP.%26aulast%3DGomez%26aufirst%3DE.%2BC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DH.%2BW.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DEllis%26aufirst%3DL.%26aulast%3DGoodrich%26aufirst%3DD.%2BW.%26atitle%3DRb1%2520and%2520Trp53%2520cooperate%2520to%2520suppress%2520prostate%2520cancer%2520lineage%2520plasticity%252C%2520metastasis%252C%2520and%2520antiandrogen%2520resistance%26jtitle%3DScience%26date%3D2017%26volume%3D355%26spage%3D78%26epage%3D83%26doi%3D10.1126%2Fscience.aah4199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Knutson, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minoshima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warholic, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadowaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uesugi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuznetsov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigle, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klaus, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allain, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raimondi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter-Scott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesworth, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilhack, H.</span><span> </span><span class="NLM_article-title">Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">842</span><span class="NLM_x">–</span> <span class="NLM_lpage">854</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1158%2F1535-7163.MCT-13-0773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=24563539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=842-854&author=S.+K.+Knutsonauthor=S.+Kawanoauthor=Y.+Minoshimaauthor=N.+M.+Warholicauthor=K.+C.+Huangauthor=Y.+Xiaoauthor=T.+Kadowakiauthor=M.+Uesugiauthor=G.+Kuznetsovauthor=N.+Kumarauthor=T.+J.+Wigleauthor=C.+R.+Klausauthor=C.+J.+Allainauthor=A.+Raimondiauthor=N.+J.+Watersauthor=J.+J.+Smithauthor=M.+Porter-Scottauthor=R.+Chesworthauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=V.+M.+Richonauthor=T.+Uenakaauthor=R.+M.+Pollockauthor=K.+W.+Kuntzauthor=A.+Yokoiauthor=H.+Keilhack&title=Selective+inhibition+of+EZH2+by+EPZ-6438+leads+to+potent+antitumor+activity+in+EZH2-mutant+non-Hodgkin+lymphoma&doi=10.1158%2F1535-7163.MCT-13-0773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma</span></div><div class="casAuthors">Knutson, Sarah K.; Kawano, Satoshi; Minoshima, Yukinori; Warholic, Natalie M.; Huang, Kuan-Chun; Xiao, Yonghong; Kadowaki, Tadashi; Uesugi, Mai; Kuznetsov, Galina; Kumar, Namita; Wigle, Tim J.; Klaus, Christine R.; Allain, Christina J.; Raimondi, Alejandra; Waters, Nigel J.; Smith, Jesse J.; Porter-Scott, Margaret; Chesworth, Richard; Moyer, Mikel P.; Copeland, Robert A.; Richon, Victoria M.; Uenaka, Toshimitsu; Pollock, Roy M.; Kuntz, Kevin W.; Yokoi, Akira; Keilhack, Heike</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-854</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutations within the catalytic domain of the histone methyltransferase EZH2 have been identified in subsets of patients with non-Hodgkin lymphoma (NHL).  These genetic alterations are hypothesized to confer an oncogenic dependency on EZH2 enzymic activity in these cancers.  We have previously reported the discovery of EPZ005678 and EPZ-6438, potent and selective S-adenosyl-methionine-competitive small mol. inhibitors of EZH2.  Although both compds. are similar with respect to their mechanism of action and selectivity, EPZ-6438 possesses superior potency and drug-like properties, including good oral bioavailability in animals.  Here, we characterize the activity of EPZ-6438 in preclin. models of NHL.  EPZ-6438 selectively inhibits intracellular lysine 27 of histone H3 (H3K27) methylation in a concn.- and time-dependent manner in both EZH2 wild-type and mutant lymphoma cells.  Inhibition of H3K27 trimethylation (H3K27Me3) leads to selective cell killing of human lymphoma cell lines bearing EZH2 catalytic domain point mutations.  Treatment of EZH2-mutant NHL xenograft-bearing mice with EPZ-6438 causes dose-dependent tumor growth inhibition, including complete and sustained tumor regressions with correlative diminution of H3K27Me3 levels in tumors and selected normal tissues.  Mice dosed orally with EPZ-6438 for 28 days remained tumor free for up to 63 days after stopping compd. treatment in two EZH2-mutant xenograft models.  These data confirm the dependency of EZH2-mutant NHL on EZH2 activity and portend the utility of EPZ-6438 as a potential treatment for these genetically defined cancers.  Mol Cancer Ther; 13(4); 842-54. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq2o1v5F3GzLVg90H21EOLACvtfcHk0lgia4JjEef1ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurw%253D&md5=89354e9453dcd7430978d1a6c5ee5846</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0773%26sid%3Dliteratum%253Aachs%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DKawano%26aufirst%3DS.%26aulast%3DMinoshima%26aufirst%3DY.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DHuang%26aufirst%3DK.%2BC.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DKadowaki%26aufirst%3DT.%26aulast%3DUesugi%26aufirst%3DM.%26aulast%3DKuznetsov%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DKlaus%26aufirst%3DC.%2BR.%26aulast%3DAllain%26aufirst%3DC.%2BJ.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DPorter-Scott%26aufirst%3DM.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DYokoi%26aufirst%3DA.%26aulast%3DKeilhack%26aufirst%3DH.%26atitle%3DSelective%2520inhibition%2520of%2520EZH2%2520by%2520EPZ-6438%2520leads%2520to%2520potent%2520antitumor%2520activity%2520in%2520EZH2-mutant%2520non-Hodgkin%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D842%26epage%3D854%26doi%3D10.1158%2F1535-7163.MCT-13-0773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Vaswani, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gehling, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasveschuk, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duplessis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantone, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audia, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gamblin, S. J.</span><span> </span><span class="NLM_article-title">Identification of (<i>R</i>)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a potent and selective inhibitor of histone methyltransferase EZH2, suitable for phase I clinical trials for B-cell lymphomas</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">9928</span><span class="NLM_x">–</span> <span class="NLM_lpage">9941</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9928-9941&author=R.+G.+Vaswaniauthor=V.+S.+Gehlingauthor=L.+A.+Dakinauthor=A.+S.+Cookauthor=C.+G.+Nasveschukauthor=M.+Duplessisauthor=P.+Iyerauthor=S.+Balasubramanianauthor=F.+Zhaoauthor=A.+C.+Goodauthor=R.+Campbellauthor=C.+Leeauthor=N.+Cantoneauthor=R.+T.+Cummingsauthor=E.+Normantauthor=S.+F.+Bellonauthor=B.+K.+Albrechtauthor=J.+C.+Harmangeauthor=P.+Trojerauthor=J.+E.+Audiaauthor=Y.+Zhangauthor=N.+Justinauthor=S.+Chenauthor=J.+R.+Wilsonauthor=S.+J.+Gamblin&title=Identification+of+%28R%29-N-%28%284-methoxy-6-methyl-2-oxo-1%2C2-dihydropyridin-3-yl%29methyl%29-2-methyl-1-%281-%281-%282%2C2%2C2-trifluoroethyl%29piperidin-4-yl%29ethyl%29-1H-indole-3-carboxamide+%28CPI-1205%29%2C+a+potent+and+selective+inhibitor+of+histone+methyltransferase+EZH2%2C+suitable+for+phase+I+clinical+trials+for+B-cell+lymphomas&doi=10.1021%2Facs.jmedchem.6b01315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas</span></div><div class="casAuthors">Vaswani, Rishi G.; Gehling, Victor S.; Dakin, Les A.; Cook, Andrew S.; Nasveschuk, Christopher G.; Duplessis, Martin; Iyer, Priyadarshini; Balasubramanian, Srividya; Zhao, Feng; Good, Andrew C.; Campbell, Robert; Lee, Christina; Cantone, Nico; Cummings, Richard T.; Normant, Emmanuel; Bellon, Steven F.; Albrecht, Brian K.; Harmange, Jean-Christophe; Trojer, Patrick; Audia, James E.; Zhang, Ying; Justin, Neil; Chen, Shuyang; Wilson, Jon R.; Gamblin, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9928-9941</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) has been shown to play a major role in transcriptional silencing in part by installing methylation marks on lysine 27 of histone 3.  Dysregulation of PRC2 function correlates with certain malignancies and poor prognosis.  EZH2 is the catalytic engine of the PRC2 complex and thus represents a key candidate oncol. target for pharmacol. intervention.  Here we report the optimization of our indole-based EZH2 inhibitor series that led to the identification of CPI-1205, a highly potent (biochem. IC50 = 0.002 μM, cellular EC50 = 0.032 μM) and selective inhibitor of EZH2.  This compd. demonstrates robust antitumor effects in a Karpas-422 xenograft model when dosed at 160 mg/kg BID and is currently in Phase I clin. trials.  Addnl., we disclose the co-crystal structure of our inhibitor series bound to the human PRC2 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrqnfg3FGdE7Vg90H21EOLACvtfcHk0lgia4JjEef1ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77I&md5=4096fa91399fef88a7ec8aabb5aaee13</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01315%26sid%3Dliteratum%253Aachs%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJustin%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DJ.%2BR.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26atitle%3DIdentification%2520of%2520%2528R%2529-N-%2528%25284-methoxy-6-methyl-2-oxo-1%252C2-dihydropyridin-3-yl%2529methyl%2529-2-methyl-1-%25281-%25281-%25282%252C2%252C2-trifluoroethyl%2529piperidin-4-yl%2529ethyl%2529-1H-indole-3-carboxamide%2520%2528CPI-1205%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520histone%2520methyltransferase%2520EZH2%252C%2520suitable%2520for%2520phase%2520I%2520clinical%2520trials%2520for%2520B-cell%2520lymphomas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9928%26epage%3D9941%26doi%3D10.1021%2Facs.jmedchem.6b01315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Morschhauser, F.; Salles, G.; McKay, P.; Tilly, H.; Schmitt, A.; Gerecitano, J.; Johnson, P.; Le Gouill, S.; Dickinson, M. J.; Fruchart, C.; Lamy, T.; Chaidos, A.; Jurczak, W.; Opat, S.; Radford, J.; Zinzani, P. L.; Assouline, S.; Cartron, G.; Clawson, A.; Picazio, N.; Ribich, S.; Blakemore, S. J.; Larus, J.; Miao, H.; Woodruff, M.; Ho, P. T.; Ribrag, V.</span><span> </span><span class="NLM_article-title">Interim report from a phase II multicenter study of tazemetostat, an EZH2 inhibitor: clinical activity and favorable safety in patients with relapsed or refractory B-cell non-Hodgkin lymphoma</span>. Presented at the 14th International Conference on Malignant Lymphoma, Switzerland, June 14–17,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=F.+Morschhauser&author=G.+Salles&author=P.+McKay&author=H.+Tilly&author=A.+Schmitt&author=J.+Gerecitano&author=P.+Johnson&author=S.+Le+Gouill&author=M.+J.+Dickinson&author=C.+Fruchart&author=T.+Lamy&author=A.+Chaidos&author=W.+Jurczak&author=S.+Opat&author=J.+Radford&author=P.+L.+Zinzani&author=S.+Assouline&author=G.+Cartron&author=A.+Clawson&author=N.+Picazio&author=S.+Ribich&author=S.+J.+Blakemore&author=J.+Larus&author=H.+Miao&author=M.+Woodruff&author=P.+T.+Ho&author=V.+Ribrag&title=Interim+report+from+a+phase+II+multicenter+study+of+tazemetostat%2C+an+EZH2+inhibitor%3A+clinical+activity+and+favorable+safety+in+patients+with+relapsed+or+refractory+B-cell+non-Hodgkin+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DMorschhauser%26aufirst%3DF.%26atitle%3DInterim%2520report%2520from%2520a%2520phase%2520II%2520multicenter%2520study%2520of%2520tazemetostat%252C%2520an%2520EZH2%2520inhibitor%253A%2520clinical%2520activity%2520and%2520favorable%2520safety%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520B-cell%2520non-Hodgkin%2520lymphoma%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Qi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fei, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, E.</span><span> </span><span class="NLM_article-title">An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">388</span><span class="refDoi"> DOI: 10.1038/nchembio.2304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnchembio.2304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=28135235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=381-388&author=W.+Qiauthor=K.+Zhaoauthor=J.+Guauthor=Y.+Huangauthor=Y.+Wangauthor=H.+Zhangauthor=M.+Zhangauthor=J.+Zhangauthor=Z.+Yuauthor=L.+Liauthor=L.+Tengauthor=S.+Chuaiauthor=C.+Zhangauthor=M.+Zhaoauthor=H.+Chanauthor=Z.+Chenauthor=D.+Fangauthor=Q.+Feiauthor=L.+Fengauthor=L.+Fengauthor=Y.+Gaoauthor=H.+Geauthor=X.+Geauthor=G.+Liauthor=A.+Lingelauthor=Y.+Linauthor=Y.+Liuauthor=F.+Luoauthor=M.+Shiauthor=L.+Wangauthor=Z.+Wangauthor=Y.+Yuauthor=J.+Zengauthor=C.+Zengauthor=L.+Zhangauthor=Q.+Zhangauthor=S.+Zhouauthor=C.+Oyangauthor=P.+Atadjaauthor=E.+Li&title=An+allosteric+PRC2+inhibitor+targeting+the+H3K27me3+binding+pocket+of+EED&doi=10.1038%2Fnchembio.2304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23aR"><div class="casContent"><span class="casTitleNuber">23a</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED</span></div><div class="casAuthors">Qi, Wei; Zhao, Kehao; Gu, Justin; Huang, Ying; Wang, Youzhen; Zhang, Hailong; Zhang, Man; Zhang, Jeff; Yu, Zhengtian; Li, Ling; Teng, Lin; Chuai, Shannon; Zhang, Chao; Zhao, Mengxi; Chan, Ho Man; Chen, Zijun; Fang, Douglas; Fei, Qi; Feng, Leying; Feng, Lijian; Gao, Yuan; Ge, Hui; Ge, Xinjian; Li, Guobin; Lingel, Andreas; Lin, Ying; Liu, Yueqin; Luo, Fangjun; Shi, Minlong; Wang, Long; Wang, Zhaofu; Yu, Yanyan; Zeng, Jue; Zeng, Chenhui; Zhang, Lijun; Zhang, Qiong; Zhou, Shaolian; Oyang, Counde; Atadja, Peter; Li, En</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">381-388</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) consists of three core subunits, EZH2, EED and SUZ12, and plays pivotal roles in transcriptional regulation.  The catalytic subunit EZH2 methylates histone H3 lysine 27 (H3K27), and its activity is further enhanced by the binding of EED to trimethylated H3K27 (H3K27me3).  Small-mol. inhibitors that compete with the cofactor S-adenosylmethionine (SAM) have been reported.  Here we report the discovery of EED226, a potent and selective PRC2 inhibitor that directly binds to the H3K27me3 binding pocket of EED.  EED226 induces a conformational change upon binding EED, leading to loss of PRC2 activity.  EED226 shows similar activity to SAM-competitive inhibitors in blocking H3K27 methylation of PRC2 target genes and inducing regression of human lymphoma xenograft tumors.  Interestingly, EED226 also effectively inhibits PRC2 contg. a mutant EZH2 protein resistant to SAM-competitive inhibitors.  Together, we show that EED226 inhibits PRC2 activity via an allosteric mechanism and offers an opportunity for treatment of PRC2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjpXExCMohI7Vg90H21EOLACvtfcHk0lgpnVD5MtPMrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsLc%253D&md5=62d10723685450ca7ffd599a61134d42</span></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2304%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DTeng%26aufirst%3DL.%26aulast%3DChuai%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DFei%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DH.%26aulast%3DGe%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLingel%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DOyang%26aufirst%3DC.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DE.%26atitle%3DAn%2520allosteric%2520PRC2%2520inhibitor%2520targeting%2520the%2520H3K27me3%2520binding%2520pocket%2520of%2520EED%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D381%26epage%3D388%26doi%3D10.1038%2Fnchembio.2304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selvaraju, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakob, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comess, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">The, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lima-Fernandes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczyk, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinge, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pliushchev, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Algire, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maag, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panchal, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petros, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweis, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torrent, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigelow, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senisterra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindley, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galasinski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsyte-Lovejoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vedadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappano, W. N.</span><span> </span><span class="NLM_article-title">The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span><span class="refDoi"> DOI: 10.1038/nchembio.2306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnchembio.2306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=28135237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=389-395&author=Y.+Heauthor=S.+Selvarajuauthor=M.+L.+Curtinauthor=C.+G.+Jakobauthor=H.+Zhuauthor=K.+M.+Comessauthor=B.+Shawauthor=J.+Theauthor=E.+Lima-Fernandesauthor=M.+M.+Szewczykauthor=D.+Chengauthor=K.+L.+Klingeauthor=H.+Q.+Liauthor=M.+Pliushchevauthor=M.+A.+Algireauthor=D.+Maagauthor=J.+Guoauthor=J.+Dietrichauthor=S.+C.+Panchalauthor=A.+M.+Petrosauthor=R.+F.+Sweisauthor=M.+Torrentauthor=L.+J.+Bigelowauthor=G.+Senisterraauthor=F.+Liauthor=S.+Kennedyauthor=Q.+Wuauthor=D.+J.+Osterlingauthor=D.+J.+Lindleyauthor=W.+Gaoauthor=S.+Galasinskiauthor=D.+Barsyte-Lovejoyauthor=M.+Vedadiauthor=F.+G.+Buchananauthor=C.+H.+Arrowsmithauthor=G.+G.+Chiangauthor=C.+Sunauthor=W.+N.+Pappano&title=The+EED+protein-protein+interaction+inhibitor+A-395+inactivates+the+PRC2+complex&doi=10.1038%2Fnchembio.2306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex</span></div><div class="casAuthors">He, Yupeng; Selvaraju, Sujatha; Curtin, Michael L.; Jakob, Clarissa G.; Zhu, Haizhong; Comess, Kenneth M.; Shaw, Bailin; The, Juliana; Lima-Fernandes, Evelyne; Szewczyk, Magdalena M.; Cheng, Dong; Klinge, Kelly L.; Li, Huan-Qiu; Pliushchev, Marina; Algire, Mikkel A.; Maag, David; Guo, Jun; Dietrich, Justin; Panchal, Sanjay C.; Petros, Andrew M.; Sweis, Ramzi F.; Torrent, Maricel; Bigelow, Lance J.; Senisterra, Guillermo; Li, Fengling; Kennedy, Steven; Wu, Qin; Osterling, Donald J.; Lindley, David J.; Gao, Wenqing; Galasinski, Scott; Barsyte-Lovejoy, Dalia; Vedadi, Masoud; Buchanan, Fritz G.; Arrowsmith, Cheryl H.; Chiang, Gary G.; Sun, Chaohong; Pappano, William N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">389-395</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) is a regulator of epigenetic states required for development and homeostasis.  PRC2 trimethylates histone H3 at lysine 27 (H3K27me3), which leads to gene silencing, and is dysregulated in many cancers.  The embryonic ectoderm development (EED) protein is an essential subunit of PRC2 that has both a scaffolding function and an H3K27me3-binding function.  Here we report the identification of A-395, a potent antagonist of the H3K27me3 binding functions of EED.  Structural studies demonstrate that A-395 binds to EED in the H3K27me3-binding pocket, thereby preventing allosteric activation of the catalytic activity of PRC2.  Phenotypic effects obsd. in vitro and in vivo are similar to those of known PRC2 enzymic inhibitors; however, A-395 retains potent activity against cell lines resistant to the catalytic inhibitors.  A-395 represents a first-in-class antagonist of PRC2 protein-protein interactions (PPI) for use as a chem. probe to investigate the roles of EED-contg. protein complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX5rHeR_Z5mLVg90H21EOLACvtfcHk0lgpnVD5MtPMrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsbs%253D&md5=d41eee098ed123f8c7f50babe93d7692</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2306%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DSelvaraju%26aufirst%3DS.%26aulast%3DCurtin%26aufirst%3DM.%2BL.%26aulast%3DJakob%26aufirst%3DC.%2BG.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DComess%26aufirst%3DK.%2BM.%26aulast%3DShaw%26aufirst%3DB.%26aulast%3DThe%26aufirst%3DJ.%26aulast%3DLima-Fernandes%26aufirst%3DE.%26aulast%3DSzewczyk%26aufirst%3DM.%2BM.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DKlinge%26aufirst%3DK.%2BL.%26aulast%3DLi%26aufirst%3DH.%2BQ.%26aulast%3DPliushchev%26aufirst%3DM.%26aulast%3DAlgire%26aufirst%3DM.%2BA.%26aulast%3DMaag%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DDietrich%26aufirst%3DJ.%26aulast%3DPanchal%26aufirst%3DS.%2BC.%26aulast%3DPetros%26aufirst%3DA.%2BM.%26aulast%3DSweis%26aufirst%3DR.%2BF.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DBigelow%26aufirst%3DL.%2BJ.%26aulast%3DSenisterra%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DKennedy%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DLindley%26aufirst%3DD.%2BJ.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DGalasinski%26aufirst%3DS.%26aulast%3DBarsyte-Lovejoy%26aufirst%3DD.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DBuchanan%26aufirst%3DF.%2BG.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DPappano%26aufirst%3DW.%2BN.%26atitle%3DThe%2520EED%2520protein-protein%2520interaction%2520inhibitor%2520A-395%2520inactivates%2520the%2520PRC2%2520complex%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D389%26epage%3D395%26doi%3D10.1038%2Fnchembio.2306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rui, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bingham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braganza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantin, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gukasyan, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kephart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krivacic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpf, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAlpine, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ninkovic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ornelas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryskin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scales, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatlock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhelle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wythes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yip, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zehnder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rollins, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span> </span><span class="NLM_article-title">Design and synthesis of pyridone-containing 3,4-dihydroisoquinoline-1(2H)-ones as a novel class of enhancer of zeste homolog 2 (EZH2) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">8306</span><span class="NLM_x">–</span> <span class="NLM_lpage">8325</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00515</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00515" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8306-8325&author=P.+P.+Kungauthor=E.+Ruiauthor=S.+Bergqvistauthor=P.+Binghamauthor=J.+Braganzaauthor=M.+Collinsauthor=M.+Cuiauthor=W.+Diehlauthor=D.+Dinhauthor=C.+Fanauthor=V.+R.+Fantinauthor=H.+J.+Gukasyanauthor=W.+Huauthor=B.+Huangauthor=S.+Kephartauthor=C.+Krivacicauthor=R.+A.+Kumpfauthor=G.+Liauthor=K.+A.+Maegleyauthor=I.+McAlpineauthor=L.+Nguyenauthor=S.+Ninkovicauthor=M.+Ornelasauthor=M.+Ryskinauthor=S.+Scalesauthor=S.+Suttonauthor=J.+Tatlockauthor=D.+Verhelleauthor=F.+Wangauthor=P.+Wellsauthor=M.+Wythesauthor=S.+Yamazakiauthor=B.+Yipauthor=X.+Yuauthor=L.+Zehnderauthor=W.+G.+Zhangauthor=R.+A.+Rollinsauthor=M.+Edwards&title=Design+and+synthesis+of+pyridone-containing+3%2C4-dihydroisoquinoline-1%282H%29-ones+as+a+novel+class+of+enhancer+of+zeste+homolog+2+%28EZH2%29+inhibitors&doi=10.1021%2Facs.jmedchem.6b00515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors</span></div><div class="casAuthors">Kung, Pei-Pei; Rui, Eugene; Bergqvist, Simon; Bingham, Patrick; Braganza, John; Collins, Michael; Cui, Mei; Diehl, Wade; Dinh, Dac; Fan, Connie; Fantin, Valeria R.; Gukasyan, Hovhannes J.; Hu, Wenyue; Huang, Buwen; Kephart, Susan; Krivacic, Cody; Kumpf, Robert A.; Li, Gary; Maegley, Karen A.; McAlpine, Indrawan; Nguyen, Lisa; Ninkovic, Sacha; Ornelas, Martha; Ryskin, Michael; Scales, Stephanie; Sutton, Scott; Tatlock, John; Verhelle, Dominique; Wang, Fen; Wells, Peter; Wythes, Martin; Yamazaki, Shinji; Yip, Brian; Yu, Xiu; Zehnder, Luke; Zhang, Wei-Guo; Rollins, Robert A.; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8306-8325</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new enhancer of zeste homolog 2 (EZH2) inhibitor series comprising a substituted Ph ring joined to a dimethylpyridone moiety via an amide linkage has been designed.  A preferential amide torsion that improved the binding properties of the compds. was identified for this series via computational anal.  Cyclization of the amide linker resulted in a six-membered lactam analog, compd. I.  This transformation significantly improved the ligand efficiency/potency of the cyclized compd. relative to its acyclic analog.  Addnl. optimization of the lactam-contg. EZH2 inhibitors focused on lipophilic efficiency (LipE) improvement, which provided compd. II.  Compd. II displayed improved LipE and on-target potency in both biochem. and cellular readouts relative to compd. I.  Inhibitor II also displayed robust in vivo antitumor growth activity and dose-dependent de-repression of EZH2 target genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr50CIrIhlikrVg90H21EOLACvtfcHk0lhiCvbMTX4RhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7rM&md5=eb6f2b053e5ba2c2d214d847ad8d9f1f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00515%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DRui%26aufirst%3DE.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBraganza%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DGukasyan%26aufirst%3DH.%2BJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DKrivacic%26aufirst%3DC.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DMcAlpine%26aufirst%3DI.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DNinkovic%26aufirst%3DS.%26aulast%3DOrnelas%26aufirst%3DM.%26aulast%3DRyskin%26aufirst%3DM.%26aulast%3DScales%26aufirst%3DS.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DTatlock%26aufirst%3DJ.%26aulast%3DVerhelle%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWells%26aufirst%3DP.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DYip%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZehnder%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%2BG.%26aulast%3DRollins%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520pyridone-containing%25203%252C4-dihydroisoquinoline-1%25282H%2529-ones%2520as%2520a%2520novel%2520class%2520of%2520enhancer%2520of%2520zeste%2520homolog%25202%2520%2528EZH2%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8306%26epage%3D8325%26doi%3D10.1021%2Facs.jmedchem.6b00515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hosea, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, R. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1177/0091270009333209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1177%2F0091270009333209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=19299532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=513-533&author=N.+A.+Hoseaauthor=W.+T.+Collardauthor=S.+Coleauthor=T.+S.+Maurerauthor=R.+X.+Fangauthor=H.+Jonesauthor=S.+M.+Kakarauthor=Y.+Nakaiauthor=B.+J.+Smithauthor=R.+Websterauthor=K.+Beaumont&title=Prediction+of+human+pharmacokinetics+from+preclinical+information%3A+comparative+accuracy+of+quantitative+prediction+approaches&doi=10.1177%2F0091270009333209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span></div><div class="casAuthors">Hosea, Natilie A.; Collard, Wendy T.; Cole, Susan; Maurer, Tristan S.; Fang, Rick X.; Jones, Hannah; Kakar, Shefali M.; Nakai, Yasuhiro; Smith, Bill J.; Webster, Rob; Beaumont, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-533</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Quant. prediction of human pharmacokinetics is crit. in assessing the viability of drug candidates and in detg. first-in-human dosing.  Numerous prediction methodologies, incorporating both in vitro and preclin. in vivo data, have been developed in recent years, each with advantages and disadvantages.  However, the lack of a comprehensive data set, both preclin. and clin., has limited efforts to evaluate the optimal strategy (or strategies) that results in quant. predictions of human pharmacokinetics.  To address this issue, the authors conducted a retrospective anal. using 50 proprietary compds. for which in vitro, preclin. pharmacokinetic data and oral single-dose human pharmacokinetic data were available.  Five predictive strategies, involving either allometry or use of unbound intrinsic clearance from microsomes or hepatocytes, were then compared for their ability to predict human oral clearance, half-life through predictions of systemic clearance, vol. of distribution, and bioavailability.  Use of a single-species scaling approach with rat, dog, or monkey was as accurate as or more accurate than using multiple-species allometry.  For those compds. cleared almost exclusively by P 450-mediated pathways, scaling from human liver microsomes was as predictive as single-species scaling of clearance based on data from rat, dog, or monkey.  These data suggest that use of predictive methods involving either single-species in vivo data or in vitro human liver microsomes can quant. predict human in vivo pharmacokinetics and suggest the possibility of streamlining the predictive methodol. through use of a single species or use only of human in vitro microsomal prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg67HcwS4O4LVg90H21EOLACvtfcHk0lhiCvbMTX4RhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D&md5=a0941d53fe43392f8fb1562ee546705e</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1177%2F0091270009333209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333209%26sid%3Dliteratum%253Aachs%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DCollard%26aufirst%3DW.%2BT.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DFang%26aufirst%3DR.%2BX.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DBeaumont%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520from%2520preclinical%2520information%253A%2520comparative%2520accuracy%2520of%2520quantitative%2520prediction%2520approaches%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D513%26epage%3D533%26doi%3D10.1177%2F0091270009333209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note">b<p class="last">Human microsomal Cl<sub>int,app</sub> ((μL/min)/mg protein) bins: <9 (low), 9–49 (moderate), and >49 (high).</p></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nkansah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney-Pickett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span> </span><span class="NLM_article-title">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1199</span><span class="NLM_x">–</span> <span class="NLM_lpage">1212</span><span class="refDoi"> DOI: 10.1021/mp2004912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2004912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1199-1212&author=M.+V.+Varmaauthor=I.+Gardnerauthor=S.+J.+Steynauthor=P.+Nkansahauthor=C.+J.+Rotterauthor=C.+Whitney-Pickettauthor=H.+Zhangauthor=L.+Diauthor=M.+Cramauthor=K.+S.+Fennerauthor=A.+F.+El-Kattan&title=pH-Dependent+solubility+and+permeability+criteria+for+provisional+biopharmaceutics+classification+%28BCS+and+BDDCS%29+in+early+drug+discovery&doi=10.1021%2Fmp2004912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span></div><div class="casAuthors">Varma, Manthena V.; Gardner, Iain; Steyn, Stefanus J.; Nkansah, Paul; Rotter, Charles J.; Whitney-Pickett, Carrie; Zhang, Hui; Di, Li; Cram, Michael; Fenner, Katherine S.; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1212</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is a scientific framework that provides a basis for predicting the oral absorption of drugs.  These concepts have been extended in the Biopharmaceutics Drug Disposition Classification System (BDDCS) to explain the potential mechanism of drug clearance and understand the effects of uptake and efflux transporters on absorption, distribution, metab., and elimination.  The objective of present work is to establish criteria for provisional biopharmaceutics classification using pH-dependent passive permeability and aq. soly. data generated from high throughput screening methodologies in drug discovery settings.  The apparent permeability across monolayers of clonal cell line of Madin-Darby canine kidney cells, selected for low endogenous efflux transporter expression, was measured for a set of 105 drugs, with known BCS and BDDCS class.  The permeability at apical pH 6.5 for acidic drugs and at pH 7.4 for nonacidic drugs showed a good correlation with the fraction absorbed in human (Fa).  Receiver operating characteristic (ROC) curve anal. was utilized to define the permeability class boundary.  At permeability ≥5 × 10-6 cm/s, the accuracy of predicting Fa of ≥0.90 was 87%.  Also, this cutoff showed more than 80% sensitivity and specificity in predicting the literature permeability classes (BCS), and the metab. classes (BDDCS).  The equil. soly. of a subset of 49 drugs was measured in pH 1.2 medium, pH 6.5 phosphate buffer, and in FaSSIF medium (pH 6.5).  Although dose was not considered, good concordance of the measured soly. with BCS and BDDCS soly. class was achieved, when soly. at pH 1.2 was used for acidic compds. and FaSSIF soly. was used for basic, neutral, and zwitterionic compds.  Using a cutoff of 200 μg/mL, the data set suggested a 93% sensitivity and 86% specificity in predicting both the BCS and BDDCS soly. classes.  In conclusion, this study identified pH-dependent permeability and soly. criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process.  Addnl., such a classification system will enable discovery scientists to assess the potential limiting factors to oral absorption, as well as help predict the drug disposition mechanisms and potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84irw4TD15rVg90H21EOLACvtfcHk0lhHX6-We4Xnew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D&md5=2bcb29ea512d2e0665973292e4a4a0a3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fmp2004912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2004912%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DNkansah%26aufirst%3DP.%26aulast%3DRotter%26aufirst%3DC.%2BJ.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCram%26aufirst%3DM.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DpH-Dependent%2520solubility%2520and%2520permeability%2520criteria%2520for%2520provisional%2520biopharmaceutics%2520classification%2520%2528BCS%2520and%2520BDDCS%2529%2520in%2520early%2520drug%2520discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D1199%26epage%3D1212%26doi%3D10.1021%2Fmp2004912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Hill, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span> </span><span class="NLM_article-title">Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">648</span><span class="NLM_x">–</span> <span class="NLM_lpage">655</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1016%2Fj.drudis.2010.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=20570751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVeksb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=648-655&author=A.+P.+Hillauthor=R.+J.+Young&title=Getting+physical+in+drug+discovery%3A+a+contemporary+perspective+on+solubility+and+hydrophobicity&doi=10.1016%2Fj.drudis.2010.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity</span></div><div class="casAuthors">Hill, Alan P.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15/16</span>),
    <span class="NLM_cas:pages">648-655</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Suboptimal phys. properties have been identified as a particular shortcoming of compds. in contemporary drug discovery, contributing to high attrition levels.  An anal. of the relationship between hydrophobicity (calcd. and measured) and ∼100 k measured kinetic soly. values has been undertaken.  In line with the General Soly. Equation, ests. of hydrophobicity, particularly ACD c log D pH7.4, give a useful indication of the likely soly. classification of particular mols.  Taking ACD c log D pH7.4 values together with the no. of arom. rings in a given mol. provides enhanced prediction.  The Soly. Forecast Index' (SFI = c log D pH7.4 + #Ar) is proposed as a simple, yet effective, guide to predicting soly.  Moreover, anal. of measured distribution/partition coeff. values highlighted statistically significant shortcomings in the applicability of octanol/water as a model system for hydrophobicity detn. with poorly sol. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdtQyfNjbFUrVg90H21EOLACvtfcHk0lhHX6-We4Xnew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVeksb3P&md5=7b201081c5586a6ea4b7af00d507d462</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%253A%2520a%2520contemporary%2520perspective%2520on%2520solubility%2520and%2520hydrophobicity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D648%26epage%3D655%26doi%3D10.1016%2Fj.drudis.2010.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">–</span> <span class="NLM_lpage">6756</span><span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lhHX6-We4Xnew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Yap, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moradian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mungall, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meissner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquez, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marra, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, S. A.</span><span> </span><span class="NLM_article-title">Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">2451</span><span class="NLM_x">–</span> <span class="NLM_lpage">2459</span><span class="refDoi"> DOI: 10.1182/blood-2010-11-321208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1182%2Fblood-2010-11-321208" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=2451-2459&author=D.+B.+Yapauthor=J.+Chuauthor=T.+Bergauthor=M.+Schapiraauthor=S.+W.+Chengauthor=A.+Moradianauthor=R.+D.+Morinauthor=A.+J.+Mungallauthor=B.+Meissnerauthor=M.+Boyleauthor=V.+E.+Marquezauthor=M.+A.+Marraauthor=R.+D.+Gascoyneauthor=R.+K.+Humphriesauthor=C.+H.+Arrowsmithauthor=G.+B.+Morinauthor=S.+A.+Aparicio&title=Somatic+mutations+at+EZH2+Y641+act+dominantly+through+a+mechanism+of+selectively+altered+PRC2+catalytic+activity%2C+to+increase+H3K27+trimethylation&doi=10.1182%2Fblood-2010-11-321208"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-11-321208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-11-321208%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DD.%2BB.%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DS.%2BW.%26aulast%3DMoradian%26aufirst%3DA.%26aulast%3DMorin%26aufirst%3DR.%2BD.%26aulast%3DMungall%26aufirst%3DA.%2BJ.%26aulast%3DMeissner%26aufirst%3DB.%26aulast%3DBoyle%26aufirst%3DM.%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DHumphries%26aufirst%3DR.%2BK.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DMorin%26aufirst%3DG.%2BB.%26aulast%3DAparicio%26aufirst%3DS.%2BA.%26atitle%3DSomatic%2520mutations%2520at%2520EZH2%2520Y641%2520act%2520dominantly%2520through%2520a%2520mechanism%2520of%2520selectively%2520altered%2520PRC2%2520catalytic%2520activity%252C%2520to%2520increase%2520H3K27%2520trimethylation%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D2451%26epage%3D2459%26doi%3D10.1182%2Fblood-2010-11-321208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Ryckmans, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, T.</span><span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A lipophilic efficiency (LipE) analysis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4406</span><span class="NLM_x">–</span> <span class="NLM_lpage">4409</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+assessment+of+a+novel+series+of+selective+CB%282%29+agonists+using+parallel+synthesis+protocols%3A+A+lipophilic+efficiency+%28LipE%29+analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0lgmTQ_bWQvLHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB%25282%2529%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520A%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span> </span><span class="NLM_article-title">Evaluating the differences in cycloalkyl ether metabolism using the design parameter “lipophilic metabolism efficiency” (LipMetE) and a matched molecular pairs analysis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6985</span><span class="NLM_x">–</span> <span class="NLM_lpage">6990</span><span class="refDoi"> DOI: 10.1021/jm4008642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4008642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6985-6990&author=A.+F.+Stepanauthor=G.+W.+Kauffmanauthor=C.+E.+Keeferauthor=P.+R.+Verhoestauthor=M.+Edwards&title=Evaluating+the+differences+in+cycloalkyl+ether+metabolism+using+the+design+parameter+%E2%80%9Clipophilic+metabolism+efficiency%E2%80%9D+%28LipMetE%29+and+a+matched+molecular+pairs+analysis&doi=10.1021%2Fjm4008642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating the Differences in Cycloalkyl Ether Metabolism Using the Design Parameter "Lipophilic Metabolism Efficiency" (LipMetE) and a Matched Molecular Pairs Analysis</span></div><div class="casAuthors">Stepan, Antonia F.; Kauffman, Gregory W.; Keefer, Christopher E.; Verhoest, Patrick R.; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6985-6990</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have obsd. previously that modification of ring size and substitution pattern may be used as a strategy to mitigate the metabolic instability of cycloalkyl ethers.  In this article, we introduce a medicinal chem. design parameter named "lipophilic metab. efficiency" (LipMetE) that indicates that these changes in metabolic stability can be largely ascribed to changes in lipophilicity.  Our matched mol. pair anal. also indicates that this finding is a general phenomenon, widely obsd. across different chemotypes.  It is our hope that both the LipMetE design parameter and the results from our pairwise anal. will be useful tools for medicinal chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpiFJ_fPxurbVg90H21EOLACvtfcHk0lgmTQ_bWQvLHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurvJ&md5=596673d35831b979b8daf5a4ccb8a218</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm4008642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4008642%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DKeefer%26aufirst%3DC.%2BE.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DEvaluating%2520the%2520differences%2520in%2520cycloalkyl%2520ether%2520metabolism%2520using%2520the%2520design%2520parameter%2520%25E2%2580%259Clipophilic%2520metabolism%2520efficiency%25E2%2580%259D%2520%2528LipMetE%2529%2520and%2520a%2520matched%2520molecular%2520pairs%2520analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6985%26epage%3D6990%26doi%3D10.1021%2Fjm4008642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bingham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grable, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span> </span><span class="NLM_article-title">Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">11384</span><span class="refDoi"> DOI: 10.1038/ncomms11384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fncomms11384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=27122193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFeiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=11384&author=A.+Broounauthor=K.+S.+Gajiwalaauthor=Y.+L.+Dengauthor=W.+Liuauthor=B.+Bolanosauthor=P.+Binghamauthor=Y.+A.+Heauthor=W.+Diehlauthor=N.+Grableauthor=P.+P.+Kungauthor=S.+Suttonauthor=K.+A.+Maegleyauthor=X.+Yuauthor=A.+E.+Stewart&title=Polycomb+repressive+complex+2+structure+with+inhibitor+reveals+a+mechanism+of+activation+and+drug+resistance&doi=10.1038%2Fncomms11384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance</span></div><div class="casAuthors">Brooun, Alexei; Gajiwala, Ketan S.; Deng, Ya-Li; Liu, Wei; Bolanos, Ben; Bingham, Patrick; He, You-Ai; Diehl, Wade; Grable, Nicole; Kung, Pei-Pei; Sutton, Scott; Maegley, Karen A.; Yu, Xiu; Stewart, Al E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11384</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) mediates gene silencing through chromatin reorganization by methylation of histone H3 lysine 27 (H3K27).  Overexpression of the complex and point mutations in the individual subunits of PRC2 have been shown to contribute to tumorigenesis.  Several inhibitors of the PRC2 activity have shown efficacy in EZH2-mutated lymphomas and are currently in clin. development, although the mol. basis of inhibitor recognition remains unknown.  Here we report the crystal structures of the inhibitor-bound wild-type and Y641N PRC2.  The structures illuminate an important role played by a stretch of 17 residues in the N-terminal region of EZH2, we call the activation loop, in the stimulation of the enzyme activity, inhibitor recognition and the potential development of the mutation-mediated drug resistance.  The work presented here provides new avenues for the design and development of next-generation PRC2 inhibitors through establishment of a structure-based drug design platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuWyWQoRoObVg90H21EOLACvtfcHk0lgmTQ_bWQvLHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFeiu7w%253D&md5=15ded613fdc3cafe35bee914678ab65e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fncomms11384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11384%26sid%3Dliteratum%253Aachs%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DGrable%26aufirst%3DN.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26atitle%3DPolycomb%2520repressive%2520complex%25202%2520structure%2520with%2520inhibitor%2520reveals%2520a%2520mechanism%2520of%2520activation%2520and%2520drug%2520resistance%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D11384%26doi%3D10.1038%2Fncomms11384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="note"><p class="first last">The coordinate error for a 3 Å crystal structure is between 0.2 and 0.3 Å. Therefore, we believe that the two compounds make hydrogen bonds of similar strength to the key residues (Trp624 and Tyr111).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span> </span><span class="NLM_article-title">Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">aac4383</span><span class="refDoi"> DOI: 10.1126/science.aac4383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1126%2Fscience.aac4383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=26472914" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2015&pages=aac4383&author=L.+Jiaoauthor=X.+Liu&title=Structural+basis+of+histone+H3K27+trimethylation+by+an+active+polycomb+repressive+complex+2&doi=10.1126%2Fscience.aac4383"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1126%2Fscience.aac4383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aac4383%26sid%3Dliteratum%253Aachs%26aulast%3DJiao%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DStructural%2520basis%2520of%2520histone%2520H3K27%2520trimethylation%2520by%2520an%2520active%2520polycomb%2520repressive%2520complex%25202%26jtitle%3DScience%26date%3D2015%26volume%3D350%26spage%3Daac4383%26doi%3D10.1126%2Fscience.aac4383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit34b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Justin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarricone, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underwood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Marco, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haire, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gamblin, S. J.</span><span> </span><span class="NLM_article-title">Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">11316</span><span class="refDoi"> DOI: 10.1038/ncomms11316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fncomms11316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=27121947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFeiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=11316&author=N.+Justinauthor=Y.+Zhangauthor=C.+Tarriconeauthor=S.+R.+Martinauthor=S.+Chenauthor=E.+Underwoodauthor=V.+De+Marcoauthor=L.+F.+Haireauthor=P.+A.+Walkerauthor=D.+Reinbergauthor=J.+R.+Wilsonauthor=S.+J.+Gamblin&title=Structural+basis+of+oncogenic+histone+H3K27M+inhibition+of+human+polycomb+repressive+complex+2&doi=10.1038%2Fncomms11316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2</span></div><div class="casAuthors">Justin, Neil; Zhang, Ying; Tarricone, Cataldo; Martin, Stephen R.; Chen, Shuyang; Underwood, Elizabeth; De Marco, Valeria; Haire, Lesley F.; Walker, Philip A.; Reinberg, Danny; Wilson, Jon R.; Gamblin, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11316</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) silences gene expression through trimethylation of K27 of histone H3 (H3K27me3) via its catalytic SET domain.  A missense mutation in the substrate of PRC2, histone H3K27M, is assocd. with certain pediatric brain cancers and is linked to a global decrease of H3K27me3 in the affected cells thought to be mediated by inhibition of PRC2 activity.  We present here the crystal structure of human PRC2 in complex with the inhibitory H3K27M peptide bound to the active site of the SET domain, with the methionine residue located in the pocket that normally accommodates the target lysine residue.  The structure and binding studies suggest a mechanism for the oncogenic inhibition of H3K27M.  The structure also reveals how binding of repressive marks, like H3K27me3, to the EED subunit of the complex leads to enhancement of the catalytic efficiency of the SET domain and thus the propagation of this repressive histone modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIwqJGbneSdbVg90H21EOLACvtfcHk0lhFWuBv0-cQVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFeiu78%253D&md5=516a8ef27712c9776e8ee0681cd91289</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1038%2Fncomms11316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11316%26sid%3Dliteratum%253Aachs%26aulast%3DJustin%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTarricone%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%2BR.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DUnderwood%26aufirst%3DE.%26aulast%3DDe%2BMarco%26aufirst%3DV.%26aulast%3DHaire%26aufirst%3DL.%2BF.%26aulast%3DWalker%26aufirst%3DP.%2BA.%26aulast%3DReinberg%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DJ.%2BR.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26atitle%3DStructural%2520basis%2520of%2520oncogenic%2520histone%2520H3K27M%2520inhibition%2520of%2520human%2520polycomb%2520repressive%2520complex%25202%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D11316%26doi%3D10.1038%2Fncomms11316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Tsuzuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchimaru, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, A.</span><span> </span><span class="NLM_article-title">Magnitude and directionality of the interaction energy of the aliphatic CH/π interaction: significant difference from hydrogen bond</span> <span class="citation_source-journal">J. Phys. Chem. A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">10163</span><span class="NLM_x">–</span> <span class="NLM_lpage">10168</span><span class="refDoi"> DOI: 10.1021/jp064206j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp064206j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFGqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2006&pages=10163-10168&author=S.+Tsuzukiauthor=K.+Hondaauthor=T.+Uchimaruauthor=M.+Mikamiauthor=A.+Fujii&title=Magnitude+and+directionality+of+the+interaction+energy+of+the+aliphatic+CH%2F%CF%80+interaction%3A+significant+difference+from+hydrogen+bond&doi=10.1021%2Fjp064206j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Magnitude and Directionality of the Interaction Energy of the Aliphatic CH/π Interaction: Significant Difference from Hydrogen Bond</span></div><div class="casAuthors">Tsuzuki, Seiji; Honda, Kazumasa; Uchimaru, Tadafumi; Mikami, Masuhiro; Fujii, Asuka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry A</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">10163-10168</span>CODEN:
                <span class="NLM_cas:coden">JPCAFH</span>;
        ISSN:<span class="NLM_cas:issn">1089-5639</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The CCSD(T) level interaction energies of CH/π complexes at the basis set limit were estd.  The estd. interaction energies of the benzene complexes with CH4, CH3CH3, CH2CH2, CHCH, CH3NH2, CH3OH, CH3OCH3, CH3F, CH3Cl, CH3ClNH2, CH3ClOH, CH2Cl2, CH2FCl, CH2F2, CHCl3, and CH3F3 are -1.45, -1.82, -2.06, -2.83, -1.94, -1.98, -2.06, -2.31, -2.99, -3.57, -3.71, -4.54, -3.88, -3.22, -5.64, and -4.18 kcal/mol, resp.  Dispersion is the major source of attraction, even if substituents are attached to the carbon atom of the C-H bond.  The dispersion interaction between benzene and chlorine atoms, which is not the CH/π interaction, is the cause of the very large interaction energy of the CHCl3 complex.  Activated CH/π interaction (acetylene and substituted methanes with two or three electron-withdrawing groups) is not very weak.  The nature of the activated CH/π interaction may be similar to the hydrogen bond.  On the other hand, the nature of other typical (nonactivated) CH/π interactions is completely different from that of the hydrogen bond.  The typical CH/π interaction is significantly weaker than the hydrogen bond.  Dispersion interaction is mainly responsible for the attraction in the CH/π interaction, whereas electrostatic interaction is the major source of attraction in the hydrogen bond.  The orientation dependence of the interaction energy of the typical CH/π interaction energy is very small, whereas the hydrogen bond has strong directionality.  The weak directionality suggests that the hydrogen atom of the interacting C-H bond is not essential for the attraction and that the typical CH/π interaction does not play crit. roles in detg. the mol. orientation in mol. assemblies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIhqHUUsd5irVg90H21EOLACvtfcHk0lhFWuBv0-cQVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFGqurc%253D&md5=d389696efd9b0b90f624879306de6a0d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjp064206j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp064206j%26sid%3Dliteratum%253Aachs%26aulast%3DTsuzuki%26aufirst%3DS.%26aulast%3DHonda%26aufirst%3DK.%26aulast%3DUchimaru%26aufirst%3DT.%26aulast%3DMikami%26aufirst%3DM.%26aulast%3DFujii%26aufirst%3DA.%26atitle%3DMagnitude%2520and%2520directionality%2520of%2520the%2520interaction%2520energy%2520of%2520the%2520aliphatic%2520CH%252F%25CF%2580%2520interaction%253A%2520significant%2520difference%2520from%2520hydrogen%2520bond%26jtitle%3DJ.%2520Phys.%2520Chem.%2520A%26date%3D2006%26volume%3D110%26spage%3D10163%26epage%3D10168%26doi%3D10.1021%2Fjp064206j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Hoffmann, R. W.</span><span> </span><span class="NLM_article-title">Allylic 1,3-strain as a controlling factor in stereoselective transformations</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1841</span><span class="NLM_x">–</span> <span class="NLM_lpage">1860</span><span class="refDoi"> DOI: 10.1021/cr00098a009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00098a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADyaL1MXmtlWnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1989&pages=1841-1860&author=R.+W.+Hoffmann&title=Allylic+1%2C3-strain+as+a+controlling+factor+in+stereoselective+transformations&doi=10.1021%2Fcr00098a009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Allylic 1,3-strain as a controlling factor in stereoselective transformations</span></div><div class="casAuthors">Hoffmann, Reinhard W.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1841-60</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">A review with 155 refs. on the manifestation of allylic strain in the stereochem. of a host of chem. reactions, including cyclizations, intermol. addn., hydrogenation, cyclopropanation, and others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDZG59Whd3WbVg90H21EOLACvtfcHk0liXnc2B57_fOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmtlWnurc%253D&md5=91540e91c0c31a112831dd5ac9d73f4d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fcr00098a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00098a009%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DR.%2BW.%26atitle%3DAllylic%25201%252C3-strain%2520as%2520a%2520controlling%2520factor%2520in%2520stereoselective%2520transformations%26jtitle%3DChem.%2520Rev.%26date%3D1989%26volume%3D89%26spage%3D1841%26epage%3D1860%26doi%3D10.1021%2Fcr00098a009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Taylor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennard, O.</span><span> </span><span class="NLM_article-title">Hydrogen-bond geometry in organic crystals</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">320</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1021/ar00105a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar00105a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADyaL2cXlsVWitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1984&pages=320-326&author=R.+Taylorauthor=O.+Kennard&title=Hydrogen-bond+geometry+in+organic+crystals&doi=10.1021%2Far00105a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrogen-bond geometry in organic crystals</span></div><div class="casAuthors">Taylor, Robin; Kennard, Olga</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">320-6</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    </div><div class="casAbstract">A review with 34 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCSKO2ZfkARLVg90H21EOLACvtfcHk0liXnc2B57_fOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXlsVWitLk%253D&md5=ef444116e1ee4eedae1e8048d711c12f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Far00105a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far00105a004%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DR.%26aulast%3DKennard%26aufirst%3DO.%26atitle%3DHydrogen-bond%2520geometry%2520in%2520organic%2520crystals%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1984%26volume%3D17%26spage%3D320%26epage%3D326%26doi%3D10.1021%2Far00105a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span> </span><span class="NLM_article-title">Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">3593</span><span class="NLM_x">–</span> <span class="NLM_lpage">3608</span><span class="refDoi"> DOI: 10.1021/jm400102x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400102x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVWrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3593-3608&author=A.+Liauthor=Y.+Ouyangauthor=Z.+Wangauthor=Y.+Caoauthor=X.+Liuauthor=L.+Ranauthor=C.+Liauthor=L.+Liauthor=L.+Zhangauthor=K.+Qiaoauthor=W.+Xuauthor=Y.+Huangauthor=Z.+Zhangauthor=C.+Tianauthor=Z.+Liuauthor=S.+Jiangauthor=Y.+Shaoauthor=Y.+Duauthor=L.+Maauthor=X.+Wangauthor=J.+Liu&title=Novel+pyridinone+derivatives+as+non-nucleoside+reverse+transcriptase+inhibitors+%28NNRTIs%29+with+high+potency+against+NNRTI-resistant+HIV-1+strains&doi=10.1021%2Fjm400102x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Pyridinone Derivatives As Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) with High Potency against NNRTI-Resistant HIV-1 Strains</span></div><div class="casAuthors">Li, Amin; Ouyang, Yabo; Wang, Ziyun; Cao, Yuanyuan; Liu, Xiangyi; Ran, Li; Li, Chao; Li, Li; Zhang, Liang; Qiao, Kang; Xu, Weisi; Huang, Yang; Zhang, Zhili; Tian, Chao; Liu, Zhenming; Jiang, Shibo; Shao, Yiming; Du, Yansheng; Ma, Liying; Wang, Xiaowei; Liu, Junyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3593-3608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel 6-substituted-4-cycloalkyloxy-pyridin-2(1H)-ones were synthesized as non-nucleoside reverse transcriptase inhibitors (NNRTIs), and their biol. activity was evaluated.  Most of the compds., esp. 26 and 22 (XXVI and XXII), bearing a 3-iso-Pr and 3-iodine group, resp., exhibited highly potent activity against wild-type HIV-1 strains and those resistant to reverse transcriptase inhibitors (RTIs).  The diastereoisomers of 26-trans and 26-cis were synthesized sep. and confirmed with HPLC and NOESY spectra.  The 26-trans isomers had an activity about 400-fold more potent than that of 26-cis.  The pair of 26-trans enantiomers, one of the most potent inhibitors with EC50 of 4 nM and selectivity index (SI) of 75000, was highly effective against a panel of RTIs-resistant strains with single (Y181C and K103N) or double (A17) mutations in reverse transcriptase.  The results suggest that these novel pyridinone derivs. have the potential to be further developed as new antiretroviral drugs with improved antiviral efficacy and drug resistance profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYvVz2YpBIGLVg90H21EOLACvtfcHk0liXnc2B57_fOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVWrs7w%253D&md5=f077204b0fc3bd46c80c36fca58b4778</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm400102x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400102x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DA.%26aulast%3DOuyang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DRan%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DQiao%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DNovel%2520pyridinone%2520derivatives%2520as%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520%2528NNRTIs%2529%2520with%2520high%2520potency%2520against%2520NNRTI-resistant%2520HIV-1%2520strains%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3593%26epage%3D3608%26doi%3D10.1021%2Fjm400102x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, N. C.</span><span> </span><span class="NLM_article-title">An efficient approach to 3,4-disubstituted pyridin-2-ones. formal synthesis of mappicine ketone</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">5688</span><span class="NLM_x">–</span> <span class="NLM_lpage">5691</span><span class="refDoi"> DOI: 10.1021/jo034042s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo034042s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=5688-5691&author=C.+H.+Linauthor=M.+R.+Tsaiauthor=Y.+S.+Wangauthor=N.+C.+Chang&title=An+efficient+approach+to+3%2C4-disubstituted+pyridin-2-ones.+formal+synthesis+of+mappicine+ketone&doi=10.1021%2Fjo034042s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjo034042s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo034042s%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DTsai%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BS.%26aulast%3DChang%26aufirst%3DN.%2BC.%26atitle%3DAn%2520efficient%2520approach%2520to%25203%252C4-disubstituted%2520pyridin-2-ones.%2520formal%2520synthesis%2520of%2520mappicine%2520ketone%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D5688%26epage%3D5691%26doi%3D10.1021%2Fjo034042s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Hama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culkin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartwig, J. F.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed α-arylation of esters and amides under more neutral conditions</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">11176</span><span class="NLM_x">–</span> <span class="NLM_lpage">11177</span><span class="refDoi"> DOI: 10.1021/ja036792p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja036792p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVynsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2003&pages=11176-11177&author=T.+Hamaauthor=X.+Liuauthor=D.+A.+Culkinauthor=J.+F.+Hartwig&title=Palladium-catalyzed+%CE%B1-arylation+of+esters+and+amides+under+more+neutral+conditions&doi=10.1021%2Fja036792p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed α-Arylation of Esters and Amides under More Neutral Conditions</span></div><div class="casAuthors">Hama, Takuo; Liu, Xiaoxiang; Culkin, Darcy A.; Hartwig, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">11176-11177</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two procedures for the α-arylation of carbonyl compds., under more neutral conditions than those for reactions of aryl halides with alkali metal enolates, are reported.  The first procedure rests upon the development of catalysts bearing the hindered pentaphenylferrocenyl di-tert-butylphosphine (Q-phos), and the highly reactive dimeric Pd(I) complex {[P(t-Bu)3]PdBr}2.  Zinc enolates, prepd. from α-bromo esters and amides, react with aryl bromides to form α-aryl esters, e.g., I (R1 = OCMe3, R2 = H), and amides, e.g., I (R1 = NEt2, R2 = Me), in high yields, and with remarkable functional group tolerance.  The second procedure; silyl ketenes II (R3 = t-Bu, R4 = H; R3 = R4 = Me) and silyl ketimine acetals react with aryl bromides in the presence of substoichiometric amts. of zinc fluoride, Pd(dba)2, and P(t-Bu)3 to give α-aryl esters and amides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUgTDi6U6CcbVg90H21EOLACvtfcHk0ljmbeT998PbLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVynsbY%253D&md5=c15ec36ca3047c7815add05ecbaf0ba1</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fja036792p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja036792p%26sid%3Dliteratum%253Aachs%26aulast%3DHama%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCulkin%26aufirst%3DD.%2BA.%26aulast%3DHartwig%26aufirst%3DJ.%2BF.%26atitle%3DPalladium-catalyzed%2520%25CE%25B1-arylation%2520of%2520esters%2520and%2520amides%2520under%2520more%2520neutral%2520conditions%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2003%26volume%3D125%26spage%3D11176%26epage%3D11177%26doi%3D10.1021%2Fja036792p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Li-Yuan Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span> </span><span class="NLM_article-title">Progress and developments in the turbo Grignard reagent i-PrMgCl·LiCl: a ten-year journey</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6884</span><span class="NLM_x">–</span> <span class="NLM_lpage">6900</span><span class="refDoi"> DOI: 10.1039/C4CC10194D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1039%2FC4CC10194D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=25714498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVeltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=6884-6900&author=R.+Li-Yuan+Baoauthor=R.+Zhaoauthor=L.+Shi&title=Progress+and+developments+in+the+turbo+Grignard+reagent+i-PrMgCl%C2%B7LiCl%3A+a+ten-year+journey&doi=10.1039%2FC4CC10194D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Progress and developments in the turbo Grignard reagent i-PrMgCl·LiCl: a ten-year journey</span></div><div class="casAuthors">Li-Yuan Bao, Robert; Zhao, Rong; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">6884-6900</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Over the past decade, the effectiveness of i-PrMgCl·LiCl has been constantly highlighted by a no. of research groups.  Its enhanced nucleophilicity brings prosperity to highly functionalized Grignard reagents, other useful bimetallic (alkali-metal) agents and nucleophilic alkylation products under mild reaction conditions.  In this feature article, a comprehensive, systematical and in-depth overview of i-PrMgCl·LiCl is provided in a multidisciplinary idea.  It involves the structural and kinetic perspectives of i-PrMgCl·LiCl as well as its unique reactivity and selectivity, with knowledge of the former helping to rationalize trends of the later.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHU-x1ob4nvLVg90H21EOLACvtfcHk0ljmbeT998PbLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVeltro%253D&md5=ad9c174821be3788331078e27f63a85b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2FC4CC10194D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC10194D%26sid%3Dliteratum%253Aachs%26aulast%3DLi-Yuan%2BBao%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DProgress%2520and%2520developments%2520in%2520the%2520turbo%2520Grignard%2520reagent%2520i-PrMgCl%25C2%25B7LiCl%253A%2520a%2520ten-year%2520journey%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D6884%26epage%3D6900%26doi%3D10.1039%2FC4CC10194D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><div class="note"><p class="first last">For an alternative synthesis of oxetane-3-carbaldehyde see the following:</p></div><span class="NLM_contrib-group">Kephart, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zehnder, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S. C.</span><span> </span><span class="NLM_article-title">Synthesis of oxetane-3-carboxaldehyde and methyl oxetane-3-carboxylate via homologation of oxetane-3-one</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3641</span><span class="NLM_x">–</span> <span class="NLM_lpage">3646</span><span class="refDoi"> DOI: 10.1016/j.tet.2016.03.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1016%2Fj.tet.2016.03.078" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=3641-3646&author=S.+E.+Kephartauthor=L.+R.+Zehnderauthor=B.+Huangauthor=S.+C.+Sutton&title=Synthesis+of+oxetane-3-carboxaldehyde+and+methyl+oxetane-3-carboxylate+via+homologation+of+oxetane-3-one&doi=10.1016%2Fj.tet.2016.03.078"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2016.03.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2016.03.078%26sid%3Dliteratum%253Aachs%26aulast%3DKephart%26aufirst%3DS.%2BE.%26aulast%3DZehnder%26aufirst%3DL.%2BR.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DSutton%26aufirst%3DS.%2BC.%26atitle%3DSynthesis%2520of%2520oxetane-3-carboxaldehyde%2520and%2520methyl%2520oxetane-3-carboxylate%2520via%2520homologation%2520of%2520oxetane-3-one%26jtitle%3DTetrahedron%26date%3D2016%26volume%3D72%26spage%3D3641%26epage%3D3646%26doi%3D10.1016%2Fj.tet.2016.03.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span> </span><span class="NLM_article-title">Catalytic asymmetric nucleophilic openings of 3-substituted oxetanes</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6028</span><span class="NLM_x">–</span> <span class="NLM_lpage">6032</span><span class="refDoi"> DOI: 10.1039/C4OB00920G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1039%2FC4OB00920G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=24968137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGnsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=6028-6032&author=Z.+Wangauthor=Z.+Chenauthor=J.+Sun&title=Catalytic+asymmetric+nucleophilic+openings+of+3-substituted+oxetanes&doi=10.1039%2FC4OB00920G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic asymmetric nucleophilic openings of 3-substituted oxetanes</span></div><div class="casAuthors">Wang, Zhaobin; Chen, Zhilong; Sun, Jianwei</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">6028-6032</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Asym. ring-opening of 3-substituted oxetanes provides rapid access to highly functionalized chiral building blocks.  However, progress in this field is limited.  Recently the authors developed a new catalytic system based on chiral Bronsted acids for this type of reaction and demonstrated the synthesis of a range of useful mols. under mild and operationally simple conditions.  In this perspective, the authors describe the challenges, progress, and potential future efforts on this topic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM9rqwK5NcjbVg90H21EOLACvtfcHk0ljmbeT998PbLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGnsL3I&md5=b96914862c1e5e6d86ec259132cdb8ce</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1039%2FC4OB00920G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4OB00920G%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DCatalytic%2520asymmetric%2520nucleophilic%2520openings%2520of%25203-substituted%2520oxetanes%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2014%26volume%3D12%26spage%3D6028%26epage%3D6032%26doi%3D10.1039%2FC4OB00920G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23a','cit23b'],'ref24':['cit24'],'ref25':['cit25a'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':[],'ref34':['cit34a','cit34b'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 30 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Daohai Du, Dandan Xu, Licheng Zhu, Giulia Stazi, Clemens Zwergel, Yanli Liu, Zhongyuan Luo, Yuanqing Li, Yuanyuan Zhang, Kongkai Zhu, Yiluan Ding, Jingqiu Liu, Shijie Fan, Kaiyan Zhao, Naixia Zhang, Xiangqian Kong, Hualiang Jiang, Kaixian Chen, Kehao Zhao, Sergio Valente, Jinrong Min, Wenhu Duan, <span class="NLM_string-name hlFld-ContribAuthor">Cheng Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2–EED Interaction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8194-8207. <a href="https://doi.org/10.1021/acs.jmedchem.0c02261" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02261</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02261%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Guided%252BDevelopment%252Bof%252BSmall-Molecule%252BPRC2%252BInhibitors%252BTargeting%252BEZH2%2525E2%252580%252593EED%252BInteraction%26aulast%3DDu%26aufirst%3DDaohai%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D30122020%26date%3D02062021%26volume%3D64%26issue%3D12%26spage%3D8194%26epage%3D8207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhihao Liu, Xi Hu, Qiwei Wang, Xiuli Wu, Qiangsheng Zhang, Wei Wei, Xingping Su, Hualong He, Shuyan Zhou, Rong Hu, Tinghong Ye, Yongxia Zhu, Ningyu Wang, <span class="NLM_string-name hlFld-ContribAuthor">Luoting Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2829-2848. <a href="https://doi.org/10.1021/acs.jmedchem.0c02234" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02234</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02234%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BEZH2-Based%252BPROTACs%252Bto%252BDegrade%252Bthe%252BPRC2%252BComplex%252Bfor%252BTargeting%252Bthe%252BNoncatalytic%252BActivity%252Bof%252BEZH2%26aulast%3DLiu%26aufirst%3DZhihao%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D24122020%26date%3D19022021%26volume%3D64%26issue%3D5%26spage%3D2829%26epage%3D2848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">M. Cynthia Martin, Guihua Zeng, Jindan Yu, <span class="NLM_string-name hlFld-ContribAuthor">Gary E. Schiltz</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15344-15370. <a href="https://doi.org/10.1021/acs.jmedchem.0c01344" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01344</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01344%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BApproaches%252Bfor%252BTargeting%252Bthe%252BPolycomb%252BRepressive%252BComplex%252B2%252B%252528PRC2%252529%252Bin%252BCancer%26aulast%3DMartin%26aufirst%3DM.%2BCynthia%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D31072020%26date%3D07122020%26volume%3D63%26issue%3D24%26spage%3D15344%26epage%3D15370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Emily J. Hanan, Jun Liang, Xiaojing Wang, Robert A. Blake, Nicole Blaquiere, <span class="NLM_string-name hlFld-ContribAuthor">Steven T. Staben</span>. </span><span class="cited-content_cbyCitation_article-title">Monomeric Targeted Protein Degraders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11330-11361. <a href="https://doi.org/10.1021/acs.jmedchem.0c00093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMonomeric%252BTargeted%252BProtein%252BDegraders%26aulast%3DHanan%26aufirst%3DEmily%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17012020%26date%3D15062020%26date%3D30042020%26volume%3D63%26issue%3D20%26spage%3D11330%26epage%3D11361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Avinash Khanna, Alexandre Côté, Shilpi Arora, Ludivine Moine, Victor S. Gehling, Jehrod Brenneman, Nico Cantone, Jacob I. Stuckey, Shruti Apte, Ashwin Ramakrishnan, Kamil Bruderek, William D. Bradley, James E. Audia, Richard T. Cummings, Robert J. Sims III, Patrick Trojer, <span class="NLM_string-name hlFld-ContribAuthor">Julian R. Levell</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1205-1212. <a href="https://doi.org/10.1021/acsmedchemlett.0c00045" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00045%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BPharmacological%252BEvaluation%252Bof%252BSecond%252BGeneration%252BEZH2%252BInhibitors%252Bwith%252BLong%252BResidence%252BTime%26aulast%3DKhanna%26aufirst%3DAvinash%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28012020%26date%3D26032020%26date%3D02042020%26date%3D26032020%26volume%3D11%26issue%3D6%26spage%3D1205%26epage%3D1212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kunal  Nepali</span>, <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomedical Science</span><span> <strong>2021,</strong> <em>28 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12929-021-00721-x" title="DOI URL">https://doi.org/10.1186/s12929-021-00721-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12929-021-00721-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12929-021-00721-x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomedical%2520Science%26atitle%3DRecent%252Bdevelopments%252Bin%252Bepigenetic%252Bcancer%252Btherapeutics%25253A%252Bclinical%252Badvancement%252Band%252Bemerging%252Btrends%26aulast%3DNepali%26aufirst%3DKunal%26date%3D2021%26date%3D2021%26volume%3D28%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Su H.  Park</span>, <span class="hlFld-ContribAuthor ">Ka-Wing  Fong</span>, <span class="hlFld-ContribAuthor ">Ezinne  Mong</span>, <span class="hlFld-ContribAuthor ">M. Cynthia  Martin</span>, <span class="hlFld-ContribAuthor ">Gary E.  Schiltz</span>, <span class="hlFld-ContribAuthor ">Jindan  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Going beyond Polycomb: EZH2 functions in prostate cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2021,</strong> <em>276 </em><a href="https://doi.org/10.1038/s41388-021-01982-4" title="DOI URL">https://doi.org/10.1038/s41388-021-01982-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41388-021-01982-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41388-021-01982-4%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DGoing%252Bbeyond%252BPolycomb%25253A%252BEZH2%252Bfunctions%252Bin%252Bprostate%252Bcancer%26aulast%3DPark%26aufirst%3DSu%2BH.%26date%3D2021%26date%3D2021%26volume%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuai  Zou</span>, <span class="hlFld-ContribAuthor ">Li  Pan</span>, <span class="hlFld-ContribAuthor ">Tian  Xue</span>, <span class="hlFld-ContribAuthor ">Huang  Huang</span>, <span class="hlFld-ContribAuthor ">Shu  Geng</span>, <span class="hlFld-ContribAuthor ">Jun-Jie  Ding</span>, <span class="hlFld-ContribAuthor ">Fei-Yan  Fu</span>, <span class="hlFld-ContribAuthor ">Feng  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Metal-free visible-light-catalyzed synthesis of 3-methyl-3,4-dihydroisoquinolin-1(2H)-one: mechanism, DFT calculation and optical properties. </span><span class="cited-content_cbyCitation_journal-name">Chemical Papers</span><span> <strong>2021,</strong> <em>75 </em>
                                    (8)
                                     , 4069-4074. <a href="https://doi.org/10.1007/s11696-021-01639-2" title="DOI URL">https://doi.org/10.1007/s11696-021-01639-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11696-021-01639-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11696-021-01639-2%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Papers%26atitle%3DMetal-free%252Bvisible-light-catalyzed%252Bsynthesis%252Bof%252B3-methyl-3%25252C4-dihydroisoquinolin-1%2525282H%252529-one%25253A%252Bmechanism%25252C%252BDFT%252Bcalculation%252Band%252Boptical%252Bproperties%26aulast%3DZou%26aufirst%3DShuai%26date%3D2021%26date%3D2021%26volume%3D75%26issue%3D8%26spage%3D4069%26epage%3D4074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahesh R.  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Nitin P.  Lad</span>, <span class="hlFld-ContribAuthor ">Vijay M.  Khedkar</span>, <span class="hlFld-ContribAuthor ">Nitin D.  Gaikwad</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, in vitro cytotoxicity, and molecular docking study of novel 3,
              4‐dihydroisoquinolin
              ‐1(
              
                2
                H
              
              )‐one based piperlongumine analogues. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2021,</strong> <em>58 </em>
                                    (6)
                                     , 1359-1370. <a href="https://doi.org/10.1002/jhet.4264" title="DOI URL">https://doi.org/10.1002/jhet.4264</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.4264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.4264%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DSynthesis%25252C%252Bin%252Bvitro%252Bcytotoxicity%25252C%252Band%252Bmolecular%252Bdocking%252Bstudy%252Bof%252Bnovel%252B3%25252C%252B4%2525E2%252580%252590dihydroisoquinolin%252B%2525E2%252580%2525901%252528%252B2%252BH%252B%252529%2525E2%252580%252590one%252Bbased%252Bpiperlongumine%252Banalogues%26aulast%3DKulkarni%26aufirst%3DMahesh%2BR.%26date%3D2021%26date%3D2021%26volume%3D58%26issue%3D6%26spage%3D1359%26epage%3D1370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Milly  Dockerill</span>, <span class="hlFld-ContribAuthor ">Clare  Gregson</span>, <span class="hlFld-ContribAuthor ">Daniel H.  O’ Donovan</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (2)
                                     , 119-135. <a href="https://doi.org/10.1080/13543776.2021.1841167" title="DOI URL">https://doi.org/10.1080/13543776.2021.1841167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1841167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1841167%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DTargeting%252BPRC2%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%25253A%252Ban%252Bupdated%252Bpatent%252Breview%252B%2525282016%252B-%252B2020%252529%26aulast%3DDockerill%26aufirst%3DMilly%26date%3D2021%26date%3D2021%26volume%3D31%26issue%3D2%26spage%3D119%26epage%3D135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacob I.  Stuckey</span>, <span class="hlFld-ContribAuthor ">Nico R.  Cantone</span>, <span class="hlFld-ContribAuthor ">Alexandre  Côté</span>, <span class="hlFld-ContribAuthor ">Shilpi  Arora</span>, <span class="hlFld-ContribAuthor ">Valerie  Vivat</span>, <span class="hlFld-ContribAuthor ">Ashwin  Ramakrishnan</span>, <span class="hlFld-ContribAuthor ">Jennifer A.  Mertz</span>, <span class="hlFld-ContribAuthor ">Avinash  Khanna</span>, <span class="hlFld-ContribAuthor ">Jehrod  Brenneman</span>, <span class="hlFld-ContribAuthor ">Victor S.  Gehling</span>, <span class="hlFld-ContribAuthor ">Ludivine  Moine</span>, <span class="hlFld-ContribAuthor ">Robert J.  Sims</span>, <span class="hlFld-ContribAuthor ">James E.  Audia</span>, <span class="hlFld-ContribAuthor ">Patrick  Trojer</span>, <span class="hlFld-ContribAuthor ">Julian R.  Levell</span>, <span class="hlFld-ContribAuthor ">Richard T.  Cummings</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2021,</strong> <em>296 </em>, 100349. <a href="https://doi.org/10.1016/j.jbc.2021.100349" title="DOI URL">https://doi.org/10.1016/j.jbc.2021.100349</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jbc.2021.100349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jbc.2021.100349%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DIdentification%252Band%252Bcharacterization%252Bof%252Bsecond-generation%252BEZH2%252Binhibitors%252Bwith%252Bextended%252Bresidence%252Btimes%252Band%252Bimproved%252Bbiological%252Bactivity%26aulast%3DStuckey%26aufirst%3DJacob%2BI.%26date%3D2021%26volume%3D296%26spage%3D100349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marie-Lisa  Eich</span>, <span class="hlFld-ContribAuthor ">Mohammad  Athar</span>, <span class="hlFld-ContribAuthor ">James E.  Ferguson</span>, <span class="hlFld-ContribAuthor ">Sooryanarayana  Varambally</span>. </span><span class="cited-content_cbyCitation_article-title">EZH2-Targeted Therapies in Cancer: Hype or a Reality. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2020,</strong> <em>80 </em>
                                    (24)
                                     , 5449-5458. <a href="https://doi.org/10.1158/0008-5472.CAN-20-2147" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-20-2147</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-20-2147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-20-2147%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DEZH2-Targeted%252BTherapies%252Bin%252BCancer%25253A%252BHype%252Bor%252Ba%252BReality%26aulast%3DEich%26aufirst%3DMarie-Lisa%26date%3D2020%26date%3D2020%26volume%3D80%26issue%3D24%26spage%3D5449%26epage%3D5458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ran  Duan</span>, <span class="hlFld-ContribAuthor ">Wenfang  Du</span>, <span class="hlFld-ContribAuthor ">Weijian  Guo</span>. </span><span class="cited-content_cbyCitation_article-title">EZH2: a novel target for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-020-00937-8" title="DOI URL">https://doi.org/10.1186/s13045-020-00937-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-020-00937-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-020-00937-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DEZH2%25253A%252Ba%252Bnovel%252Btarget%252Bfor%252Bcancer%252Btreatment%26aulast%3DDuan%26aufirst%3DRan%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahesh R.  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Nitin D.  Gaikwad</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Synthesis of 3,4‐Dihydroisoquinolin‐1(2
              H
              )‐one. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2020,</strong> <em>5 </em>
                                    (27)
                                     , 8157-8184. <a href="https://doi.org/10.1002/slct.202002131" title="DOI URL">https://doi.org/10.1002/slct.202002131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202002131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202002131%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DRecent%252BAdvances%252Bin%252BSynthesis%252Bof%252B3%25252C4%2525E2%252580%252590Dihydroisoquinolin%2525E2%252580%2525901%2525282%252BH%252B%252529%2525E2%252580%252590one%26aulast%3DKulkarni%26aufirst%3DMahesh%2BR.%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D27%26spage%3D8157%26epage%3D8184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ritika  Tiwari</span>, <span class="hlFld-ContribAuthor ">Nishat  Manzar</span>, <span class="hlFld-ContribAuthor ">Bushra  Ateeq</span>. </span><span class="cited-content_cbyCitation_article-title">Dynamics of Cellular Plasticity in Prostate Cancer Progression. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Molecular Biosciences</span><span> <strong>2020,</strong> <em>7 </em><a href="https://doi.org/10.3389/fmolb.2020.00130" title="DOI URL">https://doi.org/10.3389/fmolb.2020.00130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmolb.2020.00130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmolb.2020.00130%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Molecular%2520Biosciences%26atitle%3DDynamics%252Bof%252BCellular%252BPlasticity%252Bin%252BProstate%252BCancer%252BProgression%26aulast%3DTiwari%26aufirst%3DRitika%26date%3D2020%26date%3D2020%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hope S.  Rugo</span>, <span class="hlFld-ContribAuthor ">Ira  Jacobs</span>, <span class="hlFld-ContribAuthor ">Shikhar  Sharma</span>, <span class="hlFld-ContribAuthor ">Frank  Scappaticci</span>, <span class="hlFld-ContribAuthor ">Thomas A.  Paul</span>, <span class="hlFld-ContribAuthor ">Kristen  Jensen-Pergakes</span>, <span class="hlFld-ContribAuthor ">Gabriel G.  Malouf</span>. </span><span class="cited-content_cbyCitation_article-title">The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review. </span><span class="cited-content_cbyCitation_journal-name">Advances in Therapy</span><span> <strong>2020,</strong> <em>37 </em>
                                    (7)
                                     , 3059-3082. <a href="https://doi.org/10.1007/s12325-020-01379-x" title="DOI URL">https://doi.org/10.1007/s12325-020-01379-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12325-020-01379-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12325-020-01379-x%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvances%2520in%2520Therapy%26atitle%3DThe%252BPromise%252Bfor%252BHistone%252BMethyltransferase%252BInhibitors%252Bfor%252BEpigenetic%252BTherapy%252Bin%252BClinical%252BOncology%25253A%252BA%252BNarrative%252BReview%26aulast%3DRugo%26aufirst%3DHope%2BS.%26date%3D2020%26date%3D2020%26volume%3D37%26issue%3D7%26spage%3D3059%26epage%3D3082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laia  Richart</span>, <span class="hlFld-ContribAuthor ">Raphaël  Margueron</span>. </span><span class="cited-content_cbyCitation_article-title">Drugging histone methyltransferases in cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2020,</strong> <em>56 </em>, 51-62. <a href="https://doi.org/10.1016/j.cbpa.2019.11.009" title="DOI URL">https://doi.org/10.1016/j.cbpa.2019.11.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2019.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2019.11.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DDrugging%252Bhistone%252Bmethyltransferases%252Bin%252Bcancer%26aulast%3DRichart%26aufirst%3DLaia%26date%3D2020%26volume%3D56%26spage%3D51%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shinji  Yamazaki</span>, <span class="hlFld-ContribAuthor ">Hovhannes J.  Gukasyan</span>, <span class="hlFld-ContribAuthor ">Hui  Wang</span>, <span class="hlFld-ContribAuthor ">Sean  Uryu</span>, <span class="hlFld-ContribAuthor ">Shikhar  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2020,</strong> <em>373 </em>
                                    (2)
                                     , 220-229. <a href="https://doi.org/10.1124/jpet.119.263491" title="DOI URL">https://doi.org/10.1124/jpet.119.263491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.119.263491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.119.263491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DTranslational%252BPharmacokinetic-Pharmacodynamic%252BModeling%252Bfor%252Ban%252BOrally%252BAvailable%252BNovel%252BInhibitor%252Bof%252BEpigenetic%252BRegulator%252BEnhancer%252Bof%252BZeste%252BHomolog%252B2%26aulast%3DYamazaki%26aufirst%3DShinji%26date%3D2020%26date%3D2020%26volume%3D373%26issue%3D2%26spage%3D220%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fangyu  Du</span>, <span class="hlFld-ContribAuthor ">Qifan  Zhou</span>, <span class="hlFld-ContribAuthor ">Wenjiao  Sun</span>, <span class="hlFld-ContribAuthor ">Cheng  Yang</span>, <span class="hlFld-ContribAuthor ">Chunfu  Wu</span>, <span class="hlFld-ContribAuthor ">Lihui  Wang</span>, <span class="hlFld-ContribAuthor ">Guoliang  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">5-Hydroxyindole-Based EZH2 Inhibitors Assembled via TCCA-Catalyzed Condensation and Nenitzescu Reactions. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (9)
                                     , 2059. <a href="https://doi.org/10.3390/molecules25092059" title="DOI URL">https://doi.org/10.3390/molecules25092059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25092059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25092059%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3D5-Hydroxyindole-Based%252BEZH2%252BInhibitors%252BAssembled%252Bvia%252BTCCA-Catalyzed%252BCondensation%252Band%252BNenitzescu%252BReactions%26aulast%3DDu%26aufirst%3DFangyu%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D9%26spage%3D2059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qifan  Zhou</span>, <span class="hlFld-ContribAuthor ">Lina  Jia</span>, <span class="hlFld-ContribAuthor ">Fangyu  Du</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Dong</span>, <span class="hlFld-ContribAuthor ">Wanyu  Sun</span>, <span class="hlFld-ContribAuthor ">Lihui  Wang</span>, <span class="hlFld-ContribAuthor ">Guoliang  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (6)
                                     , 2247-2255. <a href="https://doi.org/10.1039/C9NJ04713A" title="DOI URL">https://doi.org/10.1039/C9NJ04713A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9NJ04713A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9NJ04713A%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bactivities%252Bof%252Bpyrrole-3-carboxamide%252Bderivatives%252Bas%252BEZH2%252B%252528enhancer%252Bof%252Bzeste%252Bhomologue%252B2%252529%252Binhibitors%252Band%252Banticancer%252Bagents%26aulast%3DZhou%26aufirst%3DQifan%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D6%26spage%3D2247%26epage%3D2255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anqi  Ma</span>, <span class="hlFld-ContribAuthor ">Elias  Stratikopoulos</span>, <span class="hlFld-ContribAuthor ">Kwang-Su  Park</span>, <span class="hlFld-ContribAuthor ">Jieli  Wei</span>, <span class="hlFld-ContribAuthor ">Tiphaine C.  Martin</span>, <span class="hlFld-ContribAuthor ">Xiaobao  Yang</span>, <span class="hlFld-ContribAuthor ">Megan  Schwarz</span>, <span class="hlFld-ContribAuthor ">Violetta  Leshchenko</span>, <span class="hlFld-ContribAuthor ">Alexander  Rialdi</span>, <span class="hlFld-ContribAuthor ">Brandon  Dale</span>, <span class="hlFld-ContribAuthor ">Alessandro  Lagana</span>, <span class="hlFld-ContribAuthor ">Ernesto  Guccione</span>, <span class="hlFld-ContribAuthor ">Samir  Parekh</span>, <span class="hlFld-ContribAuthor ">Ramon  Parsons</span>, <span class="hlFld-ContribAuthor ">Jian  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a first-in-class EZH2 selective degrader. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2020,</strong> <em>16 </em>
                                    (2)
                                     , 214-222. <a href="https://doi.org/10.1038/s41589-019-0421-4" title="DOI URL">https://doi.org/10.1038/s41589-019-0421-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41589-019-0421-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41589-019-0421-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DDiscovery%252Bof%252Ba%252Bfirst-in-class%252BEZH2%252Bselective%252Bdegrader%26aulast%3DMa%26aufirst%3DAnqi%26date%3D2020%26date%3D2019%26volume%3D16%26issue%3D2%26spage%3D214%26epage%3D222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">P. Ann  Boriack‐Sjodin</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic Proteins as Emerging Drug Targets. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 423-448. <a href="https://doi.org/10.1002/9781118681121.ch18" title="DOI URL">https://doi.org/10.1002/9781118681121.ch18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118681121.ch18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118681121.ch18%26sid%3Dliteratum%253Aachs%26atitle%3DEpigenetic%252BProteins%252Bas%252BEmerging%252BDrug%252BTargets%26aulast%3DBoriack%25E2%2580%2590Sjodin%26aufirst%3DP.%2BAnn%26date%3D2020%26date%3D2020%26spage%3D423%26epage%3D448%26pub%3DWiley%26atitle%3DStructural%252BBiology%252Bin%252BDrug%252BDiscovery%26aulast%3DRenaud%26aufirst%3DJean%25E2%2580%2590Paul%26date%3D2020%26date%3D2020%26volume%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soufiane  Boumahdi</span>, <span class="hlFld-ContribAuthor ">Frederic J.  de Sauvage</span>. </span><span class="cited-content_cbyCitation_article-title">The great escape: tumour cell plasticity in resistance to targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2020,</strong> <em>19 </em>
                                    (1)
                                     , 39-56. <a href="https://doi.org/10.1038/s41573-019-0044-1" title="DOI URL">https://doi.org/10.1038/s41573-019-0044-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-019-0044-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-019-0044-1%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DThe%252Bgreat%252Bescape%25253A%252Btumour%252Bcell%252Bplasticity%252Bin%252Bresistance%252Bto%252Btargeted%252Btherapy%26aulast%3DBoumahdi%26aufirst%3DSoufiane%26date%3D2020%26date%3D2019%26volume%3D19%26issue%3D1%26spage%3D39%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Ye</span>, <span class="hlFld-ContribAuthor ">Jing  Huang</span>, <span class="hlFld-ContribAuthor ">Hongbo  Wang</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>, <span class="hlFld-ContribAuthor ">Kehao  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting epigenetic machinery: Emerging novel allosteric inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2019,</strong> <em>204 </em>, 107406. <a href="https://doi.org/10.1016/j.pharmthera.2019.107406" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2019.107406</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2019.107406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2019.107406%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DTargeting%252Bepigenetic%252Bmachinery%25253A%252BEmerging%252Bnovel%252Ballosteric%252Binhibitors%26aulast%3DYe%26aufirst%3DFei%26date%3D2019%26volume%3D204%26spage%3D107406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lixin  Yang</span>, <span class="hlFld-ContribAuthor ">Yongqing  Liu</span>, <span class="hlFld-ContribAuthor ">Minghua  Fan</span>, <span class="hlFld-ContribAuthor ">Guiwang  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongwei  Jin</span>, <span class="hlFld-ContribAuthor ">Jing  Liang</span>, <span class="hlFld-ContribAuthor ">Zhenming  Liu</span>, <span class="hlFld-ContribAuthor ">Zhuo  Huang</span>, <span class="hlFld-ContribAuthor ">Liangren  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and characterization of benzo[d]oxazol-2(3H)-one derivatives as the first potent and selective small-molecule inhibitors of chromodomain protein CDYL. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>182 </em>, 111656. <a href="https://doi.org/10.1016/j.ejmech.2019.111656" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111656%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Band%252Bcharacterization%252Bof%252Bbenzo%25255Bd%25255Doxazol-2%2525283H%252529-one%252Bderivatives%252Bas%252Bthe%252Bfirst%252Bpotent%252Band%252Bselective%252Bsmall-molecule%252Binhibitors%252Bof%252Bchromodomain%252Bprotein%252BCDYL%26aulast%3DYang%26aufirst%3DLixin%26date%3D2019%26volume%3D182%26spage%3D111656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fred  Saad</span>, <span class="hlFld-ContribAuthor ">Neal  Shore</span>, <span class="hlFld-ContribAuthor ">Tian  Zhang</span>, <span class="hlFld-ContribAuthor ">Shikhar  Sharma</span>, <span class="hlFld-ContribAuthor ">Helen K.  Cho</span>, <span class="hlFld-ContribAuthor ">Ira A.  Jacobs</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging therapeutic targets for patients with advanced prostate cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Treatment Reviews</span><span> <strong>2019,</strong> <em>76 </em>, 1-9. <a href="https://doi.org/10.1016/j.ctrv.2019.03.002" title="DOI URL">https://doi.org/10.1016/j.ctrv.2019.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ctrv.2019.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ctrv.2019.03.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Treatment%2520Reviews%26atitle%3DEmerging%252Btherapeutic%252Btargets%252Bfor%252Bpatients%252Bwith%252Badvanced%252Bprostate%252Bcancer%26aulast%3DSaad%26aufirst%3DFred%26date%3D2019%26volume%3D76%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Helai P.  Mohammad</span>, <span class="hlFld-ContribAuthor ">Olena  Barbash</span>, <span class="hlFld-ContribAuthor ">Caretha L.  Creasy</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. </span><span class="cited-content_cbyCitation_journal-name">Nature Medicine</span><span> <strong>2019,</strong> <em>25 </em>
                                    (3)
                                     , 403-418. <a href="https://doi.org/10.1038/s41591-019-0376-8" title="DOI URL">https://doi.org/10.1038/s41591-019-0376-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41591-019-0376-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41591-019-0376-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Medicine%26atitle%3DTargeting%252Bepigenetic%252Bmodifications%252Bin%252Bcancer%252Btherapy%25253A%252Berasing%252Bthe%252Broadmap%252Bto%252Bcancer%26aulast%3DMohammad%26aufirst%3DHelai%2BP.%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D3%26spage%3D403%26epage%3D418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuai  Zou</span>, <span class="hlFld-ContribAuthor ">Shu  Geng</span>, <span class="hlFld-ContribAuthor ">Lina  Chen</span>, <span class="hlFld-ContribAuthor ">Haitao  Wang</span>, <span class="hlFld-ContribAuthor ">Feng  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Visible light driven metal-free intramolecular cyclization: a facile synthesis of 3-position substituted 3,4-dihydroisoquinolin-1(2
              H
              )-one. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (2)
                                     , 380-387. <a href="https://doi.org/10.1039/C8OB02560F" title="DOI URL">https://doi.org/10.1039/C8OB02560F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB02560F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB02560F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DVisible%252Blight%252Bdriven%252Bmetal-free%252Bintramolecular%252Bcyclization%25253A%252Ba%252Bfacile%252Bsynthesis%252Bof%252B3-position%252Bsubstituted%252B3%25252C4-dihydroisoquinolin-1%2525282%252BH%252B%252529-one%26aulast%3DZou%26aufirst%3DShuai%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D2%26spage%3D380%26epage%3D387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rossella  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Giulia  Stazi</span>, <span class="hlFld-ContribAuthor ">Clemens  Zwergel</span>, <span class="hlFld-ContribAuthor ">Sergio  Valente</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>. </span><span class="cited-content_cbyCitation_article-title">Six Years (2012–2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2‐Pyridone Compounds. </span><span class="cited-content_cbyCitation_journal-name">The Chemical Record</span><span> <strong>2018,</strong> <em>18 </em>
                                    (12)
                                     , 1818-1832. <a href="https://doi.org/10.1002/tcr.201800091" title="DOI URL">https://doi.org/10.1002/tcr.201800091</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/tcr.201800091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Ftcr.201800091%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Chemical%2520Record%26atitle%3DSix%252BYears%252B%2525282012%2525E2%252580%2525932018%252529%252Bof%252BResearches%252Bon%252BCatalytic%252BEZH2%252BInhibitors%25253A%252BThe%252BBoom%252Bof%252Bthe%252B2%2525E2%252580%252590Pyridone%252BCompounds%26aulast%3DFioravanti%26aufirst%3DRossella%26date%3D2018%26date%3D2018%26volume%3D18%26issue%3D12%26spage%3D1818%26epage%3D1832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. In vitro properties of compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of minimized ligand conformations of <b>2a</b> and <b>2b</b> with compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. LipE and HLM clearance/permeability comparison of compounds depicted in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. Symbols indicate binned compound permeability (MDCK-LE): (×) MDCK-LE < 5 × 10<sup>–6</sup> cm/s; (○) MDCK-LE > 5 ×10<sup>–6</sup> cm/s. Colors indicate binned compound HLM clearance (HLM CL): blue, low; yellow, moderate; red, high. The log <i>D</i> was measured at pH 7.4. LipE = −[log<sub>10</sub>(Y641N <i>K</i><sub>i</sub>)] – log <i>D</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. LipE and HLM clearance/permeability comparison of compounds depicted in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. Symbols indicate binned compound permeability (MDCK-LE): (×) MDCK-LE < 5 × 10<sup>–6</sup> cm/s; (○) MDCK-LE > 5 × 10<sup>–6</sup> cm/s. Colors indicate binned compound HLM clearance (HLM CL): blue, low; yellow, moderate; red, high. The log <i>D</i> was measured at pH 7.4. LipE = −[log<sub>10</sub>(Y641N <i>K</i><sub>i</sub>)] – log <i>D</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PK/TGI relationship for <b>23a</b> in Karpas-422 xenograft model: (A) tumor growth inhibition graph for all treatment groups; (B) body weight measurement; (C) H3K27me3 reduction for all treatment groups at day 9 (4 h after last dose); (D) plasma exposure of <b>23a</b> po 7 h/17 h b.i.d. dosing; (E) plasma exposure of <b>23a</b> sc q.d. dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Cocrystal structure of compound <b>23a</b> in complex with EZH2 (2.8 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W2R">4W2R</a>). (B) Cocrystal structure of compound <b>1</b> in complex with EZH2 (3.0 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B3W">6B3W</a>). EZH2 residues involved in key interactions with <b>23a</b> or <b>1</b> are depicted in pink.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Optimized MM-GBSA models for stereochemical ligand pairs <b>6a</b>/<b>6c</b> and <b>4a</b>/<b>4b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 4-Methoxy-6-methylpyridine Template <b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) BnBr, Ag<sub>2</sub>CO<sub>3</sub>, THF, 60 °C, 62%; (ii) MeI, K<sub>2</sub>CO<sub>3</sub>, DMF, 89%; (iii) LiAlH<sub>4</sub>, THF, 0–25 °C, 97%; (iv) SOCl<sub>2</sub>, EtOAc, 0 °C, 95%; (v) <b>26</b>, KO<sup><i>t</i></sup>Bu, EtOAc, 75 °C, 81%.</p></p></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Synthetic Route of Primary Alcohols<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) [(<i>t-</i>Bu)<sub>3</sub>P]<sub>2</sub>Pd, LiF, DMF, 61%; (ii) CH<sub>3</sub>I, NaH, DMF, 0 °C, 56%; (iii) LiBH<sub>4</sub>, THF, 50 °C, 79%; (iv) TFA, DCM; then K<sub>2</sub>CO<sub>3</sub>, MeOH, 99%; (v) chiral SFC, (<i>S</i>)-isomer <b>4a</b>, 42%; (<i>R</i>)-isomer <b>4b</b>, 40%.</p></p></figure><figure data-id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Secondary Alcohols and Ethers <b>2a</b>, <b>2b</b>, <b>3a</b>, <b>3b</b>, <b>9a</b>, and <b>9b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) isopropenylboronic acid pinacol ester, Pd(dppf)Cl<sub>2</sub>–DCM, Na<sub>2</sub>CO<sub>3</sub>, dioxane, 70 °C, 66%; (ii) (<i>Z</i>)-3-hexenyl-3-boronic acid catechol ester, CsF, Pd(PPh<sub>3</sub>)<sub>4</sub>, dioxane, 100 °C, 88%; (iii) ozone, DCM, −70 °C, 67–94%; (iv) NaBH<sub>4</sub>, MeOH; (v) TFA, DCM; (vi) KO<sup><i>t</i></sup>Bu, MeI, DMF; (vii) chiral SFC.</p></p></figure><figure data-id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Representative Synthetic Route of Secondary Alcohols and Ethers from Aldehydes<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>i</i>-PrMgCl–LiCl, tetrahydro-2<i>H</i>-pyran-4-carbaldehyde, THF, −40 to 0 °C, 46%; (ii) KO<sup>t</sup>Bu, CH<sub>3</sub>I, THF, 0–25 °C, 65%; (iii) TFA, DCM; (iv) chiral SFC; <b>11a</b>, 35%; <b>11b</b>, 34%.</p></p></figure><figure data-id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/medium/jm-2017-013752_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Oxetane Analogs <b>23a</b> and <b>23b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01375/20180201/images/large/jm-2017-013752_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01375&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) PDC, DCM, rt, 26%; (ii) <i>i</i>-PrMgCl·LiCl, THF, −65 to −10 °C, 59%; (iii) CH<sub>3</sub>I, KO<sup><i>t</i></sup>Bu, THF, 0 °C, 91%; (iv) PtO<sub>2</sub>, H<sub>2</sub> (1 atm), EtOAc, rt, 54%; (v) chiral SFC, 36% (<i>R</i>) isomer <b>23a</b> and 16% (<i>S</i>) isomer <b>23b</b>.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i29">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74608" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74608" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 43 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Schuettengruber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, G.</span><span> </span><span class="NLM_article-title">Recruitment of polycomb group complexes and their role in the dynamic regulation of cell fate choice</span> <span class="citation_source-journal">Development</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">3531</span><span class="NLM_x">–</span> <span class="NLM_lpage">3542</span><span class="refDoi"> DOI: 10.1242/dev.033902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1242%2Fdev.033902" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=3531-3542&author=B.+Schuettengruberauthor=G.+Cavalli&title=Recruitment+of+polycomb+group+complexes+and+their+role+in+the+dynamic+regulation+of+cell+fate+choice&doi=10.1242%2Fdev.033902"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1242%2Fdev.033902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdev.033902%26sid%3Dliteratum%253Aachs%26aulast%3DSchuettengruber%26aufirst%3DB.%26aulast%3DCavalli%26aufirst%3DG.%26atitle%3DRecruitment%2520of%2520polycomb%2520group%2520complexes%2520and%2520their%2520role%2520in%2520the%2520dynamic%2520regulation%2520of%2520cell%2520fate%2520choice%26jtitle%3DDevelopment%26date%3D2009%26volume%3D136%26spage%3D3531%26epage%3D3542%26doi%3D10.1242%2Fdev.033902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Lewis, E. B.</span><span> </span><span class="NLM_article-title">A gene complex controlling segmentation in Drosophila</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span><span class="refDoi"> DOI: 10.1038/276565a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2F276565a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=103000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A280%3ADyaE1M%252FntlWgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1978&pages=565-570&author=E.+B.+Lewis&title=A+gene+complex+controlling+segmentation+in+Drosophila&doi=10.1038%2F276565a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A gene complex controlling segmentation in Drosophila</span></div><div class="casAuthors">Lewis E B</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">5688</span>),
    <span class="NLM_cas:pages">565-70</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The bithorax gene complex in Drosophila contains a minimum of eight genes that seem to code for substances controlling levels of thoracic and abdominal development.  The state of repression of at least four of these genes is controlled by cis-regulatory elements and a separate locus (Polycomb) seems to code for a repressor of the complex.  The wild-type and mutant segmentation patterns are consistent with an antero-posterior gradient in repressor concentration along the embryo and a proximo-distal gradient along the chromosome in the affinities for repressor of each gene's cis-regulatory element.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkFLr2ycH_oSsZ1x6zOs0vfW6udTcc2eZH9zO_7WpN2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE1M%252FntlWgsQ%253D%253D&md5=984f6a3650a54711616639bbdc5fa131</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F276565a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F276565a0%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DE.%2BB.%26atitle%3DA%2520gene%2520complex%2520controlling%2520segmentation%2520in%2520Drosophila%26jtitle%3DNature%26date%3D1978%26volume%3D276%26spage%3D565%26epage%3D570%26doi%3D10.1038%2F276565a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Margueron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinberg, D.</span><span> </span><span class="NLM_article-title">The polycomb complex PRC2 and its mark in life</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">469</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span><span class="refDoi"> DOI: 10.1038/nature09784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnature09784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=21248841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVOisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=343-349&author=R.+Margueronauthor=D.+Reinberg&title=The+polycomb+complex+PRC2+and+its+mark+in+life&doi=10.1038%2Fnature09784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The Polycomb complex PRC2 and its mark in life</span></div><div class="casAuthors">Margueron, Raphael; Reinberg, Danny</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7330</span>),
    <span class="NLM_cas:pages">343-349</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Polycomb group proteins maintain the gene-expression pattern of different cells that is set during early development by regulating chromatin structure.  In mammals, 2 main Polycomb group complexes exist: Polycomb repressive complex 1 (PRC1) and 2 (PRC2).  PRC1 compacts chromatin and catalyzes the monoubiquitination of histone H2A.  PRC2 also contributes to chromatin compaction, and catalyzes the methylation of histone H3 at Lys-27.  PRC2 is involved in various biol. processes, including differentiation, maintaining cell identity and proliferation, and stem-cell plasticity.  Recent studies of PRC2 have expanded the perspectives on its function and regulation, and uncovered a role for non-coding RNA in the recruitment of PRC2 to target genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7fYmuBqnMA7Vg90H21EOLACvtfcHk0lgQQ_r9fvP8nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVOisA%253D%253D&md5=5f15e91cc6ff765f649842041f333841</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature09784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09784%26sid%3Dliteratum%253Aachs%26aulast%3DMargueron%26aufirst%3DR.%26aulast%3DReinberg%26aufirst%3DD.%26atitle%3DThe%2520polycomb%2520complex%2520PRC2%2520and%2520its%2520mark%2520in%2520life%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D343%26epage%3D349%26doi%3D10.1038%2Fnature09784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Di Croce, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helin, K.</span><span> </span><span class="NLM_article-title">Transcriptional regulation by polycomb group proteins</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1147</span><span class="NLM_x">–</span> <span class="NLM_lpage">1155</span><span class="refDoi"> DOI: 10.1038/nsmb.2669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnsmb.2669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=24096405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOiurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1147-1155&author=L.+Di+Croceauthor=K.+Helin&title=Transcriptional+regulation+by+polycomb+group+proteins&doi=10.1038%2Fnsmb.2669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional regulation by Polycomb group proteins</span></div><div class="casAuthors">Di Croce, Luciano; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1147-1155</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Polycomb group (PcG) proteins are epigenetic regulators of transcription that have key roles in stem-cell identity, differentiation and disease.  Mechanistically, they function within multiprotein complexes, called Polycomb repressive complexes (PRCs), which modify histones (and other proteins) and silence target genes.  The dynamics of PRC1 and PRC2 components has been the focus of recent research.  Here we discuss our current knowledge of the PRC complexes, how they are targeted to chromatin and how the high diversity of the PcG proteins allows these complexes to influence cell identity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrArNyrbNU897Vg90H21EOLACvtfcHk0liKXkBnhBrRmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOiurrP&md5=004c2682edbda681e9f6de84ba87e639</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2669%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BCroce%26aufirst%3DL.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DTranscriptional%2520regulation%2520by%2520polycomb%2520group%2520proteins%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1147%26epage%3D1155%26doi%3D10.1038%2Fnsmb.2669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Yamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span> </span><span class="NLM_article-title">Regulation and role of EZH2 in cancer</span> <span class="citation_source-journal">Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span><span class="refDoi"> DOI: 10.4143/crt.2014.46.3.209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.4143%2Fcrt.2014.46.3.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=25038756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlaisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=209-222&author=H.+Yamaguchiauthor=M.+C.+Hung&title=Regulation+and+role+of+EZH2+in+cancer&doi=10.4143%2Fcrt.2014.46.3.209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and role of EZH2 in cancer</span></div><div class="casAuthors">Yamaguchi, Hirohito; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-222</span>CODEN:
                <span class="NLM_cas:coden">CRTAC2</span>;
        ISSN:<span class="NLM_cas:issn">2005-9256</span>.
    
            (<span class="NLM_cas:orgname">Korean Cancer Association</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) is the epigenetic regulator that induces histone H3 lysine 27 methylation (H3K27me3) and silences specific gene transcription.  Enhancer of zeste homolog 2 (EZH2) is an enzymic subunit of PRC2, and evidence shows that EZH2 plays an essential role in cancer initiation, development, progression, metastasis, and drug resistance.  EZH2 expression is indeed regulated by various oncogenic transcription factors, tumor suppressor miRNAs, and cancer-assocd. non-coding RNA.  EZH2 activity is also controlled by post-translational modifications, which are deregulated in cancer.  The canonical role of EZH2 is gene silencing through H3K27me3, but accumulating evidence shows that EZH2 methlyates substrates other than histone and has methylase-independent functions.  These non-canonical functions of EZH2 are shown to play a role in cancer progression.  In this review, we summarize current information on the regulation and roles of EZH2 in cancer.  We also discuss various therapeutic approaches to targeting EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdVidEmS4fsrVg90H21EOLACvtfcHk0liKXkBnhBrRmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlaisLk%253D&md5=78ba72a545b0b8c2c8bb8b255cc76259</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2014.46.3.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2014.46.3.209%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DRegulation%2520and%2520role%2520of%2520EZH2%2520in%2520cancer%26jtitle%3DCancer%2520Res.%2520Treat.%26date%3D2014%26volume%3D46%26spage%3D209%26epage%3D222%26doi%3D10.4143%2Fcrt.2014.46.3.209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Morin, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mungall, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goya, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolcock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuchenbauer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, O. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimbara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shashkin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlot, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tcherpakov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varhol, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smailus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moksa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birol, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirst, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marra, M. A.</span><span> </span><span class="NLM_article-title">Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1038/ng.518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fng.518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=20081860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntVGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=181-185&author=R.+D.+Morinauthor=N.+A.+Johnsonauthor=T.+M.+Seversonauthor=A.+J.+Mungallauthor=J.+Anauthor=R.+Goyaauthor=J.+E.+Paulauthor=M.+Boyleauthor=B.+W.+Woolcockauthor=F.+Kuchenbauerauthor=D.+Yapauthor=R.+K.+Humphriesauthor=O.+L.+Griffithauthor=S.+Shahauthor=H.+Zhuauthor=M.+Kimbaraauthor=P.+Shashkinauthor=J.+F.+Charlotauthor=M.+Tcherpakovauthor=R.+Corbettauthor=A.+Tamauthor=R.+Varholauthor=D.+Smailusauthor=M.+Moksaauthor=Y.+Zhaoauthor=A.+Delaneyauthor=H.+Qianauthor=I.+Birolauthor=J.+Scheinauthor=R.+Mooreauthor=R.+Holtauthor=D.+E.+Horsmanauthor=J.+M.+Connorsauthor=S.+Jonesauthor=S.+Aparicioauthor=M.+Hirstauthor=R.+D.+Gascoyneauthor=M.+A.+Marra&title=Somatic+mutations+altering+EZH2+%28Tyr641%29+in+follicular+and+diffuse+large+B-cell+lymphomas+of+germinal-center+origin&doi=10.1038%2Fng.518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin</span></div><div class="casAuthors">Morin, Ryan D.; Johnson, Nathalie A.; Severson, Tesa M.; Mungall, Andrew J.; An, Jianghong; Goya, Rodrigo; Paul, Jessica E.; Boyle, Merrill; Woolcock, Bruce W.; Kuchenbauer, Florian; Yap, Damian; Humphries, R. Keith; Griffith, Obi L.; Shah, Sohrab; Zhu, Henry; Kimbara, Michelle; Shashkin, Pavel; Charlot, Jean F.; Tcherpakov, Marianna; Corbett, Richard; Tam, Angela; Varhol, Richard; Smailus, Duane; Moksa, Michelle; Zhao, Yongjun; Delaney, Allen; Qian, Hong; Birol, Inanc; Schein, Jacqueline; Moore, Richard; Holt, Robert; Horsman, Doug E.; Connors, Joseph M.; Jones, Steven; Aparicio, Samuel; Hirst, Martin; Gascoyne, Randy D.; Marra, Marco A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-185</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Follicular lymphoma (FL) and the GCB subtype of diffuse large B-cell lymphoma (DLBCL) derive from germinal center B cells.  Targeted resequencing studies have revealed mutations in various genes encoding proteins in the NF-κB pathway that contribute to the activated B-cell (ABC) DLBCL subtype, but thus far few GCB-specific mutations have been identified.  Here the authors report recurrent somatic mutations affecting the polycomb-group oncogene EZH2, which encodes a histone methyltransferase responsible for trimethylating Lys27 of histone H3 (H3K27).  After the recent discovery of mutations in KDM6A (UTX), which encodes the histone H3K27me3 demethylase UTX, in several cancer types, EZH2 is the second histone methyltransferase gene mutated in cancer.  These mutations, which result in the replacement of a single tyrosine in the SET domain of the EZH2 protein (Tyr641), occur in 21.7% of GCB DLBCLs and 7.2% of FLs and are absent from ABC DLBCLs.  The authors' data are consistent with the notion that EZH2 proteins with mutant Tyr641 have reduced enzymic activity in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvpFnajONCXbVg90H21EOLACvtfcHk0liKXkBnhBrRmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntVGitQ%253D%253D&md5=ab68fe6e8932e720c4e7be82fe35932a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fng.518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.518%26sid%3Dliteratum%253Aachs%26aulast%3DMorin%26aufirst%3DR.%2BD.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DSeverson%26aufirst%3DT.%2BM.%26aulast%3DMungall%26aufirst%3DA.%2BJ.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DGoya%26aufirst%3DR.%26aulast%3DPaul%26aufirst%3DJ.%2BE.%26aulast%3DBoyle%26aufirst%3DM.%26aulast%3DWoolcock%26aufirst%3DB.%2BW.%26aulast%3DKuchenbauer%26aufirst%3DF.%26aulast%3DYap%26aufirst%3DD.%26aulast%3DHumphries%26aufirst%3DR.%2BK.%26aulast%3DGriffith%26aufirst%3DO.%2BL.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DKimbara%26aufirst%3DM.%26aulast%3DShashkin%26aufirst%3DP.%26aulast%3DCharlot%26aufirst%3DJ.%2BF.%26aulast%3DTcherpakov%26aufirst%3DM.%26aulast%3DCorbett%26aufirst%3DR.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DVarhol%26aufirst%3DR.%26aulast%3DSmailus%26aufirst%3DD.%26aulast%3DMoksa%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DDelaney%26aufirst%3DA.%26aulast%3DQian%26aufirst%3DH.%26aulast%3DBirol%26aufirst%3DI.%26aulast%3DSchein%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DHolt%26aufirst%3DR.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DAparicio%26aufirst%3DS.%26aulast%3DHirst%26aufirst%3DM.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26atitle%3DSomatic%2520mutations%2520altering%2520EZH2%2520%2528Tyr641%2529%2520in%2520follicular%2520and%2520diffuse%2520large%2520B-cell%2520lymphomas%2520of%2520germinal-center%2520origin%26jtitle%3DNat.%2520Genet.%26date%3D2010%26volume%3D42%26spage%3D181%26epage%3D185%26doi%3D10.1038%2Fng.518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Morin, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez-Lago, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mungall, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goya, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mungall, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzywinski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinh, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura-Wells, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firme, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakovenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smailus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moksa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chittaranjan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimsza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks-Wilson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinelli, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Neriah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meissner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolcock, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterfield, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birol, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirst, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marra, M. A.</span><span> </span><span class="NLM_article-title">Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">476</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">303</span><span class="refDoi"> DOI: 10.1038/nature10351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnature10351" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=476&publication_year=2011&pages=298-303&author=R.+D.+Morinauthor=M.+Mendez-Lagoauthor=A.+J.+Mungallauthor=R.+Goyaauthor=K.+L.+Mungallauthor=R.+D.+Corbettauthor=N.+A.+Johnsonauthor=T.+M.+Seversonauthor=R.+Chiuauthor=M.+Fieldauthor=S.+Jackmanauthor=M.+Krzywinskiauthor=D.+W.+Scottauthor=D.+L.+Trinhauthor=J.+Tamura-Wellsauthor=S.+Liauthor=M.+R.+Firmeauthor=S.+Rogicauthor=M.+Griffithauthor=S.+Chanauthor=O.+Yakovenkoauthor=I.+M.+Meyerauthor=E.+Y.+Zhaoauthor=D.+Smailusauthor=M.+Moksaauthor=S.+Chittaranjanauthor=L.+Rimszaauthor=A.+Brooks-Wilsonauthor=J.+J.+Spinelliauthor=S.+Ben-Neriahauthor=B.+Meissnerauthor=B.+Woolcockauthor=M.+Boyleauthor=H.+McDonaldauthor=A.+Tamauthor=Y.+Zhaoauthor=A.+Delaneyauthor=T.+Zengauthor=K.+Tseauthor=Y.+Butterfieldauthor=I.+Birolauthor=R.+Holtauthor=J.+Scheinauthor=D.+E.+Horsmanauthor=R.+Mooreauthor=S.+J.+Jonesauthor=J.+M.+Connorsauthor=M.+Hirstauthor=R.+D.+Gascoyneauthor=M.+A.+Marra&title=Frequent+mutation+of+histone-modifying+genes+in+non-Hodgkin+lymphoma&doi=10.1038%2Fnature10351"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature10351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10351%26sid%3Dliteratum%253Aachs%26aulast%3DMorin%26aufirst%3DR.%2BD.%26aulast%3DMendez-Lago%26aufirst%3DM.%26aulast%3DMungall%26aufirst%3DA.%2BJ.%26aulast%3DGoya%26aufirst%3DR.%26aulast%3DMungall%26aufirst%3DK.%2BL.%26aulast%3DCorbett%26aufirst%3DR.%2BD.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DSeverson%26aufirst%3DT.%2BM.%26aulast%3DChiu%26aufirst%3DR.%26aulast%3DField%26aufirst%3DM.%26aulast%3DJackman%26aufirst%3DS.%26aulast%3DKrzywinski%26aufirst%3DM.%26aulast%3DScott%26aufirst%3DD.%2BW.%26aulast%3DTrinh%26aufirst%3DD.%2BL.%26aulast%3DTamura-Wells%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DFirme%26aufirst%3DM.%2BR.%26aulast%3DRogic%26aufirst%3DS.%26aulast%3DGriffith%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DYakovenko%26aufirst%3DO.%26aulast%3DMeyer%26aufirst%3DI.%2BM.%26aulast%3DZhao%26aufirst%3DE.%2BY.%26aulast%3DSmailus%26aufirst%3DD.%26aulast%3DMoksa%26aufirst%3DM.%26aulast%3DChittaranjan%26aufirst%3DS.%26aulast%3DRimsza%26aufirst%3DL.%26aulast%3DBrooks-Wilson%26aufirst%3DA.%26aulast%3DSpinelli%26aufirst%3DJ.%2BJ.%26aulast%3DBen-Neriah%26aufirst%3DS.%26aulast%3DMeissner%26aufirst%3DB.%26aulast%3DWoolcock%26aufirst%3DB.%26aulast%3DBoyle%26aufirst%3DM.%26aulast%3DMcDonald%26aufirst%3DH.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DDelaney%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DT.%26aulast%3DTse%26aufirst%3DK.%26aulast%3DButterfield%26aufirst%3DY.%26aulast%3DBirol%26aufirst%3DI.%26aulast%3DHolt%26aufirst%3DR.%26aulast%3DSchein%26aufirst%3DJ.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DS.%2BJ.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DHirst%26aufirst%3DM.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26atitle%3DFrequent%2520mutation%2520of%2520histone-modifying%2520genes%2520in%2520non-Hodgkin%2520lymphoma%26jtitle%3DNature%26date%3D2011%26volume%3D476%26spage%3D298%26epage%3D303%26doi%3D10.1038%2Fnature10351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">McCabe, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganji, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halsey, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitheman, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappalardi, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Pietra, A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dul, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thrall, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruger, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creasy, C. L.</span><span> </span><span class="NLM_article-title">Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">2989</span><span class="NLM_x">–</span> <span class="NLM_lpage">2994</span><span class="refDoi"> DOI: 10.1073/pnas.1116418109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1073%2Fpnas.1116418109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=22323599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wmtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=2989-2994&author=M.+T.+McCabeauthor=A.+P.+Gravesauthor=G.+Ganjiauthor=E.+Diazauthor=W.+S.+Halseyauthor=Y.+Jiangauthor=K.+N.+Smithemanauthor=H.+M.+Ottauthor=M.+B.+Pappalardiauthor=K.+E.+Allenauthor=S.+B.+Chenauthor=A.+Della+Pietraauthor=E.+Dulauthor=A.+M.+Hughesauthor=S.+A.+Gilbertauthor=S.+H.+Thrallauthor=P.+J.+Tumminoauthor=R.+G.+Krugerauthor=M.+Brandtauthor=B.+Schwartzauthor=C.+L.+Creasy&title=Mutation+of+A677+in+histone+methyltransferase+EZH2+in+human+B-cell+lymphoma+promotes+hypertrimethylation+of+histone+H3+on+lysine+27+%28H3K27%29&doi=10.1073%2Fpnas.1116418109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)</span></div><div class="casAuthors">McCabe, Michael T.; Graves, Alan P.; Ganji, Gopinath; Diaz, Elsie; Halsey, Wendy S.; Jiang, Yong; Smitheman, Kimberly N.; Ott, Heidi M.; Pappalardi, Melissa B.; Allen, Kimberly E.; Chen, Stephanie B.; Della Pietra, Anthony, III; Dul, Edward; Hughes, Ashley M.; Gilbert, Seth A.; Thrall, Sara H.; Tummino, Peter J.; Kruger, Ryan G.; Brandt, Martin; Schwartz, Benjamin; Creasy, Caretha L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2989-2994, S2989/1-S2989/21</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Trimethylation of histone H3 on lysine 27 (H3K27me3) is a repressive posttranslational modification mediated by the histone methyltransferase EZH2.  EZH2 is a component of the polycomb repressive complex 2 and is overexpressed in many cancers.  In B-cell lymphomas, its substrate preference is frequently altered through somatic mutation of the EZH2 Y641 residue.  Herein, we identify mutation of EZH2 A677 to a glycine (A677G) among lymphoma cell lines and primary tumor specimens.  Similar to Y641 mutant cell lines, an A677G mutant cell line revealed aberrantly elevated H3K27me3 and decreased monomethylated H3K27 (H3K27me1) and dimethylated H3K27 (H3K27me2).  A677G EZH2 possessed catalytic activity with a substrate specificity that was distinct from those of both WT EZH2 and Y641 mutants.  Whereas WT EZH2 displayed a preference for substrates with less methylation [unmethylated H3K27 (H3K27me0):me1:me2 kcat/Km ratio = 9:6:1] and Y641 mutants preferred substrates with greater methylation (H3K27me0:me1:me2 kcat/Km ratio = 1:2:13), the A677G EZH2 demonstrated nearly equal efficiency for all three substrates (H3K27me0:me1:me2 kcat/Km ratio = 1.1:0.6:1).  When transiently expressed in cells, A677G EZH2, but not WT EZH2, increased global H3K27me3 and decreased H3K27me2.  Structural modeling of WT and mutant EZH2 suggested that the A677G mutation acquires the ability to methylate H3K27me2 through enlargement of the lysine tunnel while preserving activity with H3K27me0/me1 substrates through retention of the Y641 residue that is crucial for orientation of these smaller substrates.  This mutation highlights the interplay between Y641 and A677 residues in the substrate specificity of EZH2 and identifies another lymphoma patient population that harbors an activating mutation of EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-iaHX1dsb2rVg90H21EOLACvtfcHk0lhl-BPgrh1hQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wmtrc%253D&md5=4c7febc82c66aa88f27642eb7267291b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1116418109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1116418109%26sid%3Dliteratum%253Aachs%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DGraves%26aufirst%3DA.%2BP.%26aulast%3DGanji%26aufirst%3DG.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DHalsey%26aufirst%3DW.%2BS.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DOtt%26aufirst%3DH.%2BM.%26aulast%3DPappalardi%26aufirst%3DM.%2BB.%26aulast%3DAllen%26aufirst%3DK.%2BE.%26aulast%3DChen%26aufirst%3DS.%2BB.%26aulast%3DDella%2BPietra%26aufirst%3DA.%26aulast%3DDul%26aufirst%3DE.%26aulast%3DHughes%26aufirst%3DA.%2BM.%26aulast%3DGilbert%26aufirst%3DS.%2BA.%26aulast%3DThrall%26aufirst%3DS.%2BH.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26atitle%3DMutation%2520of%2520A677%2520in%2520histone%2520methyltransferase%2520EZH2%2520in%2520human%2520B-cell%2520lymphoma%2520promotes%2520hypertrimethylation%2520of%2520histone%2520H3%2520on%2520lysine%252027%2520%2528H3K27%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D2989%26epage%3D2994%26doi%3D10.1073%2Fpnas.1116418109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Sneeringer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutson, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span> </span><span class="NLM_article-title">Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">20980</span><span class="NLM_x">–</span> <span class="NLM_lpage">20985</span><span class="refDoi"> DOI: 10.1073/pnas.1012525107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1073%2Fpnas.1012525107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=21078963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFyrsbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=20980-20985&author=C.+J.+Sneeringerauthor=M.+P.+Scottauthor=K.+W.+Kuntzauthor=S.+K.+Knutsonauthor=R.+M.+Pollockauthor=V.+M.+Richonauthor=R.+A.+Copeland&title=Coordinated+activities+of+wild-type+plus+mutant+EZH2+drive+tumor-associated+hypertrimethylation+of+lysine+27+on+histone+H3+%28H3K27%29+in+human+B-cell+lymphomas&doi=10.1073%2Fpnas.1012525107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas</span></div><div class="casAuthors">Sneeringer, Christopher J.; Scott, Margaret Porter; Kuntz, Kevin W.; Knutson, Sarah K.; Pollock, Roy M.; Richon, Victoria M.; Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">20980-20985, S20980/1-S20980/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">EZH2, the catalytic subunit of the PRC2 complex, catalyzes the mono- through trimethylation of lysine 27 on histone H3 (H3K27).  Histone H3K27 trimethylation is a mechanism for suppressing transcription of specific genes that are proximal to the site of histone modification.  Point mutations of the EZH2 gene (Tyr641) have been reported to be linked to subsets of human B-cell lymphoma.  The mutant allele is always found assocd. with a wild-type allele (heterozygous) in disease cells, and the mutations were reported to ablate the enzymic activity of the PRC2 complex for methylating an unmodified peptide substrate.  Here we demonstrate that the WT enzyme displays greatest catalytic efficiency (kcat/K) for the zero to monomethylation reaction of H3K27 and diminished efficiency for subsequent (mono- to di- and di- to trimethylation) reactions.  In stark contrast, the disease-assocd. Y641 mutations display very limited ability to perform the first methylation reaction, but have enhanced catalytic efficiency for the subsequent reactions, relative to the WT enzyme.  These results imply that the malignant phenotype of disease requires the combined activities of a H3K27 monomethylating enzyme (PRC2 contg. WT EZH2 or EZH1) together with the mutant PRC2s for augmented conversion of H3K27 to the trimethylated form.  To our knowledge, this is the first example of a human disease that is dependent on the coordinated activities of normal and disease-assocd. mutant enzymic function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSX_ULvZOGabVg90H21EOLACvtfcHk0ljW1eF3EruRPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFyrsbnF&md5=6766432aad387c36c29e7763750e4254</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1012525107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1012525107%26sid%3Dliteratum%253Aachs%26aulast%3DSneeringer%26aufirst%3DC.%2BJ.%26aulast%3DScott%26aufirst%3DM.%2BP.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DCoordinated%2520activities%2520of%2520wild-type%2520plus%2520mutant%2520EZH2%2520drive%2520tumor-associated%2520hypertrimethylation%2520of%2520lysine%252027%2520on%2520histone%2520H3%2520%2528H3K27%2529%2520in%2520human%2520B-cell%2520lymphomas%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D20980%26epage%3D20985%26doi%3D10.1073%2Fpnas.1012525107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">McCabe, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganji, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korenchuk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Aller, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Pietra, A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaFrance, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duquenne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruger, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhanak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creasy, C. L.</span><span> </span><span class="NLM_article-title">EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">492</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1038/nature11606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnature11606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=23051747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyktbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=108-112&author=M.+T.+McCabeauthor=H.+M.+Ottauthor=G.+Ganjiauthor=S.+Korenchukauthor=C.+Thompsonauthor=G.+S.+Van+Allerauthor=Y.+Liuauthor=A.+P.+Gravesauthor=A.+Della+Pietraauthor=E.+Diazauthor=L.+V.+LaFranceauthor=M.+Mellingerauthor=C.+Duquenneauthor=X.+Tianauthor=R.+G.+Krugerauthor=C.+F.+McHughauthor=M.+Brandtauthor=W.+H.+Millerauthor=D.+Dhanakauthor=S.+K.+Vermaauthor=P.+J.+Tumminoauthor=C.+L.+Creasy&title=EZH2+inhibition+as+a+therapeutic+strategy+for+lymphoma+with+EZH2-activating+mutations&doi=10.1038%2Fnature11606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations</span></div><div class="casAuthors">McCabe, Michael T.; Ott, Heidi M.; Ganji, Gopinath; Korenchuk, Susan; Thompson, Christine; Van Aller, Glenn S.; Liu, Yan; Graves, Alan P.; Della Pietra, Anthony , III; Diaz, Elsie; LaFrance, Louis V.; Mellinger, Mark; Duquenne, Celine; Tian, Xinrong; Kruger, Ryan G.; McHugh, Charles F.; Brandt, Martin; Miller, William H.; Dhanak, Dashyant; Verma, Sharad K.; Tummino, Peter J.; Creasy, Caretha L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7427</span>),
    <span class="NLM_cas:pages">108-112</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In eukaryotes, post-translational modification of histones is crit. for regulation of chromatin structure and gene expression.  EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is involved in repressing gene expression through methylation of histone H3 on lysine 27 (H3K27).  EZH2 overexpression is implicated in tumorigenesis and correlates with poor prognosis in several tumor types.  Addnl., somatic heterozygous mutations of Y641 and A677 residues within the catalytic SET domain of EZH2 occur in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.  The Y641 residue is the most frequently mutated residue, with up to 22% of germinal center B-cell DLBCL and follicular lymphoma harbouring mutations at this site.  These lymphomas have increased H3K27 tri-methylation (H3K27me3) owing to altered substrate preferences of the mutant enzymes.  However, it is unknown whether specific, direct inhibition of EZH2 methyltransferase activity will be effective in treating EZH2 mutant lymphomas.  Here we demonstrate that GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-mol. inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes.  GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice.  Together, these data demonstrate that pharmacol. inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxw5cLmW3Lc7Vg90H21EOLACvtfcHk0ljW1eF3EruRPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyktbjL&md5=a1dff99556de004c48aae88bc45dffab</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature11606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11606%26sid%3Dliteratum%253Aachs%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DOtt%26aufirst%3DH.%2BM.%26aulast%3DGanji%26aufirst%3DG.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGraves%26aufirst%3DA.%2BP.%26aulast%3DDella%2BPietra%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DLaFrance%26aufirst%3DL.%2BV.%26aulast%3DMellinger%26aufirst%3DM.%26aulast%3DDuquenne%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DVerma%26aufirst%3DS.%2BK.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26atitle%3DEZH2%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520lymphoma%2520with%2520EZH2-activating%2520mutations%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D108%26epage%3D112%26doi%3D10.1038%2Fnature11606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karnezis, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colborne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendricks, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlando, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kommoss, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bally, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trent, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissman, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntsman, D. G.</span><span> </span><span class="NLM_article-title">The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">242</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span><span class="refDoi"> DOI: 10.1002/path.4912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1002%2Fpath.4912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=28444909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVGgtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=242&publication_year=2017&pages=371-383&author=Y.+Wangauthor=S.+Y.+Chenauthor=A.+N.+Karnezisauthor=S.+Colborneauthor=N.+D.+Santosauthor=J.+D.+Langauthor=W.+P.+Hendricksauthor=K.+A.+Orlandoauthor=D.+Yapauthor=F.+Kommossauthor=M.+B.+Ballyauthor=G.+B.+Morinauthor=J.+M.+Trentauthor=B.+E.+Weissmanauthor=D.+G.+Huntsman&title=The+histone+methyltransferase+EZH2+is+a+therapeutic+target+in+small+cell+carcinoma+of+the+ovary%2C+hypercalcaemic+type&doi=10.1002%2Fpath.4912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type</span></div><div class="casAuthors">Wang, Yemin; Chen, Shary Yuting; Karnezis, Anthony N.; Colborne, Shane; Santos, Nancy Dos; Lang, Jessica D.; Hendricks, William P. D.; Orlando, Krystal A.; Yap, Damian; Kommoss, Friedrich; Bally, Marcel B.; Morin, Gregg B.; Trent, Jeffrey M.; Weissman, Bernard E.; Huntsman, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">242</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-383</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare but aggressive and untreatable malignancy affecting young women.  We and others recently discovered that SMARCA4, a gene encoding the ATPase of the SWI/SNF chromatin-remodelling complex, is the only gene recurrently mutated in the majority of SCCOHT.  The low somatic complexity of SCCOHT genomes and the prominent role of the SWI/SNF chromatin-remodelling complex in transcriptional control of genes suggest that SCCOHT cells may rely on epigenetic rewiring for oncogenic transformation.  Herein, we report that approx. 80% (19/24) of SCCOHT tumor samples have strong expression of the histone methyltransferase EZH2 by immunohistochem., with the rest expressing variable amts. of EZH2.  Re-expression of SMARCA4 suppressed the expression of EZH2 in SCCOHT cells.  In comparison to other ovarian cell lines, SCCOHT cells displayed hypersensitivity to EZH2 shRNAs and two selective EZH2 inhibitors, GSK126 and EPZ-6438.  EZH2 inhibitors induced cell cycle arrest, apoptosis, and cell differentiation in SCCOHT cells, along with the induction of genes involved in cell cycle regulation, apoptosis, and neuron-like differentiation.  EZH2 inhibitors suppressed tumor growth and improved the survival of mice bearing SCCOHT xenografts.  Therefore, our data suggest that loss of SMARCA4 creates a dependency on the catalytic activity of EZH2 in SCCOHT cells and that pharmacol. inhibition of EZH2 is a promising therapeutic strategy for treating this disease.  Copyright © 2017 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCsuuR8BhKEbVg90H21EOLACvtfcHk0ljW1eF3EruRPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVGgtLnE&md5=1cd2e025db63df09b8ec3bf5e1a6e1ae</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fpath.4912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4912%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DS.%2BY.%26aulast%3DKarnezis%26aufirst%3DA.%2BN.%26aulast%3DColborne%26aufirst%3DS.%26aulast%3DSantos%26aufirst%3DN.%2BD.%26aulast%3DLang%26aufirst%3DJ.%2BD.%26aulast%3DHendricks%26aufirst%3DW.%2BP.%26aulast%3DOrlando%26aufirst%3DK.%2BA.%26aulast%3DYap%26aufirst%3DD.%26aulast%3DKommoss%26aufirst%3DF.%26aulast%3DBally%26aufirst%3DM.%2BB.%26aulast%3DMorin%26aufirst%3DG.%2BB.%26aulast%3DTrent%26aufirst%3DJ.%2BM.%26aulast%3DWeissman%26aufirst%3DB.%2BE.%26aulast%3DHuntsman%26aufirst%3DD.%2BG.%26atitle%3DThe%2520histone%2520methyltransferase%2520EZH2%2520is%2520a%2520therapeutic%2520target%2520in%2520small%2520cell%2520carcinoma%2520of%2520the%2520ovary%252C%2520hypercalcaemic%2520type%26jtitle%3DJ.%2520Pathol.%26date%3D2017%26volume%3D242%26spage%3D371%26epage%3D383%26doi%3D10.1002%2Fpath.4912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Chan-Penebre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grassian, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutson, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuplast-Barr, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesworth, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilhack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribich, S. A.</span><span> </span><span class="NLM_article-title">Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type cells by inhibition of EZH2: <i>in vitro</i> and <i>in vivo</i> preclinical models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">850</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1158%2F1535-7163.MCT-16-0678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=28292935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFemt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=850-860&author=E.+Chan-Penebreauthor=K.+Armstrongauthor=A.+Drewauthor=A.+R.+Grassianauthor=I.+Feldmanauthor=S.+K.+Knutsonauthor=K.+Kuplast-Barrauthor=M.+Rocheauthor=J.+Campbellauthor=P.+Hoauthor=R.+A.+Copelandauthor=R.+Chesworthauthor=J.+J.+Smithauthor=H.+Keilhackauthor=S.+A.+Ribich&title=Selective+killing+of+SMARCA2-+and+SMARCA4-deficient+small+cell+carcinoma+of+the+ovary%2C+hypercalcemic+type+cells+by+inhibition+of+EZH2%3A+in+vitro+and+in+vivo+preclinical+models&doi=10.1158%2F1535-7163.MCT-16-0678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models</span></div><div class="casAuthors">Chan-Penebre, Elayne; Armstrong, Kelli; Drew, Allison; Grassian, Alexandra R.; Feldman, Igor; Knutson, Sarah K.; Kuplast-Barr, Kristy; Roche, Maria; Campbell, John; Ho, Peter; Copeland, Robert A.; Chesworth, Richard; Smith, Jesse J.; Keilhack, Heike; Ribich, Scott A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">850-860</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The SWI/SNF complex is a major regulator of gene expression and is increasingly thought to play an important role in human cancer, as evidenced by the high frequency of subunit mutations across virtually all cancer types.  We previously reported that in preclin. models, malignant rhabdoid tumors, which are deficient in the SWI/SNF core component INI1 (SMARCB1), are selectively killed by inhibitors of the H3K27 histone methyltransferase EZH2.  Given the demonstrated antagonistic activities of the SWI/SNF complex and the EZH2-contg. PRC2 complex, we investigated whether addnl. cancers with SWI/SNF mutations are sensitive to selective EZH2 inhibition.  It has been recently reported that ovarian cancers with dual loss of the redundant SWI/SNF components SMARCA4 and SMARCA2 are characteristic of a rare rhabdoid-like subtype known as small-cell carcinoma of the ovary hypercalcemic type (SCCOHT).  Here, we provide evidence that a subset of commonly used ovarian carcinoma cell lines were misdiagnosed and instead were derived from a SCCOHT tumor.  We also demonstrate that tazemetostat, a potent and selective EZH2 inhibitor currently in phase II clin. trials, induces potent antiproliferative and antitumor effects in SCCOHT cell lines and xenografts deficient in both SMARCA2 and SMARCA4.  These results exemplify an addnl. class of rhabdoid-like tumors that are dependent on EZH2 activity for survival.  Mol Cancer Ther; 16(5); 850-60. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVWFUB-yp1_LVg90H21EOLACvtfcHk0ljn0B-dEHpBeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFemt74%253D&md5=863efce9718055b13357361992e59242</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0678%26sid%3Dliteratum%253Aachs%26aulast%3DChan-Penebre%26aufirst%3DE.%26aulast%3DArmstrong%26aufirst%3DK.%26aulast%3DDrew%26aufirst%3DA.%26aulast%3DGrassian%26aufirst%3DA.%2BR.%26aulast%3DFeldman%26aufirst%3DI.%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DKuplast-Barr%26aufirst%3DK.%26aulast%3DRoche%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DKeilhack%26aufirst%3DH.%26aulast%3DRibich%26aufirst%3DS.%2BA.%26atitle%3DSelective%2520killing%2520of%2520SMARCA2-%2520and%2520SMARCA4-deficient%2520small%2520cell%2520carcinoma%2520of%2520the%2520ovary%252C%2520hypercalcemic%2520type%2520cells%2520by%2520inhibition%2520of%2520EZH2%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520preclinical%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D850%26epage%3D860%26doi%3D10.1158%2F1535-7163.MCT-16-0678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Bitler, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aird, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garipov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amatangelo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kossenkov, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, I.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conejo-Garcia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speicher, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span> </span><span class="NLM_article-title">Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span><span class="refDoi"> DOI: 10.1038/nm.3799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnm.3799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=25686104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVSit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=231-238&author=B.+G.+Bitlerauthor=K.+M.+Airdauthor=A.+Garipovauthor=H.+Liauthor=M.+Amatangeloauthor=A.+V.+Kossenkovauthor=D.+C.+Schultzauthor=Q.+Liuauthor=I.-M.+Shihauthor=J.+R.+Conejo-Garciaauthor=D.+W.+Speicherauthor=R.+Zhang&title=Synthetic+lethality+by+targeting+EZH2+methyltransferase+activity+in+ARID1A-mutated+cancers&doi=10.1038%2Fnm.3799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers</span></div><div class="casAuthors">Bitler, Benjamin G.; Aird, Katherine M.; Garipov, Azat; Li, Hua; Amatangelo, Michael; Kossenkov, Andrew V.; Schultz, David C.; Liu, Qin; Shih, Ie-Ming; Conejo-Garcia, Jose R.; Speicher, David W.; Zhang, Rugang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">231-238</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The gene encoding ARID1A, a chromatin remodeler, shows one of the highest mutation rates across many cancer types.  Notably, ARID1A is mutated in over 50% of ovarian clear cell carcinomas, which currently have no effective therapy.  To date, clin. applicable targeted cancer therapy based on ARID1A mutational status has not been described.  Here we show that inhibition of the EZH2 methyltransferase acts in a synthetic lethal manner in ARID1A-mutated ovarian cancer cells and that ARID1A mutational status correlated with response to the EZH2 inhibitor.  We identified PIK3IP1 as a direct target of ARID1A and EZH2 that is upregulated by EZH2 inhibition and contributed to the obsd. synthetic lethality by inhibiting PI3K-AKT signaling.  Importantly, EZH2 inhibition caused regression of ARID1A-mutated ovarian tumors in vivo.  To our knowledge, this is the first data set to demonstrate a synthetic lethality between ARID1A mutation and EZH2 inhibition.  Our data indicate that pharmacol. inhibition of EZH2 represents a novel treatment strategy for cancers involving ARID1A mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEiQfgiO8t4LVg90H21EOLACvtfcHk0lgXNFPp5D9lZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVSit7k%253D&md5=2521906b5e6ef9b7fc51a09ceb1f0c9d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnm.3799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3799%26sid%3Dliteratum%253Aachs%26aulast%3DBitler%26aufirst%3DB.%2BG.%26aulast%3DAird%26aufirst%3DK.%2BM.%26aulast%3DGaripov%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DAmatangelo%26aufirst%3DM.%26aulast%3DKossenkov%26aufirst%3DA.%2BV.%26aulast%3DSchultz%26aufirst%3DD.%2BC.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DShih%26aufirst%3DI.-M.%26aulast%3DConejo-Garcia%26aufirst%3DJ.%2BR.%26aulast%3DSpeicher%26aufirst%3DD.%2BW.%26aulast%3DZhang%26aufirst%3DR.%26atitle%3DSynthetic%2520lethality%2520by%2520targeting%2520EZH2%2520methyltransferase%2520activity%2520in%2520ARID1A-mutated%2520cancers%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D231%26epage%3D238%26doi%3D10.1038%2Fnm.3799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Wilson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, C. W.</span><span> </span><span class="NLM_article-title">SWI/SNF nucleosome remodellers and cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">492</span><span class="refDoi"> DOI: 10.1038/nrc3068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnrc3068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=21654818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntFKrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=481-492&author=B.+G.+Wilsonauthor=C.+W.+Roberts&title=SWI%2FSNF+nucleosome+remodellers+and+cancer&doi=10.1038%2Fnrc3068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">SWI/SNF nucleosome remodelers and cancer</span></div><div class="casAuthors">Wilson, Boris G.; Roberts, Charles W. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">481-492</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  SWI/SNF chromatin remodelling complexes use the energy of ATP hydrolysis to remodel nucleosomes and to modulate transcription.  Growing evidence indicates that these complexes have a widespread role in tumor suppression, as inactivating mutations in several SWI/SNF subunits have recently been identified at a high frequency in a variety of cancers.  However, the mechanisms by which mutations in these complexes drive tumorigenesis are unclear.  In this Review we discuss the contributions of SWI/SNF mutations to cancer formation, examine their normal functions and discuss opportunities for novel therapeutic interventions for SWI/SNF-mutant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOPkgJoPg1hbVg90H21EOLACvtfcHk0lgXNFPp5D9lZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntFKrsLw%253D&md5=fee4e1c406f02388a1acd75048db8511</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrc3068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3068%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DB.%2BG.%26aulast%3DRoberts%26aufirst%3DC.%2BW.%26atitle%3DSWI%252FSNF%2520nucleosome%2520remodellers%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D481%26epage%3D492%26doi%3D10.1038%2Fnrc3068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vazquez, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsherniak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haswell, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walensky, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orkin, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, C. W.</span><span> </span><span class="NLM_article-title">SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1491</span><span class="NLM_x">–</span> <span class="NLM_lpage">1496</span><span class="refDoi"> DOI: 10.1038/nm.3968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnm.3968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=26552009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1491-1496&author=K.+H.+Kimauthor=W.+Kimauthor=T.+P.+Howardauthor=F.+Vazquezauthor=A.+Tsherniakauthor=J.+N.+Wuauthor=W.+Wangauthor=J.+R.+Haswellauthor=L.+D.+Walenskyauthor=W.+C.+Hahnauthor=S.+H.+Orkinauthor=C.+W.+Roberts&title=SWI%2FSNF-mutant+cancers+depend+on+catalytic+and+non-catalytic+activity+of+EZH2&doi=10.1038%2Fnm.3968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2</span></div><div class="casAuthors">Kim, Kimberly H.; Kim, Woojin; Howard, Thomas P.; Vazquez, Francisca; Tsherniak, Aviad; Wu, Jennifer N.; Wang, Weishan; Haswell, Jeffrey R.; Walensky, Loren D.; Hahn, William C.; Orkin, Stuart H.; Roberts, Charles W. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1491-1496</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human cancer genome sequencing has recently revealed that genes that encode subunits of SWI/SNF chromatin remodeling complexes are frequently mutated across a wide variety of cancers, and several subunits of the complex have been shown to have bona fide tumor suppressor activity.  However, whether mutations in SWI/SNF subunits result in shared dependencies is unknown.  Here we show that EZH2, a catalytic subunit of the polycomb repressive complex 2 (PRC2), is essential in all tested cancer cell lines and xenografts harboring mutations of the SWI/SNF subunits ARID1A, PBRM1, and SMARCA4, which are several of the most frequently mutated SWI/SNF subunits in human cancer, but that co-occurrence of a Ras pathway mutation is correlated with abrogation of this dependence.  Notably, we demonstrate that SWI/SNF-mutant cancer cells are primarily dependent on a non-catalytic role of EZH2 in the stabilization of the PRC2 complex, and that they are only partially dependent on EZH2 histone methyltransferase activity.  These results not only reveal a shared dependency of cancers with genetic alterations in SWI/SNF subunits, but also suggest that EZH2 enzymic inhibitors now in clin. development may not fully suppress the oncogenic activity of EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNjhQKP01U5bVg90H21EOLACvtfcHk0lgXNFPp5D9lZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7nK&md5=a30c11fe7ce3c20e982e824105b8d640</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnm.3968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3968%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DHoward%26aufirst%3DT.%2BP.%26aulast%3DVazquez%26aufirst%3DF.%26aulast%3DTsherniak%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%2BN.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHaswell%26aufirst%3DJ.%2BR.%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DOrkin%26aufirst%3DS.%2BH.%26aulast%3DRoberts%26aufirst%3DC.%2BW.%26atitle%3DSWI%252FSNF-mutant%2520cancers%2520depend%2520on%2520catalytic%2520and%2520non-catalytic%2520activity%2520of%2520EZH2%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D1491%26epage%3D1496%26doi%3D10.1038%2Fnm.3968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Kawano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grassian, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutson, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warholic, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuznetsov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minoshima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilhack, H.</span><span> </span><span class="NLM_article-title">Preclinical evidence of anti-tumor activity induced by EZH2 inhibition in human models of synovial sarcoma</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0158888</span><span class="refDoi"> DOI: 10.1371/journal.pone.0158888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1371%2Fjournal.pone.0158888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=27391784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1OqtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0158888&author=S.+Kawanoauthor=A.+R.+Grassianauthor=M.+Tsudaauthor=S.+K.+Knutsonauthor=N.+M.+Warholicauthor=G.+Kuznetsovauthor=S.+Xuauthor=Y.+Xiaoauthor=R.+M.+Pollockauthor=J.+S.+Smithauthor=K.+K.+Kuntzauthor=S.+Ribichauthor=Y.+Minoshimaauthor=J.+Matsuiauthor=R.+A.+Copelandauthor=S.+Tanakaauthor=H.+Keilhack&title=Preclinical+evidence+of+anti-tumor+activity+induced+by+EZH2+inhibition+in+human+models+of+synovial+sarcoma&doi=10.1371%2Fjournal.pone.0158888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evidence of anti-tumor activity induced by EZH2 inhibition in human models of synovial sarcoma</span></div><div class="casAuthors">Kawano, Satoshi; Grassian, Alexandra R.; Tsuda, Masumi; Knutson, Sarah K.; Warholic, Natalie M.; Kuznetsov, Galina; Xu, Shanqin; Xiao, Yonghong; Pollock, Roy M.; Smith, Jesse S.; Kuntz, Kevin K.; Ribich, Scott; Minoshima, Yukinori; Matsui, Junji; Copeland, Robert A.; Tanaka, Shinya; Keilhack, Heike</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0158888/1-e0158888/22</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The catalytic activities of covalent and ATP-dependent chromatin remodeling are central to regulating the conformational state of chromatin and the resultant transcriptional output.  The enzymes that catalyze these activities are often contained within multiprotein complexes in nature.  Two such multiprotein complexes, the polycomb repressive complex 2 (PRC2) methyltransferase and the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeler have been reported to act in opposition to each other during development and homeostasis.  An imbalance in their activities induced by mutations/deletions in complex members (e.g. SMARCB1) has been suggested to be a pathogenic mechanism in certain human cancers.  Here we show that preclin. models of synovial sarcoma-a cancer characterized by functional SMARCB1 loss via its displacement from the SWI/SNF complex through the pathognomonic SS18-SSX fusion protein-display sensitivity to pharmacol. inhibition of EZH2, the catalytic subunit of PRC2.  Treatment with tazemetostat, a clinicalstage, selective and orally bioavailable small-mol. inhibitor of EZH2 enzymic activity reverses a subset of synovial sarcoma gene expression and results in concn.-dependent cell growth inhibition and cell death specifically in SS18-SSX fusion-pos. cells in vitro.  Treatment of mice bearing either a cell line or two patient-derived xenograft models of synovial sarcoma leads to dose-dependent tumor growth inhibition with correlative inhibition of trimethylation levels of the EZH2-specific substrate, lysine 27 on histone H3.  These data demonstrate a dependency of SS18-SSX-pos., SMARCB1-deficient synovial sarcomas on EZH2 enzymic activity and suggests the potential utility of EZH2-targeted drugs in these genetically defined cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo35o6Xw1yZorVg90H21EOLACvtfcHk0lghnPwJt5SDHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1OqtLbF&md5=9bb3342fc63df57ba607b297175a1f40</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0158888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0158888%26sid%3Dliteratum%253Aachs%26aulast%3DKawano%26aufirst%3DS.%26aulast%3DGrassian%26aufirst%3DA.%2BR.%26aulast%3DTsuda%26aufirst%3DM.%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DKuznetsov%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DSmith%26aufirst%3DJ.%2BS.%26aulast%3DKuntz%26aufirst%3DK.%2BK.%26aulast%3DRibich%26aufirst%3DS.%26aulast%3DMinoshima%26aufirst%3DY.%26aulast%3DMatsui%26aufirst%3DJ.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DKeilhack%26aufirst%3DH.%26atitle%3DPreclinical%2520evidence%2520of%2520anti-tumor%2520activity%2520induced%2520by%2520EZH2%2520inhibition%2520in%2520human%2520models%2520of%2520synovial%2520sarcoma%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0158888%26doi%3D10.1371%2Fjournal.pone.0158888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Gardner, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lok, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneeberger, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmeules, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khodos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Stanchina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sage, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massion, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, J. T.</span><span> </span><span class="NLM_article-title">Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">286</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span><span class="refDoi"> DOI: 10.1016/j.ccell.2017.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1016%2Fj.ccell.2017.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=28196596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=286-299&author=E.+E.+Gardnerauthor=B.+H.+Lokauthor=V.+E.+Schneebergerauthor=P.+Desmeulesauthor=L.+A.+Milesauthor=P.+K.+Arnoldauthor=A.+Niauthor=I.+Khodosauthor=E.+de+Stanchinaauthor=T.+Nguyenauthor=J.+Sageauthor=J.+E.+Campbellauthor=S.+Ribichauthor=N.+Rekhtmanauthor=A.+Dowlatiauthor=P.+P.+Massionauthor=C.+M.+Rudinauthor=J.+T.+Poirier&title=Chemosensitive+relapse+in+small+cell+lung+cancer+proceeds+through+an+EZH2-SLFN11+axis&doi=10.1016%2Fj.ccell.2017.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis</span></div><div class="casAuthors">Gardner, Eric E.; Lok, Benjamin H.; Schneeberger, Valentina E.; Desmeules, Patrice; Miles, Linde A.; Arnold, Paige K.; Ni, Andy; Khodos, Inna; de Stanchina, Elisa; Nguyen, Thuyen; Sage, Julien; Campbell, John E.; Ribich, Scott; Rekhtman, Natasha; Dowlati, Afshin; Massion, Pierre P.; Rudin, Charles M.; Poirier, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">286-299</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Small cell lung cancer is initially highly responsive to cisplatin and etoposide but in almost every case becomes rapidly chemoresistant, leading to death within 1 yr.  We modeled acquired chemoresistance in vivo using a series of patient-derived xenografts to generate paired chemosensitive and chemoresistant cancers.  Multiple chemoresistant models demonstrated suppression of SLFN11, a factor implicated in DNA-damage repair deficiency.  In vivo silencing of SLFN11 was assocd. with marked deposition of H3K27me3, a histone modification placed by EZH2, within the gene body of SLFN11, inducing local chromatin condensation and gene silencing.  Inclusion of an EZH2 inhibitor with std. cytotoxic therapies prevented emergence of acquired resistance and augmented chemotherapeutic efficacy in both chemosensitive and chemoresistant models of small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOHlJpt8Un_bVg90H21EOLACvtfcHk0lghnPwJt5SDHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yltL8%253D&md5=d3c18e960fcc543438026062387f7c40</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2017.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2017.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DGardner%26aufirst%3DE.%2BE.%26aulast%3DLok%26aufirst%3DB.%2BH.%26aulast%3DSchneeberger%26aufirst%3DV.%2BE.%26aulast%3DDesmeules%26aufirst%3DP.%26aulast%3DMiles%26aufirst%3DL.%2BA.%26aulast%3DArnold%26aufirst%3DP.%2BK.%26aulast%3DNi%26aufirst%3DA.%26aulast%3DKhodos%26aufirst%3DI.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DSage%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DRibich%26aufirst%3DS.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DMassion%26aufirst%3DP.%2BP.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DPoirier%26aufirst%3DJ.%2BT.%26atitle%3DChemosensitive%2520relapse%2520in%2520small%2520cell%2520lung%2520cancer%2520proceeds%2520through%2520an%2520EZH2-SLFN11%2520axis%26jtitle%3DCancer%2520Cell%26date%3D2017%26volume%3D31%26spage%3D286%26epage%3D299%26doi%3D10.1016%2Fj.ccell.2017.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Dardenne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gayvert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyrta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sboner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noorzad, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eilers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosquera, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elemento, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demichelis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickman, D. S.</span><span> </span><span class="NLM_article-title">N-myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">563</span><span class="NLM_x">–</span> <span class="NLM_lpage">577</span><span class="refDoi"> DOI: 10.1016/j.ccell.2016.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1016%2Fj.ccell.2016.09.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=563-577&author=E.+Dardenneauthor=H.+Beltranauthor=M.+Benelliauthor=K.+Gayvertauthor=A.+Bergerauthor=L.+Pucaauthor=J.+Cyrtaauthor=A.+Sbonerauthor=Z.+Noorzadauthor=T.+MacDonaldauthor=C.+Cheungauthor=K.+S.+Yuenauthor=D.+Gaoauthor=Y.+Chenauthor=M.+Eilersauthor=J.+M.+Mosqueraauthor=B.+D.+Robinsonauthor=O.+Elementoauthor=M.+A.+Rubinauthor=F.+Demichelisauthor=D.+S.+Rickman&title=N-myc+induces+an+EZH2-mediated+transcriptional+program+driving+neuroendocrine+prostate+cancer&doi=10.1016%2Fj.ccell.2016.09.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DDardenne%26aufirst%3DE.%26aulast%3DBeltran%26aufirst%3DH.%26aulast%3DBenelli%26aufirst%3DM.%26aulast%3DGayvert%26aufirst%3DK.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DPuca%26aufirst%3DL.%26aulast%3DCyrta%26aufirst%3DJ.%26aulast%3DSboner%26aufirst%3DA.%26aulast%3DNoorzad%26aufirst%3DZ.%26aulast%3DMacDonald%26aufirst%3DT.%26aulast%3DCheung%26aufirst%3DC.%26aulast%3DYuen%26aufirst%3DK.%2BS.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEilers%26aufirst%3DM.%26aulast%3DMosquera%26aufirst%3DJ.%2BM.%26aulast%3DRobinson%26aufirst%3DB.%2BD.%26aulast%3DElemento%26aufirst%3DO.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DDemichelis%26aufirst%3DF.%26aulast%3DRickman%26aufirst%3DD.%2BS.%26atitle%3DN-myc%2520induces%2520an%2520EZH2-mediated%2520transcriptional%2520program%2520driving%2520neuroendocrine%2520prostate%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D563%26epage%3D577%26doi%3D10.1016%2Fj.ccell.2016.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ku, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosario, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshadri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labbe, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, D. W.</span><span> </span><span class="NLM_article-title">Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span><span class="refDoi"> DOI: 10.1126/science.aah4199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1126%2Fscience.aah4199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=28059767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Wjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=78-83&author=S.+Y.+Kuauthor=S.+Rosarioauthor=Y.+Wangauthor=P.+Muauthor=M.+Seshadriauthor=Z.+W.+Goodrichauthor=M.+M.+Goodrichauthor=D.+P.+Labbeauthor=E.+C.+Gomezauthor=J.+Wangauthor=H.+W.+Longauthor=B.+Xuauthor=M.+Brownauthor=M.+Lodaauthor=C.+L.+Sawyersauthor=L.+Ellisauthor=D.+W.+Goodrich&title=Rb1+and+Trp53+cooperate+to+suppress+prostate+cancer+lineage+plasticity%2C+metastasis%2C+and+antiandrogen+resistance&doi=10.1126%2Fscience.aah4199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance</span></div><div class="casAuthors">Ku, Sheng Yu; Rosario, Spencer; Wang, Yanqing; Mu, Ping; Seshadri, Mukund; Goodrich, Zachary W.; Goodrich, Maxwell M.; Labbe, David P.; Gomez, Eduardo Cortes; Wang, Jianmin; Long, Henry W.; Xu, Bo; Brown, Myles; Loda, Massimo; Sawyers, Charles L.; Ellis, Leigh; Goodrich, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6320</span>),
    <span class="NLM_cas:pages">78-83</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Prostate cancer relapsing from antiandrogen therapies can exhibit variant histol. with altered lineage marker expression, suggesting that lineage plasticity facilitates therapeutic resistance.  The mechanisms underlying prostate cancer lineage plasticity are incompletely understood.  Studying mouse models, we demonstrate that Rb1 loss facilitates lineage plasticity and metastasis of prostate adenocarcinoma initiated by Pten mutation.  Addnl. loss of Trp53 causes resistance to antiandrogen therapy.  Gene expression profiling indicates that mouse tumors resemble human prostate cancer neuroendocrine variants; both mouse and human tumors exhibit increased expression of epigenetic reprogramming factors such as Ezh2 and Sox2.  Clin. relevant Ezh2 inhibitors restore androgen receptor expression and sensitivity to antiandrogen therapy.  These findings uncover genetic mutations that enable prostate cancer progression; identify mouse models for studying prostate cancer lineage plasticity; and suggest an epigenetic approach for extending clin. responses to antiandrogen therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDQEfrg7Zcb7Vg90H21EOLACvtfcHk0lgfeMsHlNlrRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Wjtw%253D%253D&md5=c3f2e7070cabe82a3667653a62915224</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.aah4199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aah4199%26sid%3Dliteratum%253Aachs%26aulast%3DKu%26aufirst%3DS.%2BY.%26aulast%3DRosario%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMu%26aufirst%3DP.%26aulast%3DSeshadri%26aufirst%3DM.%26aulast%3DGoodrich%26aufirst%3DZ.%2BW.%26aulast%3DGoodrich%26aufirst%3DM.%2BM.%26aulast%3DLabbe%26aufirst%3DD.%2BP.%26aulast%3DGomez%26aufirst%3DE.%2BC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DH.%2BW.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DEllis%26aufirst%3DL.%26aulast%3DGoodrich%26aufirst%3DD.%2BW.%26atitle%3DRb1%2520and%2520Trp53%2520cooperate%2520to%2520suppress%2520prostate%2520cancer%2520lineage%2520plasticity%252C%2520metastasis%252C%2520and%2520antiandrogen%2520resistance%26jtitle%3DScience%26date%3D2017%26volume%3D355%26spage%3D78%26epage%3D83%26doi%3D10.1126%2Fscience.aah4199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Knutson, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minoshima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warholic, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadowaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uesugi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuznetsov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigle, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klaus, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allain, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raimondi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter-Scott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesworth, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilhack, H.</span><span> </span><span class="NLM_article-title">Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">842</span><span class="NLM_x">–</span> <span class="NLM_lpage">854</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1158%2F1535-7163.MCT-13-0773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=24563539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=842-854&author=S.+K.+Knutsonauthor=S.+Kawanoauthor=Y.+Minoshimaauthor=N.+M.+Warholicauthor=K.+C.+Huangauthor=Y.+Xiaoauthor=T.+Kadowakiauthor=M.+Uesugiauthor=G.+Kuznetsovauthor=N.+Kumarauthor=T.+J.+Wigleauthor=C.+R.+Klausauthor=C.+J.+Allainauthor=A.+Raimondiauthor=N.+J.+Watersauthor=J.+J.+Smithauthor=M.+Porter-Scottauthor=R.+Chesworthauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=V.+M.+Richonauthor=T.+Uenakaauthor=R.+M.+Pollockauthor=K.+W.+Kuntzauthor=A.+Yokoiauthor=H.+Keilhack&title=Selective+inhibition+of+EZH2+by+EPZ-6438+leads+to+potent+antitumor+activity+in+EZH2-mutant+non-Hodgkin+lymphoma&doi=10.1158%2F1535-7163.MCT-13-0773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma</span></div><div class="casAuthors">Knutson, Sarah K.; Kawano, Satoshi; Minoshima, Yukinori; Warholic, Natalie M.; Huang, Kuan-Chun; Xiao, Yonghong; Kadowaki, Tadashi; Uesugi, Mai; Kuznetsov, Galina; Kumar, Namita; Wigle, Tim J.; Klaus, Christine R.; Allain, Christina J.; Raimondi, Alejandra; Waters, Nigel J.; Smith, Jesse J.; Porter-Scott, Margaret; Chesworth, Richard; Moyer, Mikel P.; Copeland, Robert A.; Richon, Victoria M.; Uenaka, Toshimitsu; Pollock, Roy M.; Kuntz, Kevin W.; Yokoi, Akira; Keilhack, Heike</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-854</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutations within the catalytic domain of the histone methyltransferase EZH2 have been identified in subsets of patients with non-Hodgkin lymphoma (NHL).  These genetic alterations are hypothesized to confer an oncogenic dependency on EZH2 enzymic activity in these cancers.  We have previously reported the discovery of EPZ005678 and EPZ-6438, potent and selective S-adenosyl-methionine-competitive small mol. inhibitors of EZH2.  Although both compds. are similar with respect to their mechanism of action and selectivity, EPZ-6438 possesses superior potency and drug-like properties, including good oral bioavailability in animals.  Here, we characterize the activity of EPZ-6438 in preclin. models of NHL.  EPZ-6438 selectively inhibits intracellular lysine 27 of histone H3 (H3K27) methylation in a concn.- and time-dependent manner in both EZH2 wild-type and mutant lymphoma cells.  Inhibition of H3K27 trimethylation (H3K27Me3) leads to selective cell killing of human lymphoma cell lines bearing EZH2 catalytic domain point mutations.  Treatment of EZH2-mutant NHL xenograft-bearing mice with EPZ-6438 causes dose-dependent tumor growth inhibition, including complete and sustained tumor regressions with correlative diminution of H3K27Me3 levels in tumors and selected normal tissues.  Mice dosed orally with EPZ-6438 for 28 days remained tumor free for up to 63 days after stopping compd. treatment in two EZH2-mutant xenograft models.  These data confirm the dependency of EZH2-mutant NHL on EZH2 activity and portend the utility of EPZ-6438 as a potential treatment for these genetically defined cancers.  Mol Cancer Ther; 13(4); 842-54. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq2o1v5F3GzLVg90H21EOLACvtfcHk0lgfeMsHlNlrRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurw%253D&md5=89354e9453dcd7430978d1a6c5ee5846</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0773%26sid%3Dliteratum%253Aachs%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DKawano%26aufirst%3DS.%26aulast%3DMinoshima%26aufirst%3DY.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DHuang%26aufirst%3DK.%2BC.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DKadowaki%26aufirst%3DT.%26aulast%3DUesugi%26aufirst%3DM.%26aulast%3DKuznetsov%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DKlaus%26aufirst%3DC.%2BR.%26aulast%3DAllain%26aufirst%3DC.%2BJ.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DPorter-Scott%26aufirst%3DM.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DYokoi%26aufirst%3DA.%26aulast%3DKeilhack%26aufirst%3DH.%26atitle%3DSelective%2520inhibition%2520of%2520EZH2%2520by%2520EPZ-6438%2520leads%2520to%2520potent%2520antitumor%2520activity%2520in%2520EZH2-mutant%2520non-Hodgkin%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D842%26epage%3D854%26doi%3D10.1158%2F1535-7163.MCT-13-0773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Vaswani, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gehling, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasveschuk, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duplessis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantone, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audia, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gamblin, S. J.</span><span> </span><span class="NLM_article-title">Identification of (<i>R</i>)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a potent and selective inhibitor of histone methyltransferase EZH2, suitable for phase I clinical trials for B-cell lymphomas</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">9928</span><span class="NLM_x">–</span> <span class="NLM_lpage">9941</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9928-9941&author=R.+G.+Vaswaniauthor=V.+S.+Gehlingauthor=L.+A.+Dakinauthor=A.+S.+Cookauthor=C.+G.+Nasveschukauthor=M.+Duplessisauthor=P.+Iyerauthor=S.+Balasubramanianauthor=F.+Zhaoauthor=A.+C.+Goodauthor=R.+Campbellauthor=C.+Leeauthor=N.+Cantoneauthor=R.+T.+Cummingsauthor=E.+Normantauthor=S.+F.+Bellonauthor=B.+K.+Albrechtauthor=J.+C.+Harmangeauthor=P.+Trojerauthor=J.+E.+Audiaauthor=Y.+Zhangauthor=N.+Justinauthor=S.+Chenauthor=J.+R.+Wilsonauthor=S.+J.+Gamblin&title=Identification+of+%28R%29-N-%28%284-methoxy-6-methyl-2-oxo-1%2C2-dihydropyridin-3-yl%29methyl%29-2-methyl-1-%281-%281-%282%2C2%2C2-trifluoroethyl%29piperidin-4-yl%29ethyl%29-1H-indole-3-carboxamide+%28CPI-1205%29%2C+a+potent+and+selective+inhibitor+of+histone+methyltransferase+EZH2%2C+suitable+for+phase+I+clinical+trials+for+B-cell+lymphomas&doi=10.1021%2Facs.jmedchem.6b01315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas</span></div><div class="casAuthors">Vaswani, Rishi G.; Gehling, Victor S.; Dakin, Les A.; Cook, Andrew S.; Nasveschuk, Christopher G.; Duplessis, Martin; Iyer, Priyadarshini; Balasubramanian, Srividya; Zhao, Feng; Good, Andrew C.; Campbell, Robert; Lee, Christina; Cantone, Nico; Cummings, Richard T.; Normant, Emmanuel; Bellon, Steven F.; Albrecht, Brian K.; Harmange, Jean-Christophe; Trojer, Patrick; Audia, James E.; Zhang, Ying; Justin, Neil; Chen, Shuyang; Wilson, Jon R.; Gamblin, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9928-9941</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) has been shown to play a major role in transcriptional silencing in part by installing methylation marks on lysine 27 of histone 3.  Dysregulation of PRC2 function correlates with certain malignancies and poor prognosis.  EZH2 is the catalytic engine of the PRC2 complex and thus represents a key candidate oncol. target for pharmacol. intervention.  Here we report the optimization of our indole-based EZH2 inhibitor series that led to the identification of CPI-1205, a highly potent (biochem. IC50 = 0.002 μM, cellular EC50 = 0.032 μM) and selective inhibitor of EZH2.  This compd. demonstrates robust antitumor effects in a Karpas-422 xenograft model when dosed at 160 mg/kg BID and is currently in Phase I clin. trials.  Addnl., we disclose the co-crystal structure of our inhibitor series bound to the human PRC2 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrqnfg3FGdE7Vg90H21EOLACvtfcHk0liTiUeyDpKUWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77I&md5=4096fa91399fef88a7ec8aabb5aaee13</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01315%26sid%3Dliteratum%253Aachs%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJustin%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DJ.%2BR.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26atitle%3DIdentification%2520of%2520%2528R%2529-N-%2528%25284-methoxy-6-methyl-2-oxo-1%252C2-dihydropyridin-3-yl%2529methyl%2529-2-methyl-1-%25281-%25281-%25282%252C2%252C2-trifluoroethyl%2529piperidin-4-yl%2529ethyl%2529-1H-indole-3-carboxamide%2520%2528CPI-1205%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520histone%2520methyltransferase%2520EZH2%252C%2520suitable%2520for%2520phase%2520I%2520clinical%2520trials%2520for%2520B-cell%2520lymphomas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9928%26epage%3D9941%26doi%3D10.1021%2Facs.jmedchem.6b01315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Morschhauser, F.; Salles, G.; McKay, P.; Tilly, H.; Schmitt, A.; Gerecitano, J.; Johnson, P.; Le Gouill, S.; Dickinson, M. J.; Fruchart, C.; Lamy, T.; Chaidos, A.; Jurczak, W.; Opat, S.; Radford, J.; Zinzani, P. L.; Assouline, S.; Cartron, G.; Clawson, A.; Picazio, N.; Ribich, S.; Blakemore, S. J.; Larus, J.; Miao, H.; Woodruff, M.; Ho, P. T.; Ribrag, V.</span><span> </span><span class="NLM_article-title">Interim report from a phase II multicenter study of tazemetostat, an EZH2 inhibitor: clinical activity and favorable safety in patients with relapsed or refractory B-cell non-Hodgkin lymphoma</span>. Presented at the 14th International Conference on Malignant Lymphoma, Switzerland, June 14–17,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=F.+Morschhauser&author=G.+Salles&author=P.+McKay&author=H.+Tilly&author=A.+Schmitt&author=J.+Gerecitano&author=P.+Johnson&author=S.+Le+Gouill&author=M.+J.+Dickinson&author=C.+Fruchart&author=T.+Lamy&author=A.+Chaidos&author=W.+Jurczak&author=S.+Opat&author=J.+Radford&author=P.+L.+Zinzani&author=S.+Assouline&author=G.+Cartron&author=A.+Clawson&author=N.+Picazio&author=S.+Ribich&author=S.+J.+Blakemore&author=J.+Larus&author=H.+Miao&author=M.+Woodruff&author=P.+T.+Ho&author=V.+Ribrag&title=Interim+report+from+a+phase+II+multicenter+study+of+tazemetostat%2C+an+EZH2+inhibitor%3A+clinical+activity+and+favorable+safety+in+patients+with+relapsed+or+refractory+B-cell+non-Hodgkin+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DMorschhauser%26aufirst%3DF.%26atitle%3DInterim%2520report%2520from%2520a%2520phase%2520II%2520multicenter%2520study%2520of%2520tazemetostat%252C%2520an%2520EZH2%2520inhibitor%253A%2520clinical%2520activity%2520and%2520favorable%2520safety%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520B-cell%2520non-Hodgkin%2520lymphoma%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Qi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fei, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, E.</span><span> </span><span class="NLM_article-title">An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">388</span><span class="refDoi"> DOI: 10.1038/nchembio.2304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnchembio.2304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=28135235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=381-388&author=W.+Qiauthor=K.+Zhaoauthor=J.+Guauthor=Y.+Huangauthor=Y.+Wangauthor=H.+Zhangauthor=M.+Zhangauthor=J.+Zhangauthor=Z.+Yuauthor=L.+Liauthor=L.+Tengauthor=S.+Chuaiauthor=C.+Zhangauthor=M.+Zhaoauthor=H.+Chanauthor=Z.+Chenauthor=D.+Fangauthor=Q.+Feiauthor=L.+Fengauthor=L.+Fengauthor=Y.+Gaoauthor=H.+Geauthor=X.+Geauthor=G.+Liauthor=A.+Lingelauthor=Y.+Linauthor=Y.+Liuauthor=F.+Luoauthor=M.+Shiauthor=L.+Wangauthor=Z.+Wangauthor=Y.+Yuauthor=J.+Zengauthor=C.+Zengauthor=L.+Zhangauthor=Q.+Zhangauthor=S.+Zhouauthor=C.+Oyangauthor=P.+Atadjaauthor=E.+Li&title=An+allosteric+PRC2+inhibitor+targeting+the+H3K27me3+binding+pocket+of+EED&doi=10.1038%2Fnchembio.2304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23aR"><div class="casContent"><span class="casTitleNuber">23a</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED</span></div><div class="casAuthors">Qi, Wei; Zhao, Kehao; Gu, Justin; Huang, Ying; Wang, Youzhen; Zhang, Hailong; Zhang, Man; Zhang, Jeff; Yu, Zhengtian; Li, Ling; Teng, Lin; Chuai, Shannon; Zhang, Chao; Zhao, Mengxi; Chan, Ho Man; Chen, Zijun; Fang, Douglas; Fei, Qi; Feng, Leying; Feng, Lijian; Gao, Yuan; Ge, Hui; Ge, Xinjian; Li, Guobin; Lingel, Andreas; Lin, Ying; Liu, Yueqin; Luo, Fangjun; Shi, Minlong; Wang, Long; Wang, Zhaofu; Yu, Yanyan; Zeng, Jue; Zeng, Chenhui; Zhang, Lijun; Zhang, Qiong; Zhou, Shaolian; Oyang, Counde; Atadja, Peter; Li, En</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">381-388</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) consists of three core subunits, EZH2, EED and SUZ12, and plays pivotal roles in transcriptional regulation.  The catalytic subunit EZH2 methylates histone H3 lysine 27 (H3K27), and its activity is further enhanced by the binding of EED to trimethylated H3K27 (H3K27me3).  Small-mol. inhibitors that compete with the cofactor S-adenosylmethionine (SAM) have been reported.  Here we report the discovery of EED226, a potent and selective PRC2 inhibitor that directly binds to the H3K27me3 binding pocket of EED.  EED226 induces a conformational change upon binding EED, leading to loss of PRC2 activity.  EED226 shows similar activity to SAM-competitive inhibitors in blocking H3K27 methylation of PRC2 target genes and inducing regression of human lymphoma xenograft tumors.  Interestingly, EED226 also effectively inhibits PRC2 contg. a mutant EZH2 protein resistant to SAM-competitive inhibitors.  Together, we show that EED226 inhibits PRC2 activity via an allosteric mechanism and offers an opportunity for treatment of PRC2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjpXExCMohI7Vg90H21EOLACvtfcHk0liTiUeyDpKUWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsLc%253D&md5=62d10723685450ca7ffd599a61134d42</span></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2304%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DTeng%26aufirst%3DL.%26aulast%3DChuai%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DFei%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DH.%26aulast%3DGe%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLingel%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DOyang%26aufirst%3DC.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DE.%26atitle%3DAn%2520allosteric%2520PRC2%2520inhibitor%2520targeting%2520the%2520H3K27me3%2520binding%2520pocket%2520of%2520EED%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D381%26epage%3D388%26doi%3D10.1038%2Fnchembio.2304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selvaraju, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakob, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comess, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">The, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lima-Fernandes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczyk, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinge, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pliushchev, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Algire, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maag, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panchal, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petros, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweis, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torrent, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigelow, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senisterra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindley, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galasinski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsyte-Lovejoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vedadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappano, W. N.</span><span> </span><span class="NLM_article-title">The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span><span class="refDoi"> DOI: 10.1038/nchembio.2306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fnchembio.2306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=28135237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=389-395&author=Y.+Heauthor=S.+Selvarajuauthor=M.+L.+Curtinauthor=C.+G.+Jakobauthor=H.+Zhuauthor=K.+M.+Comessauthor=B.+Shawauthor=J.+Theauthor=E.+Lima-Fernandesauthor=M.+M.+Szewczykauthor=D.+Chengauthor=K.+L.+Klingeauthor=H.+Q.+Liauthor=M.+Pliushchevauthor=M.+A.+Algireauthor=D.+Maagauthor=J.+Guoauthor=J.+Dietrichauthor=S.+C.+Panchalauthor=A.+M.+Petrosauthor=R.+F.+Sweisauthor=M.+Torrentauthor=L.+J.+Bigelowauthor=G.+Senisterraauthor=F.+Liauthor=S.+Kennedyauthor=Q.+Wuauthor=D.+J.+Osterlingauthor=D.+J.+Lindleyauthor=W.+Gaoauthor=S.+Galasinskiauthor=D.+Barsyte-Lovejoyauthor=M.+Vedadiauthor=F.+G.+Buchananauthor=C.+H.+Arrowsmithauthor=G.+G.+Chiangauthor=C.+Sunauthor=W.+N.+Pappano&title=The+EED+protein-protein+interaction+inhibitor+A-395+inactivates+the+PRC2+complex&doi=10.1038%2Fnchembio.2306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex</span></div><div class="casAuthors">He, Yupeng; Selvaraju, Sujatha; Curtin, Michael L.; Jakob, Clarissa G.; Zhu, Haizhong; Comess, Kenneth M.; Shaw, Bailin; The, Juliana; Lima-Fernandes, Evelyne; Szewczyk, Magdalena M.; Cheng, Dong; Klinge, Kelly L.; Li, Huan-Qiu; Pliushchev, Marina; Algire, Mikkel A.; Maag, David; Guo, Jun; Dietrich, Justin; Panchal, Sanjay C.; Petros, Andrew M.; Sweis, Ramzi F.; Torrent, Maricel; Bigelow, Lance J.; Senisterra, Guillermo; Li, Fengling; Kennedy, Steven; Wu, Qin; Osterling, Donald J.; Lindley, David J.; Gao, Wenqing; Galasinski, Scott; Barsyte-Lovejoy, Dalia; Vedadi, Masoud; Buchanan, Fritz G.; Arrowsmith, Cheryl H.; Chiang, Gary G.; Sun, Chaohong; Pappano, William N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">389-395</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) is a regulator of epigenetic states required for development and homeostasis.  PRC2 trimethylates histone H3 at lysine 27 (H3K27me3), which leads to gene silencing, and is dysregulated in many cancers.  The embryonic ectoderm development (EED) protein is an essential subunit of PRC2 that has both a scaffolding function and an H3K27me3-binding function.  Here we report the identification of A-395, a potent antagonist of the H3K27me3 binding functions of EED.  Structural studies demonstrate that A-395 binds to EED in the H3K27me3-binding pocket, thereby preventing allosteric activation of the catalytic activity of PRC2.  Phenotypic effects obsd. in vitro and in vivo are similar to those of known PRC2 enzymic inhibitors; however, A-395 retains potent activity against cell lines resistant to the catalytic inhibitors.  A-395 represents a first-in-class antagonist of PRC2 protein-protein interactions (PPI) for use as a chem. probe to investigate the roles of EED-contg. protein complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX5rHeR_Z5mLVg90H21EOLACvtfcHk0lii3ecYm0NWTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2hsbs%253D&md5=d41eee098ed123f8c7f50babe93d7692</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2306%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DSelvaraju%26aufirst%3DS.%26aulast%3DCurtin%26aufirst%3DM.%2BL.%26aulast%3DJakob%26aufirst%3DC.%2BG.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DComess%26aufirst%3DK.%2BM.%26aulast%3DShaw%26aufirst%3DB.%26aulast%3DThe%26aufirst%3DJ.%26aulast%3DLima-Fernandes%26aufirst%3DE.%26aulast%3DSzewczyk%26aufirst%3DM.%2BM.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DKlinge%26aufirst%3DK.%2BL.%26aulast%3DLi%26aufirst%3DH.%2BQ.%26aulast%3DPliushchev%26aufirst%3DM.%26aulast%3DAlgire%26aufirst%3DM.%2BA.%26aulast%3DMaag%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DDietrich%26aufirst%3DJ.%26aulast%3DPanchal%26aufirst%3DS.%2BC.%26aulast%3DPetros%26aufirst%3DA.%2BM.%26aulast%3DSweis%26aufirst%3DR.%2BF.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DBigelow%26aufirst%3DL.%2BJ.%26aulast%3DSenisterra%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DKennedy%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DLindley%26aufirst%3DD.%2BJ.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DGalasinski%26aufirst%3DS.%26aulast%3DBarsyte-Lovejoy%26aufirst%3DD.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DBuchanan%26aufirst%3DF.%2BG.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DPappano%26aufirst%3DW.%2BN.%26atitle%3DThe%2520EED%2520protein-protein%2520interaction%2520inhibitor%2520A-395%2520inactivates%2520the%2520PRC2%2520complex%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D389%26epage%3D395%26doi%3D10.1038%2Fnchembio.2306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rui, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bingham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braganza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantin, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gukasyan, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kephart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krivacic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpf, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAlpine, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ninkovic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ornelas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryskin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scales, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatlock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhelle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wythes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yip, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zehnder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rollins, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span> </span><span class="NLM_article-title">Design and synthesis of pyridone-containing 3,4-dihydroisoquinoline-1(2H)-ones as a novel class of enhancer of zeste homolog 2 (EZH2) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">8306</span><span class="NLM_x">–</span> <span class="NLM_lpage">8325</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00515</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00515" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8306-8325&author=P.+P.+Kungauthor=E.+Ruiauthor=S.+Bergqvistauthor=P.+Binghamauthor=J.+Braganzaauthor=M.+Collinsauthor=M.+Cuiauthor=W.+Diehlauthor=D.+Dinhauthor=C.+Fanauthor=V.+R.+Fantinauthor=H.+J.+Gukasyanauthor=W.+Huauthor=B.+Huangauthor=S.+Kephartauthor=C.+Krivacicauthor=R.+A.+Kumpfauthor=G.+Liauthor=K.+A.+Maegleyauthor=I.+McAlpineauthor=L.+Nguyenauthor=S.+Ninkovicauthor=M.+Ornelasauthor=M.+Ryskinauthor=S.+Scalesauthor=S.+Suttonauthor=J.+Tatlockauthor=D.+Verhelleauthor=F.+Wangauthor=P.+Wellsauthor=M.+Wythesauthor=S.+Yamazakiauthor=B.+Yipauthor=X.+Yuauthor=L.+Zehnderauthor=W.+G.+Zhangauthor=R.+A.+Rollinsauthor=M.+Edwards&title=Design+and+synthesis+of+pyridone-containing+3%2C4-dihydroisoquinoline-1%282H%29-ones+as+a+novel+class+of+enhancer+of+zeste+homolog+2+%28EZH2%29+inhibitors&doi=10.1021%2Facs.jmedchem.6b00515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors</span></div><div class="casAuthors">Kung, Pei-Pei; Rui, Eugene; Bergqvist, Simon; Bingham, Patrick; Braganza, John; Collins, Michael; Cui, Mei; Diehl, Wade; Dinh, Dac; Fan, Connie; Fantin, Valeria R.; Gukasyan, Hovhannes J.; Hu, Wenyue; Huang, Buwen; Kephart, Susan; Krivacic, Cody; Kumpf, Robert A.; Li, Gary; Maegley, Karen A.; McAlpine, Indrawan; Nguyen, Lisa; Ninkovic, Sacha; Ornelas, Martha; Ryskin, Michael; Scales, Stephanie; Sutton, Scott; Tatlock, John; Verhelle, Dominique; Wang, Fen; Wells, Peter; Wythes, Martin; Yamazaki, Shinji; Yip, Brian; Yu, Xiu; Zehnder, Luke; Zhang, Wei-Guo; Rollins, Robert A.; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8306-8325</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new enhancer of zeste homolog 2 (EZH2) inhibitor series comprising a substituted Ph ring joined to a dimethylpyridone moiety via an amide linkage has been designed.  A preferential amide torsion that improved the binding properties of the compds. was identified for this series via computational anal.  Cyclization of the amide linker resulted in a six-membered lactam analog, compd. I.  This transformation significantly improved the ligand efficiency/potency of the cyclized compd. relative to its acyclic analog.  Addnl. optimization of the lactam-contg. EZH2 inhibitors focused on lipophilic efficiency (LipE) improvement, which provided compd. II.  Compd. II displayed improved LipE and on-target potency in both biochem. and cellular readouts relative to compd. I.  Inhibitor II also displayed robust in vivo antitumor growth activity and dose-dependent de-repression of EZH2 target genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr50CIrIhlikrVg90H21EOLACvtfcHk0lii3ecYm0NWTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7rM&md5=eb6f2b053e5ba2c2d214d847ad8d9f1f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00515%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DRui%26aufirst%3DE.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBraganza%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DGukasyan%26aufirst%3DH.%2BJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DKrivacic%26aufirst%3DC.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DMcAlpine%26aufirst%3DI.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DNinkovic%26aufirst%3DS.%26aulast%3DOrnelas%26aufirst%3DM.%26aulast%3DRyskin%26aufirst%3DM.%26aulast%3DScales%26aufirst%3DS.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DTatlock%26aufirst%3DJ.%26aulast%3DVerhelle%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWells%26aufirst%3DP.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DYip%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZehnder%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%2BG.%26aulast%3DRollins%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520pyridone-containing%25203%252C4-dihydroisoquinoline-1%25282H%2529-ones%2520as%2520a%2520novel%2520class%2520of%2520enhancer%2520of%2520zeste%2520homolog%25202%2520%2528EZH2%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8306%26epage%3D8325%26doi%3D10.1021%2Facs.jmedchem.6b00515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hosea, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, R. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1177/0091270009333209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1177%2F0091270009333209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=19299532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=513-533&author=N.+A.+Hoseaauthor=W.+T.+Collardauthor=S.+Coleauthor=T.+S.+Maurerauthor=R.+X.+Fangauthor=H.+Jonesauthor=S.+M.+Kakarauthor=Y.+Nakaiauthor=B.+J.+Smithauthor=R.+Websterauthor=K.+Beaumont&title=Prediction+of+human+pharmacokinetics+from+preclinical+information%3A+comparative+accuracy+of+quantitative+prediction+approaches&doi=10.1177%2F0091270009333209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span></div><div class="casAuthors">Hosea, Natilie A.; Collard, Wendy T.; Cole, Susan; Maurer, Tristan S.; Fang, Rick X.; Jones, Hannah; Kakar, Shefali M.; Nakai, Yasuhiro; Smith, Bill J.; Webster, Rob; Beaumont, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-533</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Quant. prediction of human pharmacokinetics is crit. in assessing the viability of drug candidates and in detg. first-in-human dosing.  Numerous prediction methodologies, incorporating both in vitro and preclin. in vivo data, have been developed in recent years, each with advantages and disadvantages.  However, the lack of a comprehensive data set, both preclin. and clin., has limited efforts to evaluate the optimal strategy (or strategies) that results in quant. predictions of human pharmacokinetics.  To address this issue, the authors conducted a retrospective anal. using 50 proprietary compds. for which in vitro, preclin. pharmacokinetic data and oral single-dose human pharmacokinetic data were available.  Five predictive strategies, involving either allometry or use of unbound intrinsic clearance from microsomes or hepatocytes, were then compared for their ability to predict human oral clearance, half-life through predictions of systemic clearance, vol. of distribution, and bioavailability.  Use of a single-species scaling approach with rat, dog, or monkey was as accurate as or more accurate than using multiple-species allometry.  For those compds. cleared almost exclusively by P 450-mediated pathways, scaling from human liver microsomes was as predictive as single-species scaling of clearance based on data from rat, dog, or monkey.  These data suggest that use of predictive methods involving either single-species in vivo data or in vitro human liver microsomes can quant. predict human in vivo pharmacokinetics and suggest the possibility of streamlining the predictive methodol. through use of a single species or use only of human in vitro microsomal prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg67HcwS4O4LVg90H21EOLACvtfcHk0lirmHnad-i_2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D&md5=a0941d53fe43392f8fb1562ee546705e</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1177%2F0091270009333209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333209%26sid%3Dliteratum%253Aachs%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DCollard%26aufirst%3DW.%2BT.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DFang%26aufirst%3DR.%2BX.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DBeaumont%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520from%2520preclinical%2520information%253A%2520comparative%2520accuracy%2520of%2520quantitative%2520prediction%2520approaches%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D513%26epage%3D533%26doi%3D10.1177%2F0091270009333209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note">b<p class="last">Human microsomal Cl<sub>int,app</sub> ((μL/min)/mg protein) bins: <9 (low), 9–49 (moderate), and >49 (high).</p></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nkansah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney-Pickett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span> </span><span class="NLM_article-title">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1199</span><span class="NLM_x">–</span> <span class="NLM_lpage">1212</span><span class="refDoi"> DOI: 10.1021/mp2004912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2004912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1199-1212&author=M.+V.+Varmaauthor=I.+Gardnerauthor=S.+J.+Steynauthor=P.+Nkansahauthor=C.+J.+Rotterauthor=C.+Whitney-Pickettauthor=H.+Zhangauthor=L.+Diauthor=M.+Cramauthor=K.+S.+Fennerauthor=A.+F.+El-Kattan&title=pH-Dependent+solubility+and+permeability+criteria+for+provisional+biopharmaceutics+classification+%28BCS+and+BDDCS%29+in+early+drug+discovery&doi=10.1021%2Fmp2004912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span></div><div class="casAuthors">Varma, Manthena V.; Gardner, Iain; Steyn, Stefanus J.; Nkansah, Paul; Rotter, Charles J.; Whitney-Pickett, Carrie; Zhang, Hui; Di, Li; Cram, Michael; Fenner, Katherine S.; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1212</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is a scientific framework that provides a basis for predicting the oral absorption of drugs.  These concepts have been extended in the Biopharmaceutics Drug Disposition Classification System (BDDCS) to explain the potential mechanism of drug clearance and understand the effects of uptake and efflux transporters on absorption, distribution, metab., and elimination.  The objective of present work is to establish criteria for provisional biopharmaceutics classification using pH-dependent passive permeability and aq. soly. data generated from high throughput screening methodologies in drug discovery settings.  The apparent permeability across monolayers of clonal cell line of Madin-Darby canine kidney cells, selected for low endogenous efflux transporter expression, was measured for a set of 105 drugs, with known BCS and BDDCS class.  The permeability at apical pH 6.5 for acidic drugs and at pH 7.4 for nonacidic drugs showed a good correlation with the fraction absorbed in human (Fa).  Receiver operating characteristic (ROC) curve anal. was utilized to define the permeability class boundary.  At permeability ≥5 × 10-6 cm/s, the accuracy of predicting Fa of ≥0.90 was 87%.  Also, this cutoff showed more than 80% sensitivity and specificity in predicting the literature permeability classes (BCS), and the metab. classes (BDDCS).  The equil. soly. of a subset of 49 drugs was measured in pH 1.2 medium, pH 6.5 phosphate buffer, and in FaSSIF medium (pH 6.5).  Although dose was not considered, good concordance of the measured soly. with BCS and BDDCS soly. class was achieved, when soly. at pH 1.2 was used for acidic compds. and FaSSIF soly. was used for basic, neutral, and zwitterionic compds.  Using a cutoff of 200 μg/mL, the data set suggested a 93% sensitivity and 86% specificity in predicting both the BCS and BDDCS soly. classes.  In conclusion, this study identified pH-dependent permeability and soly. criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process.  Addnl., such a classification system will enable discovery scientists to assess the potential limiting factors to oral absorption, as well as help predict the drug disposition mechanisms and potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84irw4TD15rVg90H21EOLACvtfcHk0lirmHnad-i_2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D&md5=2bcb29ea512d2e0665973292e4a4a0a3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fmp2004912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2004912%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DNkansah%26aufirst%3DP.%26aulast%3DRotter%26aufirst%3DC.%2BJ.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCram%26aufirst%3DM.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DpH-Dependent%2520solubility%2520and%2520permeability%2520criteria%2520for%2520provisional%2520biopharmaceutics%2520classification%2520%2528BCS%2520and%2520BDDCS%2529%2520in%2520early%2520drug%2520discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D1199%26epage%3D1212%26doi%3D10.1021%2Fmp2004912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Hill, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span> </span><span class="NLM_article-title">Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">648</span><span class="NLM_x">–</span> <span class="NLM_lpage">655</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1016%2Fj.drudis.2010.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=20570751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVeksb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=648-655&author=A.+P.+Hillauthor=R.+J.+Young&title=Getting+physical+in+drug+discovery%3A+a+contemporary+perspective+on+solubility+and+hydrophobicity&doi=10.1016%2Fj.drudis.2010.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity</span></div><div class="casAuthors">Hill, Alan P.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15/16</span>),
    <span class="NLM_cas:pages">648-655</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Suboptimal phys. properties have been identified as a particular shortcoming of compds. in contemporary drug discovery, contributing to high attrition levels.  An anal. of the relationship between hydrophobicity (calcd. and measured) and ∼100 k measured kinetic soly. values has been undertaken.  In line with the General Soly. Equation, ests. of hydrophobicity, particularly ACD c log D pH7.4, give a useful indication of the likely soly. classification of particular mols.  Taking ACD c log D pH7.4 values together with the no. of arom. rings in a given mol. provides enhanced prediction.  The Soly. Forecast Index' (SFI = c log D pH7.4 + #Ar) is proposed as a simple, yet effective, guide to predicting soly.  Moreover, anal. of measured distribution/partition coeff. values highlighted statistically significant shortcomings in the applicability of octanol/water as a model system for hydrophobicity detn. with poorly sol. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdtQyfNjbFUrVg90H21EOLACvtfcHk0liPd7Us8F7dlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVeksb3P&md5=7b201081c5586a6ea4b7af00d507d462</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%253A%2520a%2520contemporary%2520perspective%2520on%2520solubility%2520and%2520hydrophobicity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D648%26epage%3D655%26doi%3D10.1016%2Fj.drudis.2010.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">–</span> <span class="NLM_lpage">6756</span><span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0liPd7Us8F7dlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Yap, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moradian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mungall, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meissner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquez, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marra, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, S. A.</span><span> </span><span class="NLM_article-title">Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">2451</span><span class="NLM_x">–</span> <span class="NLM_lpage">2459</span><span class="refDoi"> DOI: 10.1182/blood-2010-11-321208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1182%2Fblood-2010-11-321208" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=2451-2459&author=D.+B.+Yapauthor=J.+Chuauthor=T.+Bergauthor=M.+Schapiraauthor=S.+W.+Chengauthor=A.+Moradianauthor=R.+D.+Morinauthor=A.+J.+Mungallauthor=B.+Meissnerauthor=M.+Boyleauthor=V.+E.+Marquezauthor=M.+A.+Marraauthor=R.+D.+Gascoyneauthor=R.+K.+Humphriesauthor=C.+H.+Arrowsmithauthor=G.+B.+Morinauthor=S.+A.+Aparicio&title=Somatic+mutations+at+EZH2+Y641+act+dominantly+through+a+mechanism+of+selectively+altered+PRC2+catalytic+activity%2C+to+increase+H3K27+trimethylation&doi=10.1182%2Fblood-2010-11-321208"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-11-321208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-11-321208%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DD.%2BB.%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DS.%2BW.%26aulast%3DMoradian%26aufirst%3DA.%26aulast%3DMorin%26aufirst%3DR.%2BD.%26aulast%3DMungall%26aufirst%3DA.%2BJ.%26aulast%3DMeissner%26aufirst%3DB.%26aulast%3DBoyle%26aufirst%3DM.%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DHumphries%26aufirst%3DR.%2BK.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DMorin%26aufirst%3DG.%2BB.%26aulast%3DAparicio%26aufirst%3DS.%2BA.%26atitle%3DSomatic%2520mutations%2520at%2520EZH2%2520Y641%2520act%2520dominantly%2520through%2520a%2520mechanism%2520of%2520selectively%2520altered%2520PRC2%2520catalytic%2520activity%252C%2520to%2520increase%2520H3K27%2520trimethylation%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D2451%26epage%3D2459%26doi%3D10.1182%2Fblood-2010-11-321208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Ryckmans, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, T.</span><span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A lipophilic efficiency (LipE) analysis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4406</span><span class="NLM_x">–</span> <span class="NLM_lpage">4409</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+assessment+of+a+novel+series+of+selective+CB%282%29+agonists+using+parallel+synthesis+protocols%3A+A+lipophilic+efficiency+%28LipE%29+analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0lh4T6GyM670OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB%25282%2529%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520A%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span> </span><span class="NLM_article-title">Evaluating the differences in cycloalkyl ether metabolism using the design parameter “lipophilic metabolism efficiency” (LipMetE) and a matched molecular pairs analysis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6985</span><span class="NLM_x">–</span> <span class="NLM_lpage">6990</span><span class="refDoi"> DOI: 10.1021/jm4008642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4008642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6985-6990&author=A.+F.+Stepanauthor=G.+W.+Kauffmanauthor=C.+E.+Keeferauthor=P.+R.+Verhoestauthor=M.+Edwards&title=Evaluating+the+differences+in+cycloalkyl+ether+metabolism+using+the+design+parameter+%E2%80%9Clipophilic+metabolism+efficiency%E2%80%9D+%28LipMetE%29+and+a+matched+molecular+pairs+analysis&doi=10.1021%2Fjm4008642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating the Differences in Cycloalkyl Ether Metabolism Using the Design Parameter "Lipophilic Metabolism Efficiency" (LipMetE) and a Matched Molecular Pairs Analysis</span></div><div class="casAuthors">Stepan, Antonia F.; Kauffman, Gregory W.; Keefer, Christopher E.; Verhoest, Patrick R.; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6985-6990</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have obsd. previously that modification of ring size and substitution pattern may be used as a strategy to mitigate the metabolic instability of cycloalkyl ethers.  In this article, we introduce a medicinal chem. design parameter named "lipophilic metab. efficiency" (LipMetE) that indicates that these changes in metabolic stability can be largely ascribed to changes in lipophilicity.  Our matched mol. pair anal. also indicates that this finding is a general phenomenon, widely obsd. across different chemotypes.  It is our hope that both the LipMetE design parameter and the results from our pairwise anal. will be useful tools for medicinal chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpiFJ_fPxurbVg90H21EOLACvtfcHk0lh4T6GyM670OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurvJ&md5=596673d35831b979b8daf5a4ccb8a218</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm4008642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4008642%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DKeefer%26aufirst%3DC.%2BE.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DEvaluating%2520the%2520differences%2520in%2520cycloalkyl%2520ether%2520metabolism%2520using%2520the%2520design%2520parameter%2520%25E2%2580%259Clipophilic%2520metabolism%2520efficiency%25E2%2580%259D%2520%2528LipMetE%2529%2520and%2520a%2520matched%2520molecular%2520pairs%2520analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6985%26epage%3D6990%26doi%3D10.1021%2Fjm4008642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bingham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grable, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span> </span><span class="NLM_article-title">Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">11384</span><span class="refDoi"> DOI: 10.1038/ncomms11384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fncomms11384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=27122193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFeiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=11384&author=A.+Broounauthor=K.+S.+Gajiwalaauthor=Y.+L.+Dengauthor=W.+Liuauthor=B.+Bolanosauthor=P.+Binghamauthor=Y.+A.+Heauthor=W.+Diehlauthor=N.+Grableauthor=P.+P.+Kungauthor=S.+Suttonauthor=K.+A.+Maegleyauthor=X.+Yuauthor=A.+E.+Stewart&title=Polycomb+repressive+complex+2+structure+with+inhibitor+reveals+a+mechanism+of+activation+and+drug+resistance&doi=10.1038%2Fncomms11384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance</span></div><div class="casAuthors">Brooun, Alexei; Gajiwala, Ketan S.; Deng, Ya-Li; Liu, Wei; Bolanos, Ben; Bingham, Patrick; He, You-Ai; Diehl, Wade; Grable, Nicole; Kung, Pei-Pei; Sutton, Scott; Maegley, Karen A.; Yu, Xiu; Stewart, Al E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11384</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) mediates gene silencing through chromatin reorganization by methylation of histone H3 lysine 27 (H3K27).  Overexpression of the complex and point mutations in the individual subunits of PRC2 have been shown to contribute to tumorigenesis.  Several inhibitors of the PRC2 activity have shown efficacy in EZH2-mutated lymphomas and are currently in clin. development, although the mol. basis of inhibitor recognition remains unknown.  Here we report the crystal structures of the inhibitor-bound wild-type and Y641N PRC2.  The structures illuminate an important role played by a stretch of 17 residues in the N-terminal region of EZH2, we call the activation loop, in the stimulation of the enzyme activity, inhibitor recognition and the potential development of the mutation-mediated drug resistance.  The work presented here provides new avenues for the design and development of next-generation PRC2 inhibitors through establishment of a structure-based drug design platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuWyWQoRoObVg90H21EOLACvtfcHk0lh4T6GyM670OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFeiu7w%253D&md5=15ded613fdc3cafe35bee914678ab65e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fncomms11384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11384%26sid%3Dliteratum%253Aachs%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DGrable%26aufirst%3DN.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26atitle%3DPolycomb%2520repressive%2520complex%25202%2520structure%2520with%2520inhibitor%2520reveals%2520a%2520mechanism%2520of%2520activation%2520and%2520drug%2520resistance%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D11384%26doi%3D10.1038%2Fncomms11384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="note"><p class="first last">The coordinate error for a 3 Å crystal structure is between 0.2 and 0.3 Å. Therefore, we believe that the two compounds make hydrogen bonds of similar strength to the key residues (Trp624 and Tyr111).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span> </span><span class="NLM_article-title">Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">aac4383</span><span class="refDoi"> DOI: 10.1126/science.aac4383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1126%2Fscience.aac4383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=26472914" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2015&pages=aac4383&author=L.+Jiaoauthor=X.+Liu&title=Structural+basis+of+histone+H3K27+trimethylation+by+an+active+polycomb+repressive+complex+2&doi=10.1126%2Fscience.aac4383"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1126%2Fscience.aac4383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aac4383%26sid%3Dliteratum%253Aachs%26aulast%3DJiao%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DStructural%2520basis%2520of%2520histone%2520H3K27%2520trimethylation%2520by%2520an%2520active%2520polycomb%2520repressive%2520complex%25202%26jtitle%3DScience%26date%3D2015%26volume%3D350%26spage%3Daac4383%26doi%3D10.1126%2Fscience.aac4383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit34b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Justin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarricone, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underwood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Marco, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haire, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gamblin, S. J.</span><span> </span><span class="NLM_article-title">Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">11316</span><span class="refDoi"> DOI: 10.1038/ncomms11316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1038%2Fncomms11316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=27121947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFeiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=11316&author=N.+Justinauthor=Y.+Zhangauthor=C.+Tarriconeauthor=S.+R.+Martinauthor=S.+Chenauthor=E.+Underwoodauthor=V.+De+Marcoauthor=L.+F.+Haireauthor=P.+A.+Walkerauthor=D.+Reinbergauthor=J.+R.+Wilsonauthor=S.+J.+Gamblin&title=Structural+basis+of+oncogenic+histone+H3K27M+inhibition+of+human+polycomb+repressive+complex+2&doi=10.1038%2Fncomms11316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2</span></div><div class="casAuthors">Justin, Neil; Zhang, Ying; Tarricone, Cataldo; Martin, Stephen R.; Chen, Shuyang; Underwood, Elizabeth; De Marco, Valeria; Haire, Lesley F.; Walker, Philip A.; Reinberg, Danny; Wilson, Jon R.; Gamblin, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11316</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) silences gene expression through trimethylation of K27 of histone H3 (H3K27me3) via its catalytic SET domain.  A missense mutation in the substrate of PRC2, histone H3K27M, is assocd. with certain pediatric brain cancers and is linked to a global decrease of H3K27me3 in the affected cells thought to be mediated by inhibition of PRC2 activity.  We present here the crystal structure of human PRC2 in complex with the inhibitory H3K27M peptide bound to the active site of the SET domain, with the methionine residue located in the pocket that normally accommodates the target lysine residue.  The structure and binding studies suggest a mechanism for the oncogenic inhibition of H3K27M.  The structure also reveals how binding of repressive marks, like H3K27me3, to the EED subunit of the complex leads to enhancement of the catalytic efficiency of the SET domain and thus the propagation of this repressive histone modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIwqJGbneSdbVg90H21EOLACvtfcHk0lgLn2nSNynp-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFeiu78%253D&md5=516a8ef27712c9776e8ee0681cd91289</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1038%2Fncomms11316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11316%26sid%3Dliteratum%253Aachs%26aulast%3DJustin%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTarricone%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%2BR.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DUnderwood%26aufirst%3DE.%26aulast%3DDe%2BMarco%26aufirst%3DV.%26aulast%3DHaire%26aufirst%3DL.%2BF.%26aulast%3DWalker%26aufirst%3DP.%2BA.%26aulast%3DReinberg%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DJ.%2BR.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26atitle%3DStructural%2520basis%2520of%2520oncogenic%2520histone%2520H3K27M%2520inhibition%2520of%2520human%2520polycomb%2520repressive%2520complex%25202%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D11316%26doi%3D10.1038%2Fncomms11316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Tsuzuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchimaru, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, A.</span><span> </span><span class="NLM_article-title">Magnitude and directionality of the interaction energy of the aliphatic CH/π interaction: significant difference from hydrogen bond</span> <span class="citation_source-journal">J. Phys. Chem. A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">10163</span><span class="NLM_x">–</span> <span class="NLM_lpage">10168</span><span class="refDoi"> DOI: 10.1021/jp064206j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp064206j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFGqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2006&pages=10163-10168&author=S.+Tsuzukiauthor=K.+Hondaauthor=T.+Uchimaruauthor=M.+Mikamiauthor=A.+Fujii&title=Magnitude+and+directionality+of+the+interaction+energy+of+the+aliphatic+CH%2F%CF%80+interaction%3A+significant+difference+from+hydrogen+bond&doi=10.1021%2Fjp064206j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Magnitude and Directionality of the Interaction Energy of the Aliphatic CH/π Interaction: Significant Difference from Hydrogen Bond</span></div><div class="casAuthors">Tsuzuki, Seiji; Honda, Kazumasa; Uchimaru, Tadafumi; Mikami, Masuhiro; Fujii, Asuka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry A</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">10163-10168</span>CODEN:
                <span class="NLM_cas:coden">JPCAFH</span>;
        ISSN:<span class="NLM_cas:issn">1089-5639</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The CCSD(T) level interaction energies of CH/π complexes at the basis set limit were estd.  The estd. interaction energies of the benzene complexes with CH4, CH3CH3, CH2CH2, CHCH, CH3NH2, CH3OH, CH3OCH3, CH3F, CH3Cl, CH3ClNH2, CH3ClOH, CH2Cl2, CH2FCl, CH2F2, CHCl3, and CH3F3 are -1.45, -1.82, -2.06, -2.83, -1.94, -1.98, -2.06, -2.31, -2.99, -3.57, -3.71, -4.54, -3.88, -3.22, -5.64, and -4.18 kcal/mol, resp.  Dispersion is the major source of attraction, even if substituents are attached to the carbon atom of the C-H bond.  The dispersion interaction between benzene and chlorine atoms, which is not the CH/π interaction, is the cause of the very large interaction energy of the CHCl3 complex.  Activated CH/π interaction (acetylene and substituted methanes with two or three electron-withdrawing groups) is not very weak.  The nature of the activated CH/π interaction may be similar to the hydrogen bond.  On the other hand, the nature of other typical (nonactivated) CH/π interactions is completely different from that of the hydrogen bond.  The typical CH/π interaction is significantly weaker than the hydrogen bond.  Dispersion interaction is mainly responsible for the attraction in the CH/π interaction, whereas electrostatic interaction is the major source of attraction in the hydrogen bond.  The orientation dependence of the interaction energy of the typical CH/π interaction energy is very small, whereas the hydrogen bond has strong directionality.  The weak directionality suggests that the hydrogen atom of the interacting C-H bond is not essential for the attraction and that the typical CH/π interaction does not play crit. roles in detg. the mol. orientation in mol. assemblies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIhqHUUsd5irVg90H21EOLACvtfcHk0lgLn2nSNynp-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFGqurc%253D&md5=d389696efd9b0b90f624879306de6a0d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjp064206j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp064206j%26sid%3Dliteratum%253Aachs%26aulast%3DTsuzuki%26aufirst%3DS.%26aulast%3DHonda%26aufirst%3DK.%26aulast%3DUchimaru%26aufirst%3DT.%26aulast%3DMikami%26aufirst%3DM.%26aulast%3DFujii%26aufirst%3DA.%26atitle%3DMagnitude%2520and%2520directionality%2520of%2520the%2520interaction%2520energy%2520of%2520the%2520aliphatic%2520CH%252F%25CF%2580%2520interaction%253A%2520significant%2520difference%2520from%2520hydrogen%2520bond%26jtitle%3DJ.%2520Phys.%2520Chem.%2520A%26date%3D2006%26volume%3D110%26spage%3D10163%26epage%3D10168%26doi%3D10.1021%2Fjp064206j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Hoffmann, R. W.</span><span> </span><span class="NLM_article-title">Allylic 1,3-strain as a controlling factor in stereoselective transformations</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1841</span><span class="NLM_x">–</span> <span class="NLM_lpage">1860</span><span class="refDoi"> DOI: 10.1021/cr00098a009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00098a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADyaL1MXmtlWnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1989&pages=1841-1860&author=R.+W.+Hoffmann&title=Allylic+1%2C3-strain+as+a+controlling+factor+in+stereoselective+transformations&doi=10.1021%2Fcr00098a009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Allylic 1,3-strain as a controlling factor in stereoselective transformations</span></div><div class="casAuthors">Hoffmann, Reinhard W.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1841-60</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">A review with 155 refs. on the manifestation of allylic strain in the stereochem. of a host of chem. reactions, including cyclizations, intermol. addn., hydrogenation, cyclopropanation, and others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDZG59Whd3WbVg90H21EOLACvtfcHk0lgyxP2N_GIExA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmtlWnurc%253D&md5=91540e91c0c31a112831dd5ac9d73f4d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fcr00098a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00098a009%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DR.%2BW.%26atitle%3DAllylic%25201%252C3-strain%2520as%2520a%2520controlling%2520factor%2520in%2520stereoselective%2520transformations%26jtitle%3DChem.%2520Rev.%26date%3D1989%26volume%3D89%26spage%3D1841%26epage%3D1860%26doi%3D10.1021%2Fcr00098a009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Taylor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennard, O.</span><span> </span><span class="NLM_article-title">Hydrogen-bond geometry in organic crystals</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">320</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1021/ar00105a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar00105a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADyaL2cXlsVWitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1984&pages=320-326&author=R.+Taylorauthor=O.+Kennard&title=Hydrogen-bond+geometry+in+organic+crystals&doi=10.1021%2Far00105a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrogen-bond geometry in organic crystals</span></div><div class="casAuthors">Taylor, Robin; Kennard, Olga</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">320-6</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    </div><div class="casAbstract">A review with 34 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCSKO2ZfkARLVg90H21EOLACvtfcHk0lgyxP2N_GIExA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXlsVWitLk%253D&md5=ef444116e1ee4eedae1e8048d711c12f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Far00105a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far00105a004%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DR.%26aulast%3DKennard%26aufirst%3DO.%26atitle%3DHydrogen-bond%2520geometry%2520in%2520organic%2520crystals%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1984%26volume%3D17%26spage%3D320%26epage%3D326%26doi%3D10.1021%2Far00105a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span> </span><span class="NLM_article-title">Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">3593</span><span class="NLM_x">–</span> <span class="NLM_lpage">3608</span><span class="refDoi"> DOI: 10.1021/jm400102x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400102x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVWrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3593-3608&author=A.+Liauthor=Y.+Ouyangauthor=Z.+Wangauthor=Y.+Caoauthor=X.+Liuauthor=L.+Ranauthor=C.+Liauthor=L.+Liauthor=L.+Zhangauthor=K.+Qiaoauthor=W.+Xuauthor=Y.+Huangauthor=Z.+Zhangauthor=C.+Tianauthor=Z.+Liuauthor=S.+Jiangauthor=Y.+Shaoauthor=Y.+Duauthor=L.+Maauthor=X.+Wangauthor=J.+Liu&title=Novel+pyridinone+derivatives+as+non-nucleoside+reverse+transcriptase+inhibitors+%28NNRTIs%29+with+high+potency+against+NNRTI-resistant+HIV-1+strains&doi=10.1021%2Fjm400102x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Pyridinone Derivatives As Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) with High Potency against NNRTI-Resistant HIV-1 Strains</span></div><div class="casAuthors">Li, Amin; Ouyang, Yabo; Wang, Ziyun; Cao, Yuanyuan; Liu, Xiangyi; Ran, Li; Li, Chao; Li, Li; Zhang, Liang; Qiao, Kang; Xu, Weisi; Huang, Yang; Zhang, Zhili; Tian, Chao; Liu, Zhenming; Jiang, Shibo; Shao, Yiming; Du, Yansheng; Ma, Liying; Wang, Xiaowei; Liu, Junyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3593-3608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel 6-substituted-4-cycloalkyloxy-pyridin-2(1H)-ones were synthesized as non-nucleoside reverse transcriptase inhibitors (NNRTIs), and their biol. activity was evaluated.  Most of the compds., esp. 26 and 22 (XXVI and XXII), bearing a 3-iso-Pr and 3-iodine group, resp., exhibited highly potent activity against wild-type HIV-1 strains and those resistant to reverse transcriptase inhibitors (RTIs).  The diastereoisomers of 26-trans and 26-cis were synthesized sep. and confirmed with HPLC and NOESY spectra.  The 26-trans isomers had an activity about 400-fold more potent than that of 26-cis.  The pair of 26-trans enantiomers, one of the most potent inhibitors with EC50 of 4 nM and selectivity index (SI) of 75000, was highly effective against a panel of RTIs-resistant strains with single (Y181C and K103N) or double (A17) mutations in reverse transcriptase.  The results suggest that these novel pyridinone derivs. have the potential to be further developed as new antiretroviral drugs with improved antiviral efficacy and drug resistance profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYvVz2YpBIGLVg90H21EOLACvtfcHk0lgyxP2N_GIExA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVWrs7w%253D&md5=f077204b0fc3bd46c80c36fca58b4778</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm400102x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400102x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DA.%26aulast%3DOuyang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DRan%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DQiao%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DNovel%2520pyridinone%2520derivatives%2520as%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520%2528NNRTIs%2529%2520with%2520high%2520potency%2520against%2520NNRTI-resistant%2520HIV-1%2520strains%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3593%26epage%3D3608%26doi%3D10.1021%2Fjm400102x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, N. C.</span><span> </span><span class="NLM_article-title">An efficient approach to 3,4-disubstituted pyridin-2-ones. formal synthesis of mappicine ketone</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">5688</span><span class="NLM_x">–</span> <span class="NLM_lpage">5691</span><span class="refDoi"> DOI: 10.1021/jo034042s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo034042s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=5688-5691&author=C.+H.+Linauthor=M.+R.+Tsaiauthor=Y.+S.+Wangauthor=N.+C.+Chang&title=An+efficient+approach+to+3%2C4-disubstituted+pyridin-2-ones.+formal+synthesis+of+mappicine+ketone&doi=10.1021%2Fjo034042s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjo034042s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo034042s%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DTsai%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BS.%26aulast%3DChang%26aufirst%3DN.%2BC.%26atitle%3DAn%2520efficient%2520approach%2520to%25203%252C4-disubstituted%2520pyridin-2-ones.%2520formal%2520synthesis%2520of%2520mappicine%2520ketone%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D5688%26epage%3D5691%26doi%3D10.1021%2Fjo034042s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Hama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culkin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartwig, J. F.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed α-arylation of esters and amides under more neutral conditions</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">11176</span><span class="NLM_x">–</span> <span class="NLM_lpage">11177</span><span class="refDoi"> DOI: 10.1021/ja036792p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja036792p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVynsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2003&pages=11176-11177&author=T.+Hamaauthor=X.+Liuauthor=D.+A.+Culkinauthor=J.+F.+Hartwig&title=Palladium-catalyzed+%CE%B1-arylation+of+esters+and+amides+under+more+neutral+conditions&doi=10.1021%2Fja036792p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed α-Arylation of Esters and Amides under More Neutral Conditions</span></div><div class="casAuthors">Hama, Takuo; Liu, Xiaoxiang; Culkin, Darcy A.; Hartwig, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">11176-11177</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two procedures for the α-arylation of carbonyl compds., under more neutral conditions than those for reactions of aryl halides with alkali metal enolates, are reported.  The first procedure rests upon the development of catalysts bearing the hindered pentaphenylferrocenyl di-tert-butylphosphine (Q-phos), and the highly reactive dimeric Pd(I) complex {[P(t-Bu)3]PdBr}2.  Zinc enolates, prepd. from α-bromo esters and amides, react with aryl bromides to form α-aryl esters, e.g., I (R1 = OCMe3, R2 = H), and amides, e.g., I (R1 = NEt2, R2 = Me), in high yields, and with remarkable functional group tolerance.  The second procedure; silyl ketenes II (R3 = t-Bu, R4 = H; R3 = R4 = Me) and silyl ketimine acetals react with aryl bromides in the presence of substoichiometric amts. of zinc fluoride, Pd(dba)2, and P(t-Bu)3 to give α-aryl esters and amides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUgTDi6U6CcbVg90H21EOLACvtfcHk0lh_vOSG1MmgKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVynsbY%253D&md5=c15ec36ca3047c7815add05ecbaf0ba1</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fja036792p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja036792p%26sid%3Dliteratum%253Aachs%26aulast%3DHama%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCulkin%26aufirst%3DD.%2BA.%26aulast%3DHartwig%26aufirst%3DJ.%2BF.%26atitle%3DPalladium-catalyzed%2520%25CE%25B1-arylation%2520of%2520esters%2520and%2520amides%2520under%2520more%2520neutral%2520conditions%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2003%26volume%3D125%26spage%3D11176%26epage%3D11177%26doi%3D10.1021%2Fja036792p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Li-Yuan Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span> </span><span class="NLM_article-title">Progress and developments in the turbo Grignard reagent i-PrMgCl·LiCl: a ten-year journey</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6884</span><span class="NLM_x">–</span> <span class="NLM_lpage">6900</span><span class="refDoi"> DOI: 10.1039/C4CC10194D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1039%2FC4CC10194D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=25714498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVeltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=6884-6900&author=R.+Li-Yuan+Baoauthor=R.+Zhaoauthor=L.+Shi&title=Progress+and+developments+in+the+turbo+Grignard+reagent+i-PrMgCl%C2%B7LiCl%3A+a+ten-year+journey&doi=10.1039%2FC4CC10194D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Progress and developments in the turbo Grignard reagent i-PrMgCl·LiCl: a ten-year journey</span></div><div class="casAuthors">Li-Yuan Bao, Robert; Zhao, Rong; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">6884-6900</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Over the past decade, the effectiveness of i-PrMgCl·LiCl has been constantly highlighted by a no. of research groups.  Its enhanced nucleophilicity brings prosperity to highly functionalized Grignard reagents, other useful bimetallic (alkali-metal) agents and nucleophilic alkylation products under mild reaction conditions.  In this feature article, a comprehensive, systematical and in-depth overview of i-PrMgCl·LiCl is provided in a multidisciplinary idea.  It involves the structural and kinetic perspectives of i-PrMgCl·LiCl as well as its unique reactivity and selectivity, with knowledge of the former helping to rationalize trends of the later.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHU-x1ob4nvLVg90H21EOLACvtfcHk0lh_vOSG1MmgKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVeltro%253D&md5=ad9c174821be3788331078e27f63a85b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2FC4CC10194D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC10194D%26sid%3Dliteratum%253Aachs%26aulast%3DLi-Yuan%2BBao%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DProgress%2520and%2520developments%2520in%2520the%2520turbo%2520Grignard%2520reagent%2520i-PrMgCl%25C2%25B7LiCl%253A%2520a%2520ten-year%2520journey%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D6884%26epage%3D6900%26doi%3D10.1039%2FC4CC10194D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><div class="note"><p class="first last">For an alternative synthesis of oxetane-3-carbaldehyde see the following:</p></div><span class="NLM_contrib-group">Kephart, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zehnder, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S. C.</span><span> </span><span class="NLM_article-title">Synthesis of oxetane-3-carboxaldehyde and methyl oxetane-3-carboxylate via homologation of oxetane-3-one</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3641</span><span class="NLM_x">–</span> <span class="NLM_lpage">3646</span><span class="refDoi"> DOI: 10.1016/j.tet.2016.03.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1016%2Fj.tet.2016.03.078" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=3641-3646&author=S.+E.+Kephartauthor=L.+R.+Zehnderauthor=B.+Huangauthor=S.+C.+Sutton&title=Synthesis+of+oxetane-3-carboxaldehyde+and+methyl+oxetane-3-carboxylate+via+homologation+of+oxetane-3-one&doi=10.1016%2Fj.tet.2016.03.078"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2016.03.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2016.03.078%26sid%3Dliteratum%253Aachs%26aulast%3DKephart%26aufirst%3DS.%2BE.%26aulast%3DZehnder%26aufirst%3DL.%2BR.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DSutton%26aufirst%3DS.%2BC.%26atitle%3DSynthesis%2520of%2520oxetane-3-carboxaldehyde%2520and%2520methyl%2520oxetane-3-carboxylate%2520via%2520homologation%2520of%2520oxetane-3-one%26jtitle%3DTetrahedron%26date%3D2016%26volume%3D72%26spage%3D3641%26epage%3D3646%26doi%3D10.1016%2Fj.tet.2016.03.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span> </span><span class="NLM_article-title">Catalytic asymmetric nucleophilic openings of 3-substituted oxetanes</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6028</span><span class="NLM_x">–</span> <span class="NLM_lpage">6032</span><span class="refDoi"> DOI: 10.1039/C4OB00920G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=10.1039%2FC4OB00920G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=24968137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGnsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=6028-6032&author=Z.+Wangauthor=Z.+Chenauthor=J.+Sun&title=Catalytic+asymmetric+nucleophilic+openings+of+3-substituted+oxetanes&doi=10.1039%2FC4OB00920G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic asymmetric nucleophilic openings of 3-substituted oxetanes</span></div><div class="casAuthors">Wang, Zhaobin; Chen, Zhilong; Sun, Jianwei</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">6028-6032</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Asym. ring-opening of 3-substituted oxetanes provides rapid access to highly functionalized chiral building blocks.  However, progress in this field is limited.  Recently the authors developed a new catalytic system based on chiral Bronsted acids for this type of reaction and demonstrated the synthesis of a range of useful mols. under mild and operationally simple conditions.  In this perspective, the authors describe the challenges, progress, and potential future efforts on this topic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM9rqwK5NcjbVg90H21EOLACvtfcHk0lh_vOSG1MmgKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGnsL3I&md5=b96914862c1e5e6d86ec259132cdb8ce</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1039%2FC4OB00920G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4OB00920G%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DCatalytic%2520asymmetric%2520nucleophilic%2520openings%2520of%25203-substituted%2520oxetanes%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2014%26volume%3D12%26spage%3D6028%26epage%3D6032%26doi%3D10.1039%2FC4OB00920G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W2R" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W2R','PDB','4W2R'); return false;">PDB: 4W2R</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B3W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B3W','PDB','6B3W'); return false;">PDB: 6B3W</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i24"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01375">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_83311"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01375">10.1021/acs.jmedchem.7b01375</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic experimental procedures, analytical data, and small molecule X-ray crystal strucutres for all compounds from <a class="ref internalNav" href="#tbl1">Tables 1</a> and <a class="ref showTableEvent internalNav" href="#tbl2">2</a>, enzymatic assay, biology experimental details, and computational method (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and compound purity data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_002.xlsx">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_001.pdf">jm7b01375_si_001.pdf (1.61 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01375/suppl_file/jm7b01375_si_002.xlsx">jm7b01375_si_002.xlsx (15.07 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are the following: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B3W">6B3W</a> for compound <b>1</b> complexed with EZH2/EED/SUZ12; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W2R">4W2R</a> for compound <b>23a</b> complexed with EZH2/EED/SUZ12.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-3%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01375%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01375" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67991de94c193d4e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
